Aryl derivatives for treating TRPM3-mediated disorders
Patent Information
- Application Number
- JP2023530964
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-24
- Filing Date
- 2021-11-24
- Publication Date
- 2024-11-06
AI Technical Summary
There is a significant medical need for new, alternative, and/or better treatments for TRPM3-mediated disorders, particularly for pain such as inflammatory pain, with good efficacy, low side effects, and favorable pharmacokinetics.
Development of novel benzofuran derivatives that act as TRPM3 antagonists, which can be used to prevent or treat TRPM3-mediated disorders like pain and inflammatory hypersensitivity through specific synthesis methods involving benzoquinone reactions with β-keto esters or enamine derivatives.
The benzofuran derivatives effectively modulate TRPM3 channels, providing potential therapeutic benefits for pain and inflammatory hypersensitivity with improved safety and pharmacokinetic profiles compared to existing treatments.
Smart Images

Figure 2022112345000001 
Figure 2022112345000002 
Figure 2022112345000003
Abstract
Description
Technical field
[0001] The present invention relates to compounds useful in the prevention or treatment of TRPM3-mediated disorders, more specifically disorders selected from pain and inflammatory hypersensitivity. The invention also relates to methods for the prevention or treatment of such TRPM3-mediated disorders. [Background technology]
[0002] The TRP superfamily consists of proteins with six transmembrane domains (6TM) that assemble as homo- or heterotetramers to form cation-permeable ion channels. The name TRP is derived from the Drosophila trp (transient receptor potential) mutant, which is characterized by a transient receptor potential in fly photoreceptors in response to continuous light. In the past 15 years, TRP-related channels have been identified in yeast, parasites, insects, fish, and mammals, including 27 TRPs in humans. Based on sequence homology, TRP channels can be divided into seven subfamilies: TRPC, TRPV, TRPM, TRPA, TRPP, TRPML, and TRPN.
[0003] Members of the TRP superfamily are expressed in probably all mammalian organs and cell types, and great progress has been made in recent years in understanding their physiological roles. Customized selectivity of certain TRP channels 2+ , Mg 2+ , and play an important role in the cellular uptake and / or transepithelial transport of trace metal ions. Furthermore, the sensitivity of TRP channels to a wide range of chemical and physical stimuli allows them to function as dedicated biological sensors involved in processes from vision to taste to touch. Specifically, some members of the TRP superfamily exhibit very high sensitivity to temperature. These so-called thermo-TRPs are highly expressed in sensory neurons and / or skin keratinocytes and serve as the main thermosensors for the detection of innocuous and noxious (painful) temperatures.
[0004] It is becoming increasingly clear that TRP channel dysfunction is directly involved in the pathogenesis of various inherited and acquired diseases. Indeed, both loss-of-function and gain-of-function mutations in TRP channel genes are associated with brachiolemia, hypomagnesemia with secondary hypocalcemia, polycystic kidney disease, type IV mucolipidosis, and familial It has been identified as a direct cause of genetic disorders including segmental glomerulosclerosis. Furthermore, TRP channel function / dysfunction has been directly linked to a wide range of pathological conditions, including chronic pain, hypertension, cancer, and neurodegenerative disorders.
[0005] TRPM3 (transient receptor potential melastatin 3) represents a promising pharmacological target. TRPM3 is expressed in a large subset of small diameter sensory neurons from the dorsal root and trigeminal ganglia and is involved in heat sensing. The neurosteroid pregnenolone sulfate is a potent known activator of TRPM3 (Wagner et al., 2008). The neurosteroid pregnenolone sulfate caused pain in wild-type mice but not in knockout TRPM3 mice. It was also recently shown that CFA-induced inflammation and inflammatory pain are abolished in TRPM3 knockout mice. Therefore, TRPM3 antagonists can be used as analgesics to combat pain, such as inflammatory pain (Vriens J. et al. Neuron, May 2011).
[0006] Several TRPM3 antagonists are known, but none of them refers to the compounds of the present invention (Straub I et al. Mol Pharmacol, November 2013). For example, liquiritigenin, a putative TRPM3 blocker, has been described to reduce mechanical and cold hyperalgesia in a rat pain model (Chen L et al. Scientific reports, July 2014). There remains a significant medical need for new, alternative, and / or better treatments for the prevention or treatment of TRPM3-mediated disorders, and more specifically for pain, such as inflammatory pain. . Good efficacy for certain types of pain, low levels or no side effects (e.g., no addiction potential, no toxicity, similar to opiates) and / or good or better pharmacokinetics or very dynamic properties. is necessary.
[0007] The present invention provides novel compounds that are antagonists of TRPM3 and can be used as modulators of TRPM3-mediated disorders. [Summary of the invention]
[0008] The present invention provides benzofuran derivatives and pharmaceutical compositions containing such benzofuran derivatives. The invention also provides for use as a medicament, more particularly for use in the prevention and / or treatment of TRPM3-mediated disorders, in particular for the prevention and / or treatment of pain and / or inflammatory hypersensitivity. Benzofuran derivatives are provided for use in therapy and / or to combat pain and / or inflammatory hypersensitivity.
[0009] The present invention also provides for the prevention and / or treatment of TRPM3-mediated disorders, in particular for the prevention and / or treatment of pain and / or inflammatory hypersensitivity, and / or for the prevention and / or treatment of pain and / or inflammatory hypersensitivity. Provided is the use of benzofuran derivatives for the manufacture of pharmaceutical compositions or medicaments for combating the effects of the present invention.
[0010] The invention also provides a method for the prevention or treatment of TRPM3-mediated disorders by administering a benzofuran derivative according to the invention to a subject in need thereof. More specifically, the invention relates to such methods for the prevention and / or treatment of and / or for combating pain and / or inflammatory hypersensitivity.
[0011] The present invention is a method for the preparation of benzofuran derivatives of the present invention, comprising: - reacting the benzoquinone with a suitable β-keto ester or enamine derivative to obtain a 5-hydroxybenzofuran-3-carboxylate ester derivative; - Substitution of the previously obtained 5-hydroxybenzofuran-3-carboxylate ester derivative with a suitable derivative or alcohol derivative bearing a leaving group under Mitsunobu conditions to produce a 5-O-substituted benzofuran-3-carboxylate obtaining an ester derivative; - converting the previously obtained 5-O-substituted benzofuran-3-carboxylic acid ester derivative in carboxylic acid to obtain the desired benzofuran derivative of the present invention; - coupling the previously obtained 5-O-substituted benzofuran-3-carboxylic acid derivative with a suitable amine to obtain the desired amide derivative of the invention. [Form for carrying out the invention]
[0012] The invention will sometimes be further described with respect to particular embodiments, although the invention is not limited thereto.
[0013] A first aspect of the invention preferably provides a compound of formula (I) (also referred to as a benzofuran derivative according to the invention), a stereoisomer thereof, for use in the treatment of pain, a physiologically acceptable providing salts, solvates, and / or polymorphs; [ka] During the ceremony, R 1 is -F, -Cl, -Br, -I, -CN, -R W ,-OR W , -OC(=O)R W ,-NR W R X ,-NR W C(=O)R X ,-SR W , -S(=O)R W , -S(=O) 2 R W , -C(=O)R W , -C(=O)OR W , or -C(=O)NR W R X represents, Q is -OR 2 or -NR 3 R 4 , preferably Q represents -NR 3 R 4 represents, R 2 But -R Y represents, R 3 is -OH or -R Y represents, R 4 But -R Y or -S(=O) 2 R Y or Alternatively, R 3 and R 4 together contain 1 to 3 heteroatoms selected from N, O, and S, saturated or unsaturated, unsubstituted, or mono- or polysubstituted 4, 5, 6, Forms a 7- or 8-membered heterocycle, T represents -O- and U represents -CR 5 R 5 ’- or T is -CR 5 R 5 '-, U represents -O-, R5 and R 5 ’, independently of each other, -R Y or Alternatively, T represents -O- and U represents -CR 5 R 5 ’-, and alternatively, R 5 and R 9 together contain a saturated or unsaturated, unsubstituted, mono- or polysubstituted 4- to 8-membered carbocyclic ring, or 1 to 3 heteroatoms selected from N, O, and S forming a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 4- to 8-membered heterocycle, R 6 ,R 7 , and R 8 are, independently of each other, -F, -Cl, -Br, -I, -CN, -NO 2 ,-SCIENCE FICTION 5 ,-R W ,-OR W , -OC(=O)R W ,-NR W R X ,-NR W C(=O)R X ,-SR W , -S(=O)R W , -S(=O) 2 R W , -C(=O)R W , -C(=O)OR W , or -C(=O)NR W R X represents, R 9 ,R 10 ,R 11 ,R 12 , and R 13 are, independently of each other, -F, -Cl, -Br, -I, -CN, -NO, -NO 2 , =O, =S, -SF 5 ,-R Y ,-OR Y , -OC(=O)R Y ,-NR Y R Z ,-NR Y C(=O)R Z ,-SR Y , -S(=O)R Y , -S(=O) 2 R Y , -C(=O)R Y , -C(=O)OR Y , or -C(=O)NR Y R Z , preferably R 9 ,R 10 ,R 11 ,R 12 , and R 13 provided that at least one of them does not represent -H, During the ceremony, R W and R X but independently of each other, in each case independently, -H, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -heteroalkyl, a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl; a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered heterocycloalkyl, wherein the 3- to 14-membered heterocycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 optionally connected through -heteroalkylene-, in each case representing a saturated or unsaturated, unsubstituted, mono- or polysubstituted, 3- to 14-membered heterocycloalkyl; R Y and R Z but independently of each other, in each case independently, -H, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -heteroalkyl, a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, optionally connected through -heteroalkylene-, in each case saturated or unsaturated; a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered heterocycloalkyl, wherein the 3- to 14-membered heterocycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl, optionally connected through -heteroalkylene-, in each case saturated or unsaturated; An unsubstituted, monosubstituted or polysubstituted 6- to 14-membered aryl, wherein the 6- to 14-membered aryl is -C 1 -C 6 -alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 6- to 14-membered aryl; an unsubstituted, monosubstituted or polysubstituted 5- to 14-membered heteroaryl, wherein the 5- to 14-membered heteroaryl is -C 1 -C 6 -alkylene- or -C 1 -C 6 optionally connected through -heteroalkylene-, in each case representing a saturated or unsaturated, unsubstituted, mono- or polysubstituted 5- to 14-membered heteroaryl; "Monosubstituted or polysubstituted" in each case independently, independently of each other, -F, -Cl, -Br, -I, -CN, -C 1-6 -alkyl, -CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-6 -Alkylene-CF 3 ,-C 1-6 -Alkylene-CF 2 H, -C 1-6 -alkylene-CFH 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 ,-C 1-6 -alkylene-N(C 1-6 -alkyl)-C 1-6 -Alkylene-CF 3 , -C(=O)-C 1-6 -alkyl, -C 1-6 -alkylene-C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C 1-6 -alkylene-C(=O)-OH, -C(=O)-OC 1-6 -alkyl, -C 1-6 -alkylene-C(=O)-OC 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)-NH 2 ,-C 1-6 -alkylene-C(=O)-NH 2 , -C(=O)-NH(C 1-6 -alkyl), -C 1-6 -alkylene-C(=O)-NH(C 1-6 -alkyl), -C(=O)-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-C(=O)-N(C 1-6 -alkyl) 2 , -C(=O)-NH(OH), -C 1-6 -Alkylene-C(=O)-NH(OH), -OH, -C 1-6 -alkylene-OH, =O, -OCF 3 ,-OCF 2 H, -OCFH 2 ,-OCF 2 Cl, -OCFCl 2 ,-O-C 1-6 -alkyl, -C 1-6 -alkylene-O-C 1-6 -alkyl, -O-C 1-6 -alkylene-O-C 1-6 -alkyl, -O-C 1-6 -alkylene-NH 2 ,-O-C 1-6 -alkylene-NH-C 1-6 -Alkyl, -O-C 1-6 -alkylene-N(C 1-6 -alkyl) 2 , -O-C(=O)-C 1-6 -alkyl, -C 1-6 -alkylene-O-C(=O)-C 1-6 -Alkyl, -O-C(=O)-O-C 1-6 -alkyl, -C 1-6-Alkylene-O-C(=O)-O-C 1-6 -Alkyl, -O-C(=O)-NH(C 1-6 -alkyl), -C 1-6 -Alkylene-O-C(=O)-NH(C 1-6 -Alkyl), -O-C(=O)-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-O-C(=O)-N(C 1-6 -alkyl) 2 , -O-S(=O) 2 -NH 2 ,-C 1-6 -alkylene-O-S(=O) 2 -NH 2 , -O-S(=O) 2 -NH(C 1-6 -alkyl), -C 1-6 -alkylene-O-S(=O) 2 -NH(C 1-6 -alkyl), -O-S(=O) 2 -N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-O-S(=O) 2 -N(C 1-6 -alkyl) 2 ,-NH 2 ,-NO,-NO 2 ,-C 1-6 -alkylene-NH 2 , -NH(C 1-6 -alkyl), -C 1-6 -alkylene-NH(C 1-6 -alkyl), -N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-N(C 1-6 -alkyl) 2 , -NH-C(=O)-C 1-6 -alkyl, -C 1-6 -alkylene-NH-C(=O)-C 1-6 -Alkyl, -NH-C(=O)-O-C 1-6 -alkyl, -C 1-6 -alkylene-NH-C(=O)-O-C 1-6 -Alkyl, -NH-C(=O)-NH 2 ,-C 1-6 -alkylene-NH-C(=O)-NH 2 , -NH-C(=O)-NH(C 1-6 -alkyl), -C 1-6 -alkylene-NH-C(=O)-NH(C 1-6 -alkyl), -NH-C(=O)-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-C(=O)-N(C 1-6 -alkyl) 2 , -N(C 1-6 -Alkyl)-C(=O)-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -Alkyl)-C(=O)-C 1-6 -Alkyl, -N(C 1-6 -Alkyl)-C(=O)-O-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -Alkyl)-C(=O)-O-C 1-6 -Alkyl, -N(C 1-6 -Alkyl)-C(=O)-NH 2 ,-C 1-6 -alkylene-N(C 1-6 -Alkyl)-C(=O)-NH 2 , -N(C 1-6 -alkyl)-C(=O)-NH(C 1-6 -alkyl), -C 1-6 -alkylene-N(C 1-6 -alkyl)-C(=O)-NH(C 1-6 -alkyl), -N(C 1-6 -Alkyl)-C(=O)-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-N(C 1-6 -Alkyl)-C(=O)-N(C 1-6 -alkyl) 2 , -NH-S(=O) 2 OH, -C 1-6 -alkylene-NH-S(=O) 2 OH, -NH-S(=O) 2 -C 1-6 -alkyl, -C 1-6 -alkylene-NH-S(=O) 2 -C 1-6 -Alkyl, -NH-S(=O) 2 -O-C 1-6 -alkyl, -C 1-6 -alkylene-NH-S(=O) 2 -O-C 1-6 -Alkyl, -NH-S(=O) 2 -NH 2 ,-C 1-6 -alkylene-NH-S(=O) 2 -NH 2 , -NH-S(=O) 2 -NH(C 1-6 -alkyl), -C 1-6 -alkylene-NH-S(=O) 2 -NH(C 1-6 -alkyl), -NH-S(=O) 2 N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-S(=O) 2 N(C 1-6 -alkyl) 2 , -N(C 1-6 -Alkyl)-S(=O) 2 -OH, -C 1-6 -alkylene-N(C 1-6 -Alkyl)-S(=O) 2 -OH, -N(C 1-6 -Alkyl)-S(=O) 2 -C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -Alkyl)-S(=O) 2 -C 1-6 -Alkyl, -N(C 1-6 -Alkyl)-S(=O) 2 -O-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -Alkyl)-S(=O) 2 -O-C 1-6 -Alkyl, -N(C 1-6 -Alkyl)-S(=O) 2 -NH 2 ,-C 1-6 -alkylene-N(C 1-6 -Alkyl)-S(=O) 2 -NH 2 , -N(C 1-6 -Alkyl)-S(=O) 2 -NH(C 1-6 -alkyl), -C 1-6 -alkylene-N(C 1-6 -Alkyl)-S(=O) 2 -NH(C 1-6 -alkyl), -N(C 1-6 -Alkyl)-S(=O) 2 -N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-N(C 1-6 -Alkyl)-S(=O) 2 -N(C 1-6 -alkyl) 2 , -SH, =S, -SF 5 ,-SCF 3 ,-SCF 2 H, -SCFH 2 ,-S-C 1-6 -alkyl, -C 1-6 -Alkylene-S-C 1-6 -Alkyl, -S(=O)-C 1-6 -alkyl, -C 1-6 -alkylene-S(=O)-C 1-6 -Alkyl, -S(=O) 2 -C 1-6 -alkyl, -C 1-6 -alkylene-S(=O) 2 -C 1-6 -Alkyl, -S(=O) 2 -OH, -C 1-6 -alkylene-S(=O) 2 -OH, -S(=O) 2 -O-C 1-6 -alkyl, -C 1-6 -alkylene-S(=O) 2 -O-C 1-6 -Alkyl, -S(=O) 2 -NH 2 ,-C 1-6 -alkylene-S(=O) 2 -NH 2 , -S(=O) 2 -NH(C 1-6 -alkyl), -C 1-6 -alkylene-S(=O) 2 -NH(C 1-6 -Alkyl), -S(=O) 2 -N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-S(=O) 2 -N(C 1-6 -alkyl) 2 , 3-14 membered cycloalkyl, -C 1-6 -Alkylene-(3-14 membered cycloalkyl), 3-14 membered heterocycloalkyl, -C 1-6 -alkylene-(3-14 membered heterocycloalkyl), -phenyl, -C 1-6 -alkylene-phenyl, 5-14 membered heteroaryl, -C 1-6-Alkylene-(5-14 membered heteroaryl), -O-(3-14 membered cycloalkyl), -O-(3-14 membered heterocycloalkyl), -O-phenyl, -O-(5-14 membered heteroaryl), -C(=O)-(3-14 membered cycloalkyl), -C(=O)-(3-14 membered heterocycloalkyl), -C(=O)-phenyl, -C(= O)-(5-14 membered heteroaryl), -S(=O) 2 -(3-14 membered cycloalkyl), -S(=O) 2 -(3-14 membered heterocycloalkyl), -S(=O) 2 -Phenyl, -S(=O) 2 -(5-14 membered heteroaryl) means substituted with one or more substituents, for example, one, two, three, four, or more.
[0014] In a preferred embodiment of the benzofuran derivative according to the invention, (a-1)Q is -OR 2 represents R 1 But -CH 2 F, -CHF 2 ,-CF 3 , or represents -CN, and / or (a-2)Q is -OR 2 represents R 5 and R 5 ’ does not represent -H and R 9 ,R 10 ,R 11 ,R 12 , and R 13 at least one of them does not represent -H and / or (a-3)Q is -OR 2 represents R 8 does not represent -H, or (b-1)Q is -NR 3 R 4 represents R 1 But -CH 2 F, -CHF 2 ,-CF 3 , or represents -CN, and / or (b-2)Q is -NR 3 R 4 represents R 9 ,R 10 ,R 11 ,R 12 , and R 13 provided that at least one of them does not represent -H and the following compounds are excluded: [ka] and / or (b-3)Q is -NR 3 R 4 represents R 5 and R 5 ’ does not represent -H and / or (b-4)Q is -NR 3 R 4 represents R 6 ,R 7 , and R 8 provided that at least one of them does not represent -H and the following compounds are excluded: [ka] and / or (b-5)Q is -NR 3 R 4 represents R 3 represents -H and R 9 ,R 10 ,R 11 ,R 12 , and R 13 at least one of them does not represent -H and R 4 but, a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, optionally connected through -heteroalkylene-, in each case saturated or unsaturated; a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered heterocycloalkyl, wherein the 3- to 14-membered heterocycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl, optionally connected through -heteroalkylene-, in each case saturated or unsaturated; An unsubstituted, monosubstituted or polysubstituted 6- to 14-membered aryl, wherein the 6- to 14-membered aryl is -C 1 -C 6 -alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 6- to 14-membered aryl; an unsubstituted, monosubstituted or polysubstituted 5- to 14-membered heteroaryl, wherein the 5- to 14-membered heteroaryl is -C 1 -C 6 -alkylene- or -C 1 -C 6 optionally connected through -heteroalkylene-, and in each case represents a saturated or unsaturated, unsubstituted, mono- or polysubstituted 5- to 14-membered heteroaryl.
[0015] In a preferred embodiment of the benzofuran derivative according to the invention, T represents -O- and U represents -CR 5 R 5 ’-represents. According to this embodiment, the benzofuran derivative according to the invention is a compound of formula (II), its stereoisomers, physiologically acceptable salts, solvates and / or polymorphs. [ka]
[0016] In a preferred embodiment of the benzofuran derivative according to the invention, Q is -NR 3 R 4 represents.
[0017] In another preferred embodiment of the benzofuran derivative according to the invention, Q is -OR 2 represents.
[0018] In a preferred embodiment of the benzofuran derivative according to the invention, R 1 teeth, -H, -F, -Cl, -Br, -I, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 - 6 -Alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted -O-C 1 - 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C(=O)C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C(=O)OC 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C(=O)NHC 1-6 -alkyl, Saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted -C(=O)N(C 1-6 -alkyl) 2 , Saturated or unsaturated, unsubstituted, mono- or polysubstituted -S(=O)C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -S(=O) 2 -C 1 - 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -heteroalkyl, A saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 optionally connected through -heteroalkylene-, and in each case represents a saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl.
[0019] Preferably, R 1 -H, -F, -Cl, -Br, -I, -C 1-6 -alkyl, -O-C 1-6 -alkyl, -C 1-6 -alkylene-O-C 1-6 -alkyl, -C 1-6 -alkylene-NH(C 1-6 -alkyl), -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-6 -Alkylene-CF 3 ,-C 1-6 -Alkylene-CF 2 H, -C 1-6 -alkylene-CFH 2 ,-C 1-6 -alkylene-NH-C1-6 -Alkylene-CF 3 ,-C 1-6 -alkylene-N(C 1-6 -alkylene)-C 1-6 -Alkylene-CF 3 , -C(=O)C 1-6 -Alkyl, -C(=O)OC 1-6 -Alkyl, -C(=O)NHC 1-6 -Alkyl, -C(=O)N(C 1-6 -alkyl) 2 , -S(=O)-C 1-6 -Alkyl, -S(=O) 2 -C 1-6 -Alkyl, -O-C 1 - 6 -Alkyl, unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, or unsubstituted cyclohexyl.
[0020] Preferably, R 1 -H, -C 1-6 -alkyl, -C 1-6 -alkylene-O-C 1-6 -alkyl, -CH 2 F, -CHF 2 ,-CF 3 , or unsubstituted cyclopentyl. Preferably, R 1 is -CH 3 represents.
[0021] Preferably, R 1 is -CH 2 F, -CHF 2 ,-CF 3 , or -CN. Preferably, R 1 is -C(=O)NH 2 or-CHF 2 represents.
[0022] In a preferred embodiment of the benzofuran derivative according to the invention, R 1 is not -H.
[0023] Preferably, R 1 -H, -C 1-3 -alkyl, -CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-3 -Alkylene-CF 3 ,-C 1-3 -Alkylene-CF 2 H or -C 1-3 -alkylene-CFH 2 , more preferably -CH 3 - represents.
[0024] In a preferred embodiment of the benzofuran derivative according to the invention, R 2 teeth, -H, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -heteroalkyl, a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl; a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered heterocycloalkyl, wherein the 3- to 14-membered heterocycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 optionally connected through -heteroalkylene-, and in each case represents a saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl.
[0025] Preferably, R 2 -H, -C 1-6 -alkyl, -C 1-6 -alkylene-O-C 1-6 -alkyl, -C 1-6 -alkylene-NH(C 1-6 -alkyl), -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-6 -Alkylene-CF 3 ,-C 1-6 -Alkylene-CF 2 H, -C 1-6 -alkylene-CFH 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , or -C 1-6 -alkylene-N(C 1-6 -alkyl)-C 1-6 -Alkylene-CF 3 represents.
[0026] Preferably, R 2 is -H or -C 1-6 -Represents alkyl.
[0027] In a preferred embodiment of the benzofuran derivative according to the invention, R 3 teeth, -H, -OH, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -alkyl, or Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -Heteroalkyl.
[0028] Preferably, R 3 is -H, -OH, -C 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-C(=O)-NH 2 ,-C 1-6 -alkylene-O-C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH(C 1-6 -alkyl), -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-6 -Alkylene-CF 3 ,-C 1-6 -Alkylene-CF 2 H, -C 1-6 -alkylene-CFH 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , or -C 1-6 -alkylene-N(C 1-6 -alkyl)-C 1-6 -Alkylene-CF 3 represents. More preferably, R 3 is -H, -OH, -C 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH(C 1-6 -alkyl), -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-6 -Alkylene-CF 3 ,-C 1-6 -Alkylene-CF 2 H, -C 1-6 -alkylene-CFH 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , or -C 1-6 -alkylene-N(C 1-6 -alkyl)-C 1-6 -Alkylene-CF 3 represents.
[0029] Preferably, R 3 is -H, -OH, or -C saturated, unsubstituted, or monosubstituted with -OH 1-6 -Represents alkyl. Preferably, R 3 represents -H.
[0030] Preferably, R 3 represents -H and R 4 represents a residue other than -H.
[0031] In a preferred embodiment of the benzofuran derivative according to the invention, R 4 teeth, -H, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -S(=O)C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -S(=O) 2 -C 1 - 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -heteroalkyl, a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, optionally connected through -heteroalkylene-, in each case saturated or unsaturated; a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered heterocycloalkyl, wherein the 3- to 14-membered heterocycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl, optionally connected through -heteroalkylene-, in each case saturated or unsaturated, An unsubstituted, monosubstituted or polysubstituted 6- to 14-membered aryl, wherein the 6- to 14-membered aryl is -C 1 -C 6 -alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 6- to 14-membered aryl; an unsubstituted, monosubstituted or polysubstituted 5- to 14-membered heteroaryl, wherein the 5- to 14-membered heteroaryl is -C 1 -C 6 -alkylene- or -C 1 -C 6 optionally connected through -heteroalkylene-, and in each case represents a saturated or unsaturated, unsubstituted, mono- or polysubstituted 5- to 14-membered heteroaryl.
[0032] Preferably, R 4 teeth, saturated or unsaturated, unsubstituted, independently of each other, -F, -Cl, -C 1-6 -alkyl, -C 1-6 -Alkylene-CF 3 , -OH, =O, -OC 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -NH 2 ,-NHC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 , -NHC(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl)C(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NHC(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -alkyl), -C(=O)N(C 1-6 -alkyl) 2 , -S(=O) 2 C 1-6 -alkyl, -phenyl, -C 1-6 -alkylene-phenyl, saturated or unsaturated, unsubstituted 3- to 14-membered heterocycloalkyl, and unsubstituted 5- to 14-membered heteroaryl, mono- or polysubstituted; Yes, -S(=O) 2 C 1-6 -alkyl, -S(=O) 2 (3-14 membered cycloalkyl), wherein the 3-14 membered cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, in each case saturated or unsaturated; Unsubstituted, independently of each other, -F, -Cl, -C 1-6 -alkyl, -C 1-6 -Alkylene-CF 3 , -OH, =O, -OC 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -NH 2 ,-NHC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 , -NHC(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl)C(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NHC(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -alkyl), -C(=O)N(C 1-6 -alkyl) 2 ,S(=O) 2 C 1-6 -alkyl, -phenyl, -C 1-6 -alkylene-phenyl, saturated or unsaturated, unsubstituted 3- to 14-membered heterocycloalkyl, and unsubstituted 5- to 14-membered heteroaryl, mono- or polysubstituted; Yes, -S(=O) 2 (3-14 membered cycloalkyl), Saturated or unsaturated, unsubstituted, independently of each other, -F, -Cl, -C 1-6 -alkyl, -C 1-6 -alkylene-CF 3 , -OH, =O, -OC 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -NH 2 ,-NHC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 , -NHC(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl)C(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NHC(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-C 1-6 -alkylene-CF 3 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -alkyl), -C(=O)N(C 1-6 -alkyl) 2 , -S(=O) 2 C 1-6 -alkyl, -phenyl, -C 1-6 -alkylene-phenyl, saturated or unsaturated, unsubstituted 3- to 14-membered heterocycloalkyl, and unsubstituted 5- to 14-membered heteroaryl, mono- or polysubstituted; Yes, -C 1-6 -alkyl, 3-14 membered cycloalkyl or -C 1-6 -alkylene-(3-14 membered cycloalkyl), -C 1-6-alkylene- is unsubstituted or monosubstituted with -OH, and the 3- to 14-membered cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, in each case saturated or unsaturated, in each case unsubstituted, independently of each other, -F, -Cl, -C 1-6 -alkyl, -C 1-6 -Alkylene-CF 3 , -OH, =O, -OC 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -NH 2 ,-NHC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 , -NHC(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl)C(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NHC(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -alkyl), -C(=O)N(C 1-6 -alkyl) 2 , -S(=O) 2 C 1-6 -alkyl, -phenyl, -C 1-6 -alkylene-phenyl, saturated or unsaturated, unsubstituted 3- to 14-membered heterocycloalkyl, and unsubstituted 5- to 14-membered heteroaryl, mono- or polysubstituted; 3-14 membered cycloalkyl or -C 1-6 -alkylene-(3-14 membered cycloalkyl), 3-14 membered heterocycloalkyl or -C 1-6 -alkylene-(3-14 membered heterocycloalkyl), -C 1-6 -alkylene- is unsubstituted or monosubstituted with -OH, and the 3- to 14-membered heterocycloalkyl is in each case azepane, 1,4-oxazepane, 1,4-oxazepane, azetane , azetidine, aziridine, azocane, diazepane, dioxane, dioxolane, dithiane, dithiolane, imidazolidine, isothiazolidine, isoxalidine, morpholine, oxazolidine, oxepane, oxetane, oxirane, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, Tetrahydrothiopyran, thiazolidine, thietane, thiirane, thiolane, thiomorpholine, indoline, dihydrobenzofuran, dihydrobenzothiophene, 1,1-dioxothiacyclohexane, 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, 7-Azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, hexahydro-1H-pyrrolidine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c] pyrrole, and octahydropyrrolo[1,2-a]pyrazine, in each case unsubstituted, independently of each other, -F, -Cl, -C 1-6 -alkyl, -C 1-6 -Alkylene-CF 3 , -OH, =O, -OC 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -NH 2 ,-NHC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 , -NHC(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl)C(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NHC(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -alkyl), -C(=O)N(C 1-6 -alkyl) 2 , -S(=O) 2 C 1-6 -alkyl, -phenyl, -C 1-6 -alkylene-phenyl, saturated or unsaturated, unsubstituted 3- to 14-membered heterocycloalkyl, and unsubstituted 5- to 14-membered heteroaryl, mono- or polysubstituted; 3-14 membered heterocycloalkyl or -C 1-6 -alkylene-(3-14 membered heterocycloalkyl), Unsubstituted, independently of each other, -F, -Cl, -CN, -C 1-6 -alkyl, -C 1-6 -Alkylene-CF 3 , -OH, =O, -OC 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -NH 2 ,-NHC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 , -NHC(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl)C(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NHC(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -alkyl), -C(=O)N(C 1-6 -alkyl) 2 , -S(=O) 2 C 1-6 -alkyl, -phenyl, -C 1-6 -alkylene-phenyl, saturated or unsaturated, unsubstituted 3- to 14-membered heterocycloalkyl, and unsubstituted 5- to 14-membered heteroaryl, mono- or polysubstituted; There, -phenyl, 5-14 membered heteroaryl or -C 1-6 -alkylene-(5-14 membered heteroaryl), -C 1-6 -alkylene- is unsubstituted or monosubstituted with -OH, and the 5- to 14-membered heteroaryl is, in each case, benzimidazole, benzisoxazole, benzazole, benzodioxole, benzofuran, benzothiadiazole , benzothiazole, benzothiophene, carbazole, shinoline, dibenzofuran, furan, furazane, imidazole, imidazopyridine, indazole, indole, indolizine, isobenzofuran, isoindole, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, Oxindole, phthalazine, purine, pyrazine, pyrazole, pyridazine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazine, triazole, and [1,2,4]triazolo[4,3-a] ]pyrimidine, in each case unsubstituted, independently of each other, -F, -Cl, -CN, -C 1-6 -alkyl, -C 1-6 -Alkylene-CF 3 , -OH, =O, -OC 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -NH 2 ,-NHC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 , -NHC(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl)C(=O)O-C1-6 -alkyl, -C 1-6 -alkylene-NHC(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -alkyl), -C(=O)N(C 1-6 -alkyl) 2 , -S(=O) 2 C 1-6 -alkyl, -phenyl, -C 1-6 -alkylene-phenyl, saturated or unsaturated, unsubstituted 3- to 14-membered heterocycloalkyl, and unsubstituted 5- to 14-membered heteroaryl, mono- or polysubstituted; 5-14 membered heteroaryl or -C 1-6 -Alkylene-(5- to 14-membered heteroaryl).
[0033] Preferably, R 4 teeth, -H, Saturated, unsubstituted, mono- or polysubstituted with -F, -S(=O) 2 C 1-6 -alkyl, saturated, unsubstituted, -S(=O) 2 (3-14 membered cycloalkyl), Saturated, unsubstituted, independently of each other, -OH, =O, -OC 1-6 -alkyl, -NH 2 ,-NHC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkyl, -C(=O)NH 2 , -C(=O)-NH-C 1-3 -Alkyl, -C(=O)-N(C 1-3 -alkyl) 2 , or unsubstituted -phenyl, -C 1-6 -alkyl, 3-14 membered cycloalkyl or -C 1-6 -alkylene-(3-14 membered cycloalkyl), -C 1-6 -alkylene- is unsubstituted or monosubstituted with -OH, and the 3- to 14-membered cycloalkyl is saturated, unsubstituted, independently of each other, -C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 ,-C 1-6 -alkylene-OH, -C 1-6 -alkylene-NHC(=O)O-C 1-6 -alkyl, -OH, -OC 1-6 -alkyl, -NH 2 , -N(C 1-6 -alkyl) 2 , -NHC(=O)O-C 1-6 -3- to 14-membered cycloalkyl or -C mono- or di-substituted with a substituent selected from the group consisting of -alkyl 1-6 -alkylene-(3-14 membered cycloalkyl), 3-14 membered heterocycloalkyl or -C 1-6 -alkylene-(3-14 membered heterocycloalkyl), -C 1-6 -alkylene- is unsubstituted or monosubstituted with -OH, and the 3- to 14-membered heterocycloalkyl is in each case azetane, 1,4-oxazepane, pyrrolidine, piperidine, azepane, diazepane. , tetrahydrofuran, tetrahydropyran, oxetane, morpholine, piperazine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, octahydro-pyrrolo[1,2-a]pyrazine, 8-azabicyclo[3.2.1] Octane, 9-azabicyclo[3.3.1]nonane, quinuclidine, hexahydro-1H-pyrrolidine, 2-oxaspiro[3.3]heptane, 2-azaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 1,1-dioxo selected from thiacyclohexane, in each case unsubstituted, independently of each other, -F, -OH, =O, -C 1-6 -alkyl, -C 1-6 -Alkylene-CF 3 ,-C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -NH 2 , -N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-N(C 1-6 -alkyl) 2 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -Alkyl), -S(=O) 2 C 1-6 -alkyl, oxetanyl, pyrimidinyl, -C 1-6 3- to 14-membered heterocycloalkyl or -C mono- or polysubstituted with a substituent selected from the group consisting of -alkylene-phenyl 1-6 -alkylene-(3-14 membered heterocycloalkyl), unsubstituted phenyl, 5-14 membered heteroaryl or -C 1-6 -alkylene-(5-14 membered heteroaryl), -C 1-6 -alkylene- is unsubstituted or monosubstituted with -OH, and the 5-14 membered heteroaryl is in each case pyridine, pyridazine, pyrazine, pyrazole, isoxazole, triazole, and [1, 2,4]triazolo[4,3-a]pyrimidine, in each case unsubstituted, independently of each other, -C 1-6 5- to 14-membered heteroaryl or -C mono- or polysubstituted with a substituent selected from the group consisting of -alkyl, -OH 1-6 -Alkylene-(5- to 14-membered heteroaryl).
[0034] In a preferred embodiment of the benzofuran derivative according to the invention, R 3 and R 4 together contain 1 or 2 heteroatoms selected from N, O, and S, saturated or unsaturated, unsubstituted, or mono- or polysubstituted 5- or 6-membered form a membered heterocycle.
[0035] Preferably, R 3 and R 4 together form a heterocycle selected from the group consisting of pyrrolidine, piperidine, morpholine, and piperazine, in each case unsubstituted or independently of each other, -C 1-6 -alkyl, -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(=O)NH-C 1-6 -Alkyl, -C(=O)N(C 1-6 -alkyl) 2 , -C(=O)O-C 1-6 -Alkyl, -NHC(=O)O-C 1-6 -alkyl, unsubstituted -pyridyl, and unsubstituted, or -C 1-6 - mono- or polysubstituted with a substituent selected from the group consisting of 1,2,4-oxadiazole, which is monosubstituted with alkyl.
[0036] Preferably, R 3 and R 4 together, Unsubstituted, or -N(CH 3 ) 2 a pyrrolidine ring, monosubstituted with unsubstituted or -C 1-6 -alkyl, -NH 2 , -N(CH 3 ) 2 , -C(=O)NH-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkyl, -NHC(=O)O-C 1-6 -alkyl, and unsubstituted, or -C 1-6 - a piperidine ring monosubstituted with a substituent selected from the group consisting of 1,2,4-oxadiazole monosubstituted with alkyl, an unsubstituted morpholine ring, or unsubstituted or -C 1-6 forming a piperidine ring, N-substituted with a substituent selected from the group consisting of -alkyl and unsubstituted -pyridyl.
[0037] In a preferred embodiment, R 3 and R 4 Both do not represent -H. In a preferred embodiment, R3 and R 4 together with the nitrogen atom to which they are attached form a residue selected from the group consisting of: [ka]
[0038] In other preferred embodiments, R 3 represents -H and R 4 does not represent -H.
[0039] In a preferred embodiment, R 3 represents -H and R 4 is saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted -C 1 -C 6 -Represents alkyl. In a preferred embodiment, R 3 represents -H and R 4 represents a residue selected from the group consisting of: [ka]
[0040] In a preferred embodiment, R 3 represents -H and R 4 is the residue -CR’R’’-(CH 2 ) m -OH, in the formula, m is an integer of 1 to 6, preferably 1 to 3, and R' and R'' are, independently of each other, -H, -C 1-3 -alkyl, -CF 3 ,-CF 2 H, -CFH 2 ,-C 1-3 -Alkylene-CF 3 ,-C 1-3 -Alkylene-CF 2 H, -C 1-3 -alkylene-CFH 2 ,-C 1-3 -alkylene-O-C 1-3 -alkyl, -C 1-3 -alkylene-OH, -C(=O)-NH 2 , -C(=O)-NH-C 1-3 -Alkyl, or -C(=O)-N(C 1-3 -alkyl) 2 , preferably -H, -CH 3 ,-C 1-3 -alkylene-OH, C(=O)-NH 2 , -C(=O)-NH-C 1-3 -Alkyl, or -C(=O)-N(C 1-3 -alkyl) 2 represents. In a preferred embodiment, at least R' or R'' does not represent -H. In a preferred embodiment, neither R' nor R'' represents -H.
[0041] In other preferred embodiments, R 3 represents -H and R 4 represents saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, or saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl. represent.
[0042] In a preferred embodiment, R 3 represents -H and R 4 represents saturated or unsaturated, unsubstituted, mono- or polysubstituted 3-membered cycloalkyl, or saturated or unsaturated, unsubstituted, mono- or polysubstituted 3-membered heterocycloalkyl. In a preferred embodiment, R 3 represents -H and R 4 represents a residue selected from the group consisting of: [ka]
[0043] In a preferred embodiment, R 3 represents -H and R 4 is saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl (preferably 4-membered cycloalkyl), or saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted represents a 3- to 14-membered heterocycloalkyl (preferably a 4-membered heterocycloalkyl). In a preferred embodiment, R 3 represents -H and R 4 represents a residue selected from the group consisting of: [ka]
[0044] In a preferred embodiment, R 3 represents -H and R 4 represents a residue according to general formula (A), [ka] During the ceremony, m A is 0 or 1, Y A , -O-, -NR A6 -, and -CR A7 R A8 - selected from; R A1 ,R A2 ,R A3 ,R A4 ,R A5 ,R A6 ,R A7 , and R A8 are, independently of each other, -H, -F, -C 1-3 -alkyl, -C 1-3 -alkylene-OH, -C 1-3 -alkylene-NH 2 ,-C 1-3 -alkylene-NH(C 1-3 -alkyl), -C 1-3 -alkylene-N(C 1-3 -alkyl) 2 ,-C 1-3 -alkylene-NH(C 1-3 -Alkylene-CF 3 ), -C 1-3 -alkylene-C(=O)NH 2 ,-C 1-3 -alkylene-NH-C(=O)OC 1-4 -Alkyl, -C(=O)NH 2 , -C(=O)-NH-C 1-3 -Alkyl, -C(=O)-N(C 1-3 -alkyl) 2 , or represents -3-oxetanyl, or R A7 and R A8 together with the carbon atoms to which they are attached form a ring, -CH 2 OCH 2 -,-CH 2 OCH 2 CH 2 -or-CH 2 CH 2 OCH 2 CH 2 -,-CH 2 NHCH 2 -,-CH 2 NHCH 2 CH 2 -or-CH 2 CH 2 NHCH 2 CH 2 - represents.
[0045] In a preferred embodiment, R 3 represents -H and R 4 represents a residue according to the general formula (A) defined above, m A is 0 or 1, Y A , -O- and -CR A7 R A8 - selected from; R A1 ,R A2 ,R A3 ,R A4 ,R A5 ,R A7 , and R A8 are, independently of each other, -H, -C 1-3 -alkylene-OH, -C 1-3 -alkylene-N(C 1-3 -alkyl) 2 , or -C(=O)NH 2 , preferably R A1 ,R A2 ,R A3 ,R A4 ,R A5 ,R A7 , and R A8 provided that only one of them represents a residue that is not -H.
[0046] In a preferred embodiment, R 3 represents -H and R 4 represents a residue according to the general formula (A) defined above, m A is 0 or 1, Y A , -O- and -CR A7 R A8 - selected from; R A1 But -C 1-3 -alkylene-OH, -C 1-3 -alkylene-N(C 1-3 -alkyl) 2 , or -C(=O)NH 2 represents, R A2 ,R A3 ,R A4 ,R A5 ,R A7 , and R A8 represents -H.
[0047] In a preferred embodiment, R 3 represents -H and R 4 is saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl (preferably 5-membered cycloalkyl), or saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted represents a 3- to 14-membered heterocycloalkyl (preferably a 5-membered heterocycloalkyl), or an unsubstituted, mono- or polysubstituted 5- to 14-membered heteroaryl (preferably a 5-membered heteroaryl). In a preferred embodiment, R 3 represents -H and R 4 represents a residue selected from the group consisting of: [ka]
[0048] In a preferred embodiment, R 3 represents -H and R 4 represents a residue according to general formula (B), [ka] During the ceremony, Y B , -O-, -NR B8 -, and -CR B9 R B10 - selected from; R B1 ,R B2 ,R B3 ,R B4 ,R B5 ,R B6 ,R B7 ,R B8 ,R B9 , and R B10 are, independently of each other, -H, -F, -OH, -C(=O)-NH 2 , -C(=O)-NH-C 1-3 -Alkyl, -C(=O)-N(C 1-3 -alkyl) 2 ,-C 1-3 -alkyl, -C 1-3 -alkylene-OH, -C 1-3 -alkylene-O-C 1-3 -alkyl, -C 1-3 -Alkylene-CF 3 ,-C 1-3 -alkylene-CO 2 H or -C 1-3 -Alkylene-C(=O)O-C 1-3 -represents alkyl or R B2 and R B3 together represent =O or R B4 and R B5 together represent =O.
[0049] In a preferred embodiment, R 3 represents -H and R 4 represents a residue according to the general formula (B) defined above, Y B , -O- and -NR B8 - selected from; R B1 ,R B2 ,R B3 ,R B4 ,R B5 ,R B6 ,R B7 ,R B8 but, independently of each other, -H, -F, -C 1-3 -alkyl, -C 1-3 -alkylene - OH, -C 1-3 -Alkylene-CF 3 , or -C(=O)-NH 2 or R B2 and R B3 together represent =O or R B4 and R B5 together represent =O or, preferably, R A1 ,R A2 ,R A3 ,R A4 ,R A5 ,R A7 , and R A8 with the proviso that only one, two or three of them represent residues that are not -H, preferably R A1 ,R A2 ,R A3 ,R A4 ,R A5 ,R A7 , and R A8 at least one of them represents a residue that is not -H.
[0050] In a preferred embodiment, R 3 represents -H and R 4 is saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl (preferably 6-membered cycloalkyl), or saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted Substituted 3- to 14-membered heterocycloalkyl (preferably 6-membered heterocycloalkyl), or unsubstituted, mono- or polysubstituted 6- to 14-membered aryl (preferably 6-membered aryl), or unsubstituted monosubstituted 6- to 14-membered aryl (preferably 6-membered aryl), Represents a substituted or polysubstituted 5- to 14-membered heteroaryl (preferably a 6-membered heteroaryl). In a preferred embodiment, R 3 represents -H and R 4 represents a residue selected from the group consisting of: [ka]
[0051] In a preferred embodiment, R 3 represents -H and R 4 represents a residue according to general formula (C), [ka] During the ceremony, Y C1 , -O-, -S(=O) 2 -, -NR C8 -, and -CR C9 R C10 - selected from or Y C2 But -CR C11 R C12 - or Y C1 But -CR C9 R C10 - represents Y C2 , -O-, -S(=O) 2 -, and -NR C8 - selected from; R C1 ,R C2 ,R C3 ,R C4 ,R C5 ,R C6 ,R C7 ,R C8 ,R C9 ,R C10 ,R C11 , and R C12 but independently of each other, -H, -F, -OH, -C(=O)OC 1-3 -alkyl, -NH 2 , -NH(C 1-3 -alkyl), -N(C 1-3 -alkyl) 2 ,-C 1-3 -alkyl, -C 1-3 -alkylene-OH, -C 1-3 -Alkylene-CF 3 , -C(=O)-NH 2 , -C(=O)-NH-C 1-3 -Alkyl, or -C(=O)N-(C 1-3 -alkyl) 2 or R C2 and R C3 together represent =O or R C4 and R C5 together represent =O or R C9 and R C10 together represent =O or R C11 and R C12 together represent =O.
[0052] In a preferred embodiment, R 3 represents -H and R 4 represents a residue according to the general formula (C) defined above, Y C1 is -O- or -NR C8 - selected from Y C2 But -CR C11 R C12 - or Y C1 But -CR C9 R C10 - represents Y C2 , -O- and -NR C8 - selected from; R C1 ,R C2 ,R C3 ,R C4 ,R C5 ,R C6 ,R C7 ,R C8 ,R C9 ,R C10 ,R C11 , and R C12 but, independently of each other, -H, -F, -C 1-3 -alkyl, -C 1-3 -alkylene - OH, or -C(=O)-NH 2 or preferably, R C1 ,R C2 ,R C3 ,R C4 ,R C5 ,R C6 ,R C7 ,R C8 ,R C9 ,R C10 ,R C11 , and R C12with the proviso that only one, two or three of them represent residues that are not -H, preferably R C1 ,R C2 ,R C3 ,R C4 ,R C5 ,R C6 ,R C7 ,R C8 ,R C9 ,R C10 ,R C11 , and R C12 at least one of them represents a residue that is not -H.
[0053] In a preferred embodiment, R 3 represents -H and R 4 represents saturated or unsaturated, unsubstituted, mono- or polysubstituted 7-membered cycloalkyl, or saturated or unsaturated, unsubstituted, mono- or polysubstituted 7-membered heterocycloalkyl. In a preferred embodiment, R 3 represents -H and R 4 represents the following residues. [ka]
[0054] In a preferred embodiment, R 3 represents -H and R 4 represents a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl (preferably 4-, 5-, or 6-membered cycloalkyl), and the 3- to 14-membered cycloalkyl is Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -alkylene- or saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered heterocycloalkyl (preferably 4-, 5-, or 6-membered heterocycloalkyl); 14-membered heterocycloalkyl is saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -alkylene- or unsubstituted, mono- or polysubstituted 6- to 14-membered aryl (preferably 6-membered aryl), and the 36- to 14-membered aryl is saturated or unsaturated, unsubstituted, -C with single or multiple substitutions 1 -C 6 connected through -alkylene- or an unsubstituted, mono- or polysubstituted 5- to 14-membered heteroaryl (preferably 5- or 6-membered heteroaryl), and the 5- to 14-membered heteroaryl is saturated or unsaturated. , unsubstituted, monosubstituted or polysubstituted -C 1 -C 6 Connected through -alkylene-. In a preferred embodiment, R 3 represents -H and R 4 represents a residue selected from the group consisting of: [ka]
[0055] In a preferred embodiment, R 3 represents -H and R 4 represents a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 5-membered heterocycloalkyl; -C 1 -C 6 -alkylene- or an unsubstituted, mono- or polysubstituted 5-membered heteroaryl, and the 5-membered heteroaryl is connected through a saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 Connected through -alkylene-.
[0056] In a preferred embodiment, R 3 represents -H and R 4 represents a residue selected from the group consisting of: [ka]
[0057] In a preferred embodiment, R 3 represents -H and R 4 teeth, (i) Residue -CR’R’’-(CH 2 ) m -OH, in which m is an integer from 1 to 6, preferably an integer from 1 to 3, and R' and R'' are, independently of each other, -H, -C 1-3 -alkyl, -CF 3 ,-CF 2 H, -CFH 2 ,-C 1-3 -Alkylene-CF 3 ,-C 1-3 -Alkylene-CF 2 H, -C 1-3 -alkylene-CFH 2 ,-C 1-3 -alkylene-O-C 1-3 -alkyl or -C 1-3 -Alkylene-OH, preferably -H, -CH 3 , or -C 1-3 Residue -CR’R’’-(CH 2 ) m -Represents OH. In a preferred embodiment, at least R' or R'' does not represent -H. In a preferred embodiment, neither R' nor R'' represents -H, or (ii) a residue according to general formula (D), [ka] During the ceremony, m D and n D are, independently of each other, 0, 1, 2, or 3, preferably m D +n D Provided that ≦3, Y D1 , -O-, -S(=O) 2 -, -NR D8 -, and -CR D9 R D10 - selected from Y D2 But -CR D11 R D12 - or Y D1 But -CR D9 R D10 - represents Y D2 , -O-, -S(=O) 2 -, and -NR D8 - selected from; R D1 ,R D2 ,R D3 ,R D4 ,R D5 ,R D6 ,R D7 ,R D8 ,R D9 ,R D10 ,R D11 , and R D12 but, independently of each other, -H, -F, -OH, -C 1-3 -alkylene-OH, -C(=O)NH 2 ,-C 1-3 -alkylene-C(O)NH 2 , -C(=O)O-C 1-3 -alkyl, -NH 2 ,-C 1-3 -alkylene-NH 2 , -NH(C 1-3 -alkyl), -N(C 1-3 -alkyl) 2 , -NH(C 1-3 -Alkylene-CF 3 ), -C 1-3 -alkylene-OCH 3 ,-C 1-3 -alkyl, -C 1-3 -Alkylene-CF 3 or R D2 and R D3 together represent =O or R D4 and R D5 together represent =O or R D9 and R D10 together represent =O or R D11 and R D12 together represent =O, Preferably, m D and n D are, independently of each other, 0, 1, 2, or 3, preferably m D +n D Provided that ≦3, Y D1 , -O-, -NR D8 -, and -CR D9 R D10 - selected from Y D2 But -CR D11 R D12 - or Y D1 But -CR D9 R D10 - represents Y D2 , -O- and -NR D8 - selected from; R D1 ,R D2 ,R D3 ,R D4 ,R D5 ,R D6 ,R D7 ,R D8 ,R D9 ,R D10 ,R D11 , and R D12 but, independently of each other, -H, -F, -OH, -C 1-3 -alkylene-OH, -C(=O)NH 2 ,-CH 2 N.H. 2 ,-CH 2 N(CH 3 )2 , -NHCH 2 C.F. 3 ,-CH 3 , or -CH 2 C.F. 3 or R D2 and R D3 together represent =O or R D4 and R D5 together represent =O or R D9 and R D10 together represent =O or R D11 and R D12 together represent =O, preferably R D1 ,R D2 ,R D3 ,R D4 ,R D5 ,R D6 ,R D7 ,R D8 ,R D9 ,R D10 ,R D11 , and R D12 with the proviso that only one, two or three of them represent residues that are not -H, preferably R D1 ,R D2 ,R D3 ,R D4 ,R D5 ,R D6 ,R D7 ,R D8 ,R D9 ,R D10 ,R D11 , and R D12 at least one of them represents a residue that is not -H.
[0058] In a preferred embodiment of the benzofuran derivative according to the invention, R 5 and R 5 ’ are, independently of each other, -H, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -heteroalkyl, a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 optionally connected through -heteroalkylene-, and in each case represents a saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl.
[0059] Preferably, R 5 and R 5 ’, independently of each other, -H, -C 1 -C 6 -alkyl or -C 1 -C 6 -alkylene-N(C 1 -C 6 -alkyl) 2 shows.
[0060] In a preferred embodiment of the benzofuran derivative according to the invention, R 5 and R 5 ’ is not -H.
[0061] In a preferred embodiment of the benzofuran derivative according to the invention, R 5 and R 5 ’ are both -H.
[0062] In a preferred embodiment, T represents -O- and U represents -CR 5 R 5 ’-, the resulting part -O-CR 5 R 5 '- represents a residue selected from the group consisting of: [ka]
[0063] In a preferred embodiment, T is -CR 5 R 5 '-, U represents -O-, and the resulting part -CR 5 R 5 '-O- represents a residue. [ka]
[0064] In a preferred embodiment, R 5 represents -H and R 5 ’ is -H, -C 1-3 -alkyl, -CF 3 ,-CF 2 H, -CFH 2 ,-C 1-3 -Alkylene-CF 3 ,-C 1-3 -Alkylene-CF 2 H, -C 1-3 -alkylene-CFH 2 , and -C 1-3 -alkylene-OH, preferably -H or C 1-3 - represents a residue selected from the group consisting of alkyl.
[0065] In a preferred embodiment of the benzofuran derivative according to the invention, R 5 and R 9 together form an unsubstituted 5-6 membered carbocyclic ring, or R 5 and R 9 together form a 5-6 membered heterocycle containing one unsubstituted heteroatom O.
[0066] In a preferred embodiment of the benzofuran derivative according to the invention, R 6 ,R 7 , and R 8 are independent of each other, -H, -F, -Cl, -Br, -I, -OH, -SH, -SF 5 , -CN, -NO 2 , -C(=O)OH, -NH 2 , Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -O-C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -NHC 1-6 -alkyl, Saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted -N(C 1-6 -alkyl) 2 , Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C(=O)OC 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -OC(=O)C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1-6 -Heteroalkyl.
[0067] Preferably, R 6 ,R 7 , and R 8 but independently of each other, -H, -F, -Cl, -Br, -I, -OH, -SH, -SF 5 , -CN, -NO 2 , -C(=O)OH, -NH 2 , -C 1-6 -alkyl, -CF 3 ,-CHF 2 ,-CH 2 F, -O-C 1-6 -alkyl, -OCF 3 ,-OCHF 2 ,-OCH 2 F, Unsubstituted or independently of each other, -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 , and -C(=O)NH 2 -NHC substituted with one or more substituents selected from 1-6 -alkyl, Unsubstituted or independently of each other, -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 , and -C(=O)NH 2 -N(C 1-6 -alkyl) 2 , Unsubstituted or independently of each other, -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 , and -C(=O)NH 2 -C(=O)OC substituted with one or more substituents selected from 1-6 -alkyl, Unsubstituted or independently of each other, -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 , and -C(=O)NH 2 -OC(=O)C substituted with one or more substituents selected from 1-6 -alkyl, Unsubstituted or independently of each other, -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 , and -C(=O)NH 2 -C substituted with one or more substituents selected from 1-6 -Heteroalkyl.
[0068] In a preferred embodiment, R 6 ,R 7 , and R 8 are, independently of each other, -H, -F, -Cl, -Br, -I, -CN, C 1-3 -alkyl, -CF 3 ,-CF 2 H, and -CFH 2 , preferably represents a residue selected from the group consisting of -H or -F.
[0069] In a preferred embodiment of the benzofuran derivative according to the invention, R 6 is -H, -F, -Cl, -CN, or -C 1 -C 6 -Represents alkyl.
[0070] In a preferred embodiment, R 6 is -H, -F, -Cl, -CN, or -CH 3 , preferably -H, -F, -CN, or -CH 3 represents a residue selected from the group consisting of
[0071] In a preferred embodiment of the benzofuran derivative according to the invention, R 6 does not represent -H.
[0072] In a preferred embodiment of the benzofuran derivative according to the invention, R 7 is -H, -F, -Cl, -CN, or -C 1 -C 6 -Represents alkyl.
[0073] In a preferred embodiment of the benzofuran derivative according to the invention, R 7 does not represent -H.
[0074] In a preferred embodiment, in particular, Q is -NR 3 R 4 , then R 7 is -H, -F, -Cl, -CN, or CH 3 , preferably -H, -F, -Cl, or -CH 3 represents a residue selected from the group consisting of
[0075] In a preferred embodiment, in particular, Q is -OR 2 , then R 7 represents -H or a residue selected from the group consisting of: [ka]
[0076] In a preferred embodiment of the benzofuran derivative according to the invention, R 8 is -H, -F, -Cl, -CN, or -C 1 -C 6 -Represents alkyl.
[0077] In a preferred embodiment of the benzofuran derivative according to the invention, R 8 does not represent -H.
[0078] In a preferred embodiment, R 8 is -H, -F, -Cl, -CN, or CH 3 , preferably represents a residue selected from the group consisting of -F.
[0079] In a preferred embodiment of the benzofuran derivative according to the invention, (i)R 6 ,R 7 , and R 8 each represents -H or (ii)R 6 ,R 7 , and R 8 Two of them represent -H and R 6 ,R 7 , and R 8 the other is -F, -Cl, -CN, or -CH 3 or (iii)R 6 ,R 7 , and R 8 One of them represents -H and R 6 ,R 7 , and R 8 the other independently of each other is -F, -Cl, -CN, or -CH 3 represents.
[0080] In particularly preferred embodiments, the compound is according to general formula (I), R 1 is -CH 3 represents and / or R 3 represents -H and / or R 4 teeth, [ka] represents and / or R 6 ,R 7 , and R 8 each represents -H and / or T represents -O- and / or U is -CH 2 - represents and / or R 9 ,R 10 ,R 11 ,R 12 , and R 13 are, independently of each other, -H, -F, -Cl, -CF 3 , -CN, -CH 3 , or -O-CH 3 represents.
[0081] In a preferred embodiment of the benzofuran derivative according to the invention, R 9 ,R 10 ,R 11 ,R 12 , and R 13 are independent of each other, -H, -F, -Cl, -Br, -I, -CN, -C(=O)OH, -NH 2 ,-NO 2 , -OH, =O, -SF 5 , Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C(=O)O-C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -NHC 1-6 -alkyl, Saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted -N(C 1-6 -alkyl) 2 , Saturated or unsaturated, unsubstituted, mono- or polysubstituted -O-C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted, -S(=O) 2 -C 1 - 6 -alkyl, A saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl; a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered heterocycloalkyl, wherein the 3- to 14-membered heterocycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6optionally connected through -heteroalkylene-, and in each case represents a saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl.
[0082] Preferably, R 9 ,R 10 ,R 11 ,R 12 , and R 13 but independently of each other, -H, -OH, -F, -Cl, -Br, -I, -SH, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 , -CN, -NO 2 , -C(=O)OH, -NH 2 , or -N(CH 3 ) 2 , Saturated or unsaturated, unsubstituted, independently of each other, -F, -Cl, -Br, -I, -C 1-6 -Alkyl, C 2-6 -alkenyl, -C 2-6 -alkynyl, -OH, =O, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 ,C(=O)CHF 2 , and -C(=O)NH 2 -C mono- or polysubstituted with a substituent selected from the group consisting of 1-6 -alkyl, Saturated or unsaturated, unsubstituted, independently of each other, -F, -Cl, -Br, -I, -C 1-6 -Alkyl, C 2-6 -alkenyl, -C 2-6 -alkynyl, -OH, =O, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 ,C(=O)CHF 2 , and -C(=O)NH 2 -C mono- or polysubstituted with a substituent selected from the group consisting of 1-6 -heteroalkyl, Unsubstituted, independently of each other, -F, -Cl, -Br, -I, -C 1-6 -Alkyl, C 2-6 -alkenyl, -C 2-6 -alkynyl, -OH, =O, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 ,C(=O)CHF 2 , and -C(=O)NH 2 -OC mono- or polysubstituted with a substituent selected from the group consisting of 1-6 -alkyl, Unsubstituted, independently of each other, -F, -Cl, -Br, -I, -C 1-6 -Alkyl, C 2-6 -alkenyl, -C 2-6 -alkynyl, -OH, =O, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 ,C(=O)CHF 2 , and -C(=O)NH 2 -O(C=O)C mono- or polysubstituted with a substituent selected from the group consisting of 1-6 -alkyl, Unsubstituted, independently of each other, -F, -Cl, -Br, -I, -C 1-6 -Alkyl, C 2-6 -alkenyl, -C 2-6 -alkynyl, -OH, =O, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 ,C(=O)CHF 2 , and -C(=O)NH 2 -C(=O)OC mono- or polysubstituted with a substituent selected from the group consisting of 1-6 -alkyl, 3- to 14-membered cycloalkyl selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, in each case unsubstituted and independently of each other, -F, -Cl, -Br, -I C 1-6 -Alkyl, C 2-6 -alkenyl, -C 2-6 -alkynyl, -OH, =O, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 ,C(=O)CHF 2 , and -C(=O)NH 2 3- to 14-membered cycloalkyl, mono- or polysubstituted with a substituent selected from the group consisting of; Azepane, 1,4-oxazepane, azetane, azetidine, aziridine, azocane, diazepane, dioxane, dioxolane, dithiane, dithiolane, imidazolidine, isothiazolidine, isoxalidine, morpholine, oxazolidine, oxepane, oxetane, oxirane, piperazine, piperidine, pyrazolidine, Pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiopyran, thiazolidine, thietane, thiirane, thiolane, thiomorpholine, indoline, dihydrobenzofuran, dihydrobenzothiophene, 1,1-dioxothiacyclohexane, 2-azaspiro[3.3]heptane , 2-oxaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, hexahydro-1H-pyrrolidine, hexahydrocyclopenta[c] pyrrole, octahydrocyclopenta[c]pyrrole, and octahydropyrrolo[1,2-a]pyrazine, in each case unsubstituted, independently of each other, -F, -Cl, -Br ,-I C 1-6 -Alkyl, C 2-6 -alkenyl, -C 2-6 -alkynyl, -OH, =O, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 ,C(=O)CHF 2 , and -C(=O)NH 2 represents a 3- to 14-membered heterocycloalkyl mono- or polysubstituted with a substituent selected from the group consisting of .
[0083] Preferably, R 9 ,R 10 ,R 11 ,R 12 , and R 13 are, independently of each other, -H, -F, -Cl, -CN, -OH, =O, -C 1-6 -alkyl, -CHF 2 ,-CF 3 ,-C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NHC(=O)O-C 1-6 -Arkyri, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-NHC(=O)-O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 ,-OC 1-6 -alkyl, -OCF 3 ,-O-C 1-6 -alkylene-N(C 1-6 -alkyl) 2 , -S(=O) 2 -C 1-6 -alkyl, -azetidine, -C 1-6 -alkylene-O-tetrahydropyran, or -C 1-6 Represents -piperazine substituted with alkyl.
[0084] In a preferred embodiment of the benzofuran derivative according to the invention, (i)R 9 ,R 10 ,R 11 ,R 12 , and R 13represents -H, (ii)R 9 ,R 10 ,R 11 ,R 12 , and R 13 Four of them represent -H and R 9 ,R 10 ,R 11 ,R 12 , and R 13 the other two of which represent substituents other than -H, or (iii)R 9 ,R 10 ,R 11 ,R 12 , and R 13 Three of them represent -H and R 9 ,R 10 ,R 11 ,R 12 , and R 13 The other one represents a substituent other than -H.
[0085] In a preferred embodiment, the phenyl moiety is unsubstituted or monosubstituted in the ortho position, i.e. R 10 ,R 11 ,R 12 , and R 13 represents -H and R 9 represents a residue that is not -H. Preferably, the phenyl moiety is unsubstituted or substituted in the ortho position and is selected from the group consisting of:
table 1
[0086] In a preferred embodiment, the phenyl moiety is monosubstituted in the ortho position, i.e. R 10 ,R 11 ,R 12 , and R 13 represents -H and R 9 -F, -Cl, -Br, -I, -CN, C 1-3- Alkyl, -CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-3 -Alkylene-CF 3 ,-C 1-3 -Alkylene-CF 2 H, -C 1-3 -alkylene-CFH 2 ,-OCF 3 ,-OCF 2 H, -OCFH 2 ,-OCF 2 Cl, -OCFCl 2 ,-O-C 1-3 -alkyl, -C 1-3 -alkylene-O-C 1-3 -alkyl, and -C 1-3 -alkylene-OH, preferably -F, -Cl, -Br, -I, -CN, -CH 3 ,-CF 3 ,-CF 2 H, -CFH 2 ,-OCF 3 , and -OCH 3 Represents a residue selected from the group consisting of -.
[0087] In a preferred embodiment, the phenyl moiety is monosubstituted in the meta position, i.e. R 9 ,R 11 ,R 12 , and R 13 represents -H and R 10 represents a residue that is not -H. Preferably, the phenyl moiety substituted at the meta position is selected from the group consisting of: [ka]
[0088] In a preferred embodiment, the phenyl moiety is monosubstituted in the meta position, i.e. R 9 ,R 11 ,R 12 , and R 13 represents -H and R 10 -F, -Cl, -Br, -I, -CN, C 1-3- Alkyl, -CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-3 -Alkylene-CF 3 ,-C 1-3 -Alkylene-CF 2 H, -C 1-3 -alkylene-CFH 2 ,-OCF 3 ,-OCF 2 H, -OCFH 2 ,-OCF 2 Cl, -OCFCl 2 ,-O-C 1-3 -alkyl, -C 1-3 -alkylene-O-C 1-3 -alkyl, and -C 1-3 -alkylene-OH, preferably -F, -Cl, -Br, -I, -CN, -CH 3 ,-CF 3 ,-CF 2 H, -CFH 2 ,-OCF 3 , and -OCH 3 Represents a residue selected from the group consisting of -.
[0089] In a preferred embodiment, the phenyl moiety is monosubstituted in the para position, i.e. R 9 ,R 10 ,R 12 , and R 13 represents -H and R 11 represents a residue that is not -H. Preferably, the phenyl moiety substituted in the para position is selected from the group consisting of: [ka]
[0090] In a preferred embodiment, the phenyl moiety is monosubstituted in the para position, i.e. R 9 ,R 10 ,R 12 , and R 13 represents -H and R 11 -F, -Cl, -Br, -I, -CN, C 1-3 -alkyl, -CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-3 -Alkylene-CF 3 ,-C 1-3 -Alkylene-CF 2 H, -C 1-3 -alkylene-CFH 2 ,-OCF 3 ,-OCF 2 H, -OCFH 2 ,-OCF 2 Cl, -OCFCl 2 ,-O-C 1-3 -alkyl, -C 1-3 -alkylene-O-C 1-3 -alkyl, and -C 1-3 -alkylene-OH, preferably represents a residue selected from the group consisting of -F.
[0091] In preferred embodiments, the phenyl moiety is disubstituted. Preferably, the disubstituted phenyl moiety is selected from the group consisting of: [ka]
[0092] In a preferred embodiment, (i)R 9 ,R 10 ,R 11 ,R 12 , and R 13 One or two of them are -F, -Cl, -Br, -I, -CN, C 1-3 -alkyl, -CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-3 -Alkylene-CF 3 ,-C 1-3 -Alkylene-CF 2 H, -C 1-3 -alkylene-CFH 2 ,-OCF 3 ,-OCF 2 H, -OCFH 2 ,-OCF 2 Cl, -OCFCl 2 ,-O-C 1-3 -alkyl, -C 1-3 -alkylene-O-C 1-3 -alkyl, -C 1-3 -alkylene-OH, the other being hydrogen, or (ii)R 9 ,R 10 ,R 11 ,R 12 , and R 13 One or two of them are -F, -Cl, -Br, -I, -CN, -Me, -CF 3 ,-CF 2 H, -CFH 2 ,-OCF 3 ,-OCH 3 selected from.
[0093] In a preferred embodiment, R 9 or R 13-F, -Cl, -Br, -I, -CN, C 1-3 -alkyl, -CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-3 -Alkylene-CF 3 ,-C 1-3 -Alkylene-CF 2 H, -C 1-3 -alkylene-CFH 2 ,-OCF 3 ,-OCF 2 H, -OCFH 2 ,-OCF 2 Cl, -OCFCl 2 ,-O-C 1-3 -alkyl, -C 1-3 -alkylene-O-C 1-3 -alkyl, and -C 1-3 selected from -alkylene-OH, R 10 ,R 11 , and R 12 is hydrogen. In some embodiments, R 9 or R 13 -F, -Cl, -Br, -I, -CN, -Me, -CF 3 ,-CF 2 H, -CFH 2 ,-OCF 3 , and -OCH 3 It is.
[0094] In a preferred embodiment, R 10 or R 12 -F, -Cl, -Br, -I, -CN, C 1-3 -alkyl, -CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-3 -Alkylene-CF 3 ,-C 1-3 -Alkylene-CF 2 H, -C 1-3 -alkylene-CFH 2 ,-OCF 3 ,-OCF 2 H, -OCFH 2 ,-OCF 2 Cl, -OCFCl 2 ,-O-C 1-3 -alkyl, -C 1-3 -alkylene-O-C 1-3 -alkyl, and -C 1-3 selected from -alkylene-OH, R 9 ,R 11 , and R 13 is hydrogen. In a preferred embodiment, R 10 or R 12 -F, -Cl, -Br, -I, -CN, -Me, -CF 3 ,-CF 2 H, -CFH 2 ,-OCF 3 , and -OCH 3 selected from.
[0095] In a preferred embodiment, R 11 is selected from -F, -Cl, -Br, and -I, while R 9 ,R 10 ,R 12 , and R 13 is hydrogen.
[0096] In a preferred embodiment, R 9 and R 10 -F, -Cl, -Br, -I, -CN, C 1-3 -alkyl, -CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-3 -Alkylene-CF 3 ,-C 1-3 -Alkylene-CF 2 H, -C 1-3 -alkylene-CFH 2 ,-OCF 3 ,-OCF 2 H, -OCFH 2 ,-OCF 2 Cl, -OCFCl 2 ,-O-C 1-3 -alkyl, -C 1-3 -alkylene-O-C 1-3 -alkyl, and -C 1-3 selected from -alkylene-OH, R 11 ,R 12 , and R 13 is hydrogen.
[0097] In a preferred embodiment of the invention, the benzofuran derivative is selected from the group consisting of: [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9] [Table 2-10] [Table 2-11] [Table 2-12] [Table 2-13] [Table 2-14] [Table 2-15] and physiologically acceptable salts thereof.
[0098] The benzofuran derivatives according to the invention are preferably for use in the treatment of pain selected from nociceptive pain, inflammatory pain and neuropathic pain. More preferably, the pain is post-surgical pain.
[0099] Another aspect of the disclosure provides a compound of formula (I), [ka] With respect to its stereoisomers, physiologically acceptable salts, solvates and / or polymorphs, as defined above, preferably: (a-1)Q is -OR 2 represents R 1 But -CH 2 F, -CHF 2 , or -CF 3 represents and / or (a-2)Q is -OR 2 represents R 5 and R 5 ’ does not represent -H and R 9 ,R 10 ,R 11 ,R 12 , and R 13 at least one of them does not represent -H and / or (a-3)Q is -OR 2 represents R 8 does not represent -H, or (b-1)Q is -NR 3 R 4 represents R 1 But -CH 2 F, -CHF 2 , or -CF 3 represents and / or (b-2)Q is -NR 3 R 4 represents R 9 ,R 10 ,R 11 ,R 12 , and R 13 provided that at least one of them does not represent -H and the following compounds are excluded: [ka] and / or (b-3)Q is -NR 3 R 4 represents R 5 and R 5 ’ does not represent -H and / or (b-4)Q is -NR 3 R 4 represents R 6 ,R 7 , and R 8 provided that at least one of them does not represent -H and the following compounds are excluded: [ka] and / or (b-5)Q is -NR 3 R 4 represents R 3 represents -H and R 9 ,R 10 ,R 11 ,R 12 , and R 13 at least one of them does not represent -H and R 4 but, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -alkyl, a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, optionally connected through -heteroalkylene-, in each case saturated or unsaturated; a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered heterocycloalkyl, wherein the 3- to 14-membered heterocycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl, optionally connected through -heteroalkylene-, in each case saturated or unsaturated; An unsubstituted, monosubstituted or polysubstituted 6- to 14-membered aryl, wherein the 6- to 14-membered aryl is -C 1 -C 6 -alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted, 6- to 14-membered aryl; an unsubstituted, monosubstituted or polysubstituted 5- to 14-membered heteroaryl, wherein the 5- to 14-membered heteroaryl is -C 1 -C 6 -alkylene- or -C 1 -C 6 optionally connected through -heteroalkylene-, and in each case represents a saturated or unsaturated, unsubstituted, mono- or polysubstituted 5- to 14-membered heteroaryl.
[0100] Preferred embodiments (a-1), (a-2), (a-3), (b-1), (b-2), (b-3), (b-4) of benzofuran derivatives according to the present invention , and (b-5), T represents -O- and U represents -CR 5 R 5 ’- (ie, the benzofuran derivative is of formula (II)).
[0101] Q, T, U, R with preferred substituents 1 ,R 2 ,R 3 ,R 4 ,R 5 ,R 5 ’, R 6 ,R 7 ,R 8 ,R 9 ,R 10 ,R 11 ,R 12 , and R 13 All definitions, preferred embodiments and preferred meanings of , which also apply to the benzofuran derivatives according to the invention, include (a-1), (a-2), (a-3), (b -1), (b-2), (b-3), (b-4), and (b-5), which are not necessarily used for the treatment of pain. Not limited. This aspect of the invention therefore provides benzofuran derivatives as such, compositions comprising benzofuran derivatives, medicaments comprising benzofuran derivatives, and uses in the prevention and / or treatment of TRPM3-mediated disorders such as pain and / or inflammatory hypersensitivity. and / or for combating pain and / or inflammatory hypersensitivity. Preferably, the pain is selected from nociceptive pain, inflammatory pain, and neuropathic pain. More preferably, the pain is post-surgical pain.
[0102] In a preferred embodiment of the benzofuran derivative according to the invention, Q is -NR 3 R 4 represents R 9 ,R 10 ,R 11 ,R 12 , and R 13 The condition is that at least one of them does not represent -H, -F, or -Cl.
[0103] In a preferred embodiment of the invention, the benzofuran derivative is selected from the group consisting of compounds 001 to 308 described above and physiologically acceptable salts thereof.
[0104] Another aspect of the invention relates to a pharmaceutical composition or medicament comprising the benzofuran derivative according to the invention as described above.
[0105] References herein to "an embodiment" or "an embodiment" imply that a particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment of the invention. means. Thus, the appearances of the phrases "in one embodiment" or "in one embodiment" in various places herein are not necessarily all referring to the same embodiment, but are there is a possibility. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments, as will be apparent to those skilled in the art from this disclosure. Also, embodiments described for aspects of the invention may be used and combined with other aspects of the invention. When an indefinite or definite article is used to refer to a singular noun (eg, "a" or "an", "the"), it includes the plural form of that noun, unless otherwise specified.
[0106] Similarly, in the description of exemplary embodiments of the invention, various aspects of the invention are presented in a single may be grouped together in the embodiments, figures, or descriptions thereof.
[0107] In each of the following definitions, the number of carbon atoms represents the maximum number of carbon atoms that are generally optimally present in the substituent or linker. Where otherwise indicated in this application, the number of carbon atoms is understood to represent the optimal maximum number of carbon atoms for that particular substituent or linker.
[0108] The term "leaving group" or "LG" as used herein refers to a chemical group that is susceptible to displacement by a nucleophile or to cleavage or hydrolysis under basic or acidic conditions. In certain embodiments, the leaving group is selected from a halogen atom (eg, Cl, Br, I) or a sulfonate (eg, mesylate, tosylate, triflate).
[0109] The term "protecting group" refers to a moiety of a compound that masks or alters the properties of a functional group or of the compound as a whole. The chemical basic structure of protecting groups varies widely. One function of protecting groups is to serve as intermediates in the synthesis of the parent drug substance. Chemical protecting groups and strategies for protection / deprotection are well known in the art. See “Protective Groups in Organic Chemistry”, Theodora W. Greene (John Wiley & Sons, Inc., New York, 1991). Protective groups affect the efficiency of a desired chemical reaction, e.g. It is often utilized to mask the reactivity of certain functional groups to aid in forming and breaking bonds.Protection of functional groups in compounds can be It alters other physical properties other than the reactivity of the protected functional group, such as other properties that can be measured by common analytical tools. It can be biologically active or inactive.
[0110] Protected compounds may also exhibit altered and, in some cases, optimized properties in vitro and in vivo (crossing cell membranes and resistance to enzymatic degradation or entrapment). In this role, protected compounds with the intended therapeutic effect may be referred to as prodrugs. Another function of the protecting group is to convert the parent drug into a prodrug, whereby the parent drug is released upon conversion of the prodrug in vivo. Because the active prodrug may be absorbed more effectively than the parent drug, the prodrug may have greater in vivo potency than the parent drug. Protecting groups are removed either in vitro, in the case of chemical intermediates, or in vivo, in the case of prodrugs. Regarding chemical intermediates, it is not particularly important that the resulting product (e.g. an alcohol) after deprotection is physiologically acceptable, but it is generally better if this product is pharmacologically benign. desirable.
[0111] As used herein, the term "heteroatom" means an atom selected from nitrogen, oxygen, and sulfur, including sulfoxides and sulfones, which can be quaternized.
[0112] The term "saturated or unsaturated alkyl" as used herein includes saturated alkyl as well as unsaturated alkyl such as alkenyl, alkynyl, and the like. The term "alkyl" as used herein means a normal, secondary or tertiary, straight or branched chain hydrocarbon having no sites of unsaturation. Examples are methyl, ethyl, 1-propyl (n-propyl), 2-propyl (iPr), 1-butyl, 2-methyl-1-propyl (i-Bu), 2-butyl (s-Bu), 2 -dimethyl-2-propyl (t-Bu), 1-pentyl (n-pentyl), 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1 -butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl -3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl. As used herein, the term "alkenyl" means a normal, means a secondary or tertiary, straight or branched hydrocarbon. Examples include ethylene or vinyl (-CH=CH 2 ), allyl(-CH 2 CH=CH 2 ), and 5-hexenyl (-CH 2 CH 2 CH 2 CH 2 CH=CH 2 ), but are not limited to these. Double bonds can be in cis or trans configuration. As used herein, the term "alkynyl" refers to normal, double means secondary, tertiary, straight chain or branched chain hydrocarbons. Examples include ethynyl (-C≡CH) and 1-propynyl (propargyl, -CH 2 C≡CH), but are not limited to these.
[0113] The term "saturated or unsaturated alkylene" as used herein includes saturated alkylene as well as unsaturated alkylene such as alkenylene, alkynylene, alkenynylene. As used herein, the term "alkylene" refers to a saturated, straight chain having two monovalent radical centers obtained by the removal of two hydrogen atoms from the same or two different carbon atoms of the parent alkane. , or a branched hydrocarbon radical. A typical alkylene radical is methylene (-CH 2 -), 1,2-ethyl(-CH 2 CH 2 -), 1,3-propyl(-CH 2 CH 2 CH 2 -), 1,4-butyl(-CH 2 CH 2 CH 2 CH 2 -), but are not limited to these. As used herein, the term "alkenylene" refers to a parent alkene having at least one site of unsaturation (usually 1-3, preferably 1), i.e., a carbon-carbon, sp2 double bond. It means a straight-chain or branched hydrocarbon radical having two monovalent radical centers obtained by removing two hydrogen atoms from the same or two different carbon atoms. As used herein, the term "alkynylene" refers to the same group of parent alkenes having at least one site of unsaturation (usually 1-3, preferably 1), i.e., a carbon-carbon, sp triple bond. or a straight-chain or branched hydrocarbon radical having two monovalent radical centers obtained by removing two hydrogen atoms from two different carbon atoms.
[0114] The term "saturated or unsaturated heteroalkyl" as used herein includes saturated heteroalkyl as well as unsaturated heteroalkyl such as heteroalkenyl, heteroalkynyl, heteroalkenyl. The term "heteroalkyl" as used herein means a straight or branched chain alkyl in which one or more carbon atoms (usually 1, 2, or 3) are heteroatoms, i.e. , by oxygen, nitrogen or sulfur atoms, with the proviso that the chain must not contain two adjacent O atoms or two adjacent S atoms. -CH of one or more of the alkyls in question 3 -NH 2 and / or one or more of said alkyls may be replaced by -CH 2 - means that - can be replaced by -NH-, -O-, or -S-. The S atoms in the chain can optionally be oxidized with one or two oxygen atoms to give sulfoxides and sulfones, respectively. Furthermore, the heteroalkyl group in the benzofuran derivatives of the present invention can contain an oxo or thio group at any carbon or heteroatom that results in a stable compound. Exemplary heteroalkyl groups include alcohols, alkyl ethers (e.g., -methoxy, -ethoxy, -butoxy, etc.), primary, secondary, and tertiary alkyl amines, amides, ketones, esters, alkyl sulfides, and alkyl sulfones. including, but not limited to. The term "heteroalkenyl" means a straight or branched chain alkenyl in which one or more carbon atoms (usually 1, 2, or 3) are replaced by an oxygen, nitrogen, or sulfur atom; Provided that the chain must not contain two adjacent O atoms or two adjacent S atoms. Thus, the term heteroalkenyl includes imine, -O-alkenyl, -NH-alkenyl, -N(alkenyl) 2 , -N(alkyl)(alkenyl), and -S-alkenyl. As used herein, the term "heteroalkynyl" means a straight or branched chain alkynyl in which one or more carbon atoms (usually 1, 2, or 3) include oxygen, nitrogen, or by a sulfur atom, provided that the chain must not contain two adjacent O atoms or two adjacent S atoms. Thus, the term heteroalkynyl includes -cyano, -O-alkynyl, -NH-alkynyl, -N(alkynyl) 2 , -N(alkyl)(alkynyl), -N(alkenyl)(alkynyl), and -S-alkynyl.
[0115] The term "saturated or unsaturated heteroalkylene" as used herein includes saturated heteroalkylene as well as unsaturated heteroalkylene such as heteroalkenylene, heteroalkynylene, heteroalkenylene. The term "heteroalkylene" as used herein means a straight or branched alkylene in which one or more carbon atoms (usually 1, 2, or 3) are heteroatoms, i.e. , by oxygen, nitrogen or sulfur atoms, with the proviso that the chain must not contain two adjacent O atoms or two adjacent S atoms. As used herein, the term "heteroalkenylene" means a straight or branched alkenylene in which one or more carbon atoms (usually 1, 2, or 3) include oxygen, nitrogen, or by a sulfur atom, provided that the chain must not contain two adjacent O atoms or two adjacent S atoms. The term "heteroalkynylene" as used herein means a straight or branched alkynylene in which one or more carbon atoms (usually 1, 2, or 3) include oxygen, nitrogen, , or by a sulfur atom, with the proviso that the chain must not contain two adjacent O atoms or two adjacent S atoms.
[0116] The term "saturated or unsaturated cycloalkyl" as used herein includes saturated cycloalkyls as well as unsaturated cycloalkyls such as cycloalkenyl, cycloalkynyl. As used herein, unless otherwise specified, the term "cycloalkyl" refers to, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, fentyl, decalinyl, adamantyl, etc. means a saturated cyclic hydrocarbon radical. As used herein, the term "cycloalkenyl" refers to non-aromatic means a group cyclic hydrocarbon radical. Examples include, but are not limited to, cyclopentenyl and cyclohexenyl. Double bonds can be in cis or trans configuration. As used herein, the term "cycloalkynyl" refers to a non-aromatic cyclic group having at least one site of unsaturation (usually 1-3, preferably 1), i.e. carbon-carbon, sp triple means a hydrocarbon radical. An example is cyclohept-1-ene. A fused system of cycloalkyl rings with a heterocycloalkyl ring is considered a heterocycloalkyl, regardless of the ring attached to the core structure. A fused system of cycloalkyl rings with an aryl ring is considered aryl regardless of the ring attached to the core structure. A fused system of cycloalkyl rings with a heteroaryl ring is considered a heteroaryl, regardless of the ring attached to the core structure.
[0117] As used herein, the term "saturated or unsaturated heterocycloalkyl" refers to saturated heterocycloalkyl, as well as unsaturated Contains aromatic heterocycloalkyl. The term "heterocycloalkyl" as used herein, unless otherwise specified, means "cycloalkyl" having one or more carbon atoms (usually 1, 2, or 3) is replaced by an oxygen, nitrogen or sulfur atom, with the proviso that the chain must not contain two adjacent O atoms or two adjacent S atoms. The term "heterocycloalkenyl" as used herein, unless otherwise specified, means "cycloalkenyl" having one or more carbon atoms (usually 1, 2, or 3) is replaced by an oxygen, nitrogen or sulfur atom, with the proviso that the chain must not contain two adjacent O atoms or two adjacent S atoms. The term "heterocycloalkynyl" as used herein, unless otherwise specified, means "cycloalkynyl" having one or more carbon atoms (usually 1, 2, or 3) is replaced by an oxygen, nitrogen or sulfur atom, with the proviso that the chain must not contain two adjacent O atoms or two adjacent S atoms. Examples of saturated and unsaturated heterocycloalkyls include azepane, 1,4-oxazepane, azetane, azetidine, aziridine, azocane, diazepane, dioxane, dioxolane, dithiane, dithiolane, imidazolidine, isothiazolidine, isoxalidine, morpholine, oxazolidine. , oxepane, oxetane, oxirane, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiopyran, thiazolidine, thietane, thiirane, thiolane, thiomorpholine, indoline, dihydrobenzofuran, dihydrobenzothiophene, 1,1 -dioxothiacyclohexane, 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, Examples include, but are not limited to, hexahydro-1H-pyrrolidine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, and octahydropyrrolo[1,2-a]pyrazine. Further heterocycloalkyls within the meaning of the present invention are described in Paquette, Leo A. "Principles of Modern Heterocyclic Chemistry" (W.A. Benjamin, New York, 1968), in particular chapters 1, 3, 4, 6, 7 and 9. “The Chemistry of Heterocyclic Compounds, A series of Monographs” (John Wiley & Sons, New York, 1950-present), especially volumes 13, 14, 16, 19, and 28, Katritzky, Alan R., Rees, C.W. and Scriven, E. "Comprehensive Heterocyclic Chemistry" (Pergamon Press, 1996), and J. Am. Chem. Soc. (1960) 82:5566. If the heterocycloalkyl does not contain nitrogen as a ring member, it is typically attached through a carbon. When a heterocycloalkyl contains nitrogen as a ring member, it can be attached through nitrogen or carbon. A fused system of heterocycloalkyl rings with a cycloalkyl ring is considered a heterocycloalkyl, regardless of the ring attached to the core structure. A fused system of heterocycloalkyl rings with an aryl ring is considered a heterocycloalkyl, regardless of the ring attached to the core structure. A fused system of heterocycloalkyl rings with a heteroaryl ring is considered a heteroaryl, regardless of the ring attached to the core structure.
[0118] The term "aryl" as used herein means an aromatic hydrocarbon. Typical aryl groups include, but are not limited to, fused together one-, two-, or three-membered radicals derived from benzene, naphthalene, anthracene, biphenyl, and the like. A fused system of aryl rings with a cycloalkyl ring is considered aryl regardless of the ring attached to the core structure. A fused system of aryl rings with a heterocycloalkyl ring is considered a heterocycloalkyl, regardless of the ring attached to the core structure. Thus, indoline, dihydrobenzofuran, dihydrobenzothiophene, etc. are considered heterocycloalkyls according to the present invention. A fused system of aryl rings with a heteroaryl ring is considered a heteroaryl, regardless of the ring attached to the core structure.
[0119] The term "heteroaryl" as used herein refers to an aromatic ring system containing N, O, or S as at least one heteroatom, ie, a ring member of the aromatic ring system. Examples of heteroaryls include benzimidazole, benzisooxazole, benzazole, benzodioxole, benzofuran, benzothiadiazole, benzothiazole, benzothiophene, carbazole, shinoline, dibenzofuran, furan, furazane, imidazole, imidazopyridine, indazole, Indole, indolizine, isobenzofuran, isoindole, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, oxindole, phthalazine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, Examples include, but are not limited to, quinoxalines, tetrazoles, thiadiazoles, thiazoles, thiophenes, triazines, triazoles, and [1,2,4]triazolo[4,3-a]pyrimidines.
[0120] As a further example, a carbon-bonded heterocycle can be at the 2, 3, 4, 5 or 6 position of pyridine, at the 3, 4, 5 or 6 position of pyridazine, at the 2, 4 position of pyrimidine. , 5th or 6th position, 2nd, 3rd, 5th or 6th position of pyrazine, 2nd, 3rd, 4th or 5th position of furan, tetrahydrofuran, thiophene, pyrrole or tetrahydropyrrole, oxazole, 2nd, 4th, or 5th position of imidazole or thiazole; 3rd, 4th, or 5th position of isoxazole, prazole, or isothiazole; 2nd or 3rd position of aziridine; 2nd or 3rd position of azetidine; or 4th place, 2nd, 3rd, 4th, 5th, 6th, 7th, or 8th place of quinoline, or 1st, 3rd, 4th, 5th, 6th, 7th place of isoquinoline, or They are joined at the 8th position.
[0121] Preferred carbon-bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, and 4-pyridazinyl. Examples include pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl. For example, nitrogen-bonded heterocycles include aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, It is bonded to the 1st position of piperidine, piperazine, indole, indoline, 1H-indazole, the 2nd position of isoindole or isoindoline, the 4th position of morpholine, and the 9th position of carbazole or β-carboline. Preferred nitrogen-bonded heterocycles include 1-aziridyl, 1-azetidyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl. Further heteroaryls within the meaning of the present invention are described in Paquette, Leo A. “Principles of Modern Heterocyclic Chemistry” (W.A. Benjamin, New York, 1968), in particular chapters 1, 3, 4, 6, 7 and 9, “ "The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950-present), especially volumes 13, 14, 16, 19, and 28, Katritzky, Alan R., Rees, C.W. and Scriven, E. "Comprehensive Heterocyclic Chemistry" (Pergamon Press, 1996) and J. Am. Chem. Soc. (1960) 82:5566.
[0122] As used herein with respect to substituents, unless otherwise specified, terms such as "monosubstituted," "disubstituted," "trisubstituted," "polysubstituted," etc. are defined herein. Refers to a chemical structure in which each moiety is substituted with one or more substituents, and one or more hydrogen atoms of the moiety are each independently replaced with a substituent. For example, -C which can be polysubstituted with -F 1-6 -Alkyl is -CH 2 F, -CHF 2 ,-CF 3 ,-CH 2 C.F. 3 , C.F. 2 C.F. 3 etc. Similarly, -C may be polysubstituted with substituents selected from -F and -Cl, independently of each other. 1-6 -Alkyl is -CH 2 F, -CHF 2 ,-CF 3 ,-CH 2 C.F. 3 , C.F. 2 C.F. 3 ,-CH 2 Cl, -CHCl 2 ,-CCl 3 ,-CH 2 CCl 3 ,CCl2 CCl 3 , -CHClF, -CClF 2 ,-CCl 2 C.F. 3 ,-CF 2 CCl 3 , -CClFCCl 2 It extends to F, etc. The designation of any substituent found at more than one position in a compound of the invention shall be independently selected.
[0123] As used herein, and unless otherwise specified, the term "solvate" refers to suitable inorganic solvents, such as, but not limited to, alcohols, ketones, esters, ethers, nitriles, etc. hydrates) or organic solvents, any combination that may be formed by the derivatives of the invention.
[0124] The term "subject" as used herein refers to an animal, including a human, preferably a mammal, most preferably a human, who is the subject of treatment, observation, or experimentation.
[0125] As used herein, the term "therapeutically effective amount" refers to the amount sought by a researcher, veterinarian, physician, or other clinician, including alleviation or partial alleviation of symptoms of the disease or disorder being treated. refers to the amount of an active compound or drug that induces a biological or pharmaceutical response in a tissue system, animal, or human.
[0126] As used herein, "composition" refers to a product containing a therapeutically effective amount of the specified ingredients, as well as any product obtained directly or indirectly from a combination of the specified ingredients in the specified amounts. is intended to include products.
[0127] The terms "antagonist" or "inhibitor" as used herein refer to functional antagonists of TRPM3 ion channels, including competitive antagonists, non-competitive antagonists, desensitizing agonists, and partial agonists, as the case may be. Refers to a compound that can be produced.
[0128] For purposes of the present invention, the term "TRPM3-modulated" is used to refer to conditions affected by modulation of TRPM3 ion channels, including conditions mediated by TRPM3 ion channels.
[0129] As used herein, the term "TRPM3-mediated disorder" refers to a disorder in which the use of an antagonist of TRPM3 prevents, treats, (partially) alleviates or ameliorates the symptoms of a disorder consisting of pain and inflammatory hypersensitivity states or Refers to a disease. According to the International Association for the Study of Pain, for the purposes of this invention, pain is an unpleasant sensory and emotional experience associated with, or described in terms of, actual or potential tissue damage. be. Preferably, the TRPM3-mediated disorder is pain, preferably selected from nociceptive pain, inflammatory pain, and neuropathic pain. More preferably, the pain is post-surgical pain. For the purposes of this invention, the term "inflammatory hypersensitivity" is defined as hypersensitivity caused by one or more features of inflammation, including edema, erythema, hyperthermia, and pain, and / or by thermal, mechanical, and / or chemical hypersensitivity. used to refer to a condition characterized by an exaggerated physiological or pathophysiological response to one or more types of stimuli, including physical stimuli.
[0130] The benzofuran derivatives of the present invention have been shown to be antagonists of TRPM3 and therefore the present invention provides a therapeutically effective amount of the benzofuran of the present invention for use as a medicament as such. Compounds are provided for use as medicaments in the prevention or treatment of TRPM3-mediated disorders in subjects having derivatives.
[0131] In a preferred embodiment of the invention, the benzofuran derivative of the invention is the only pharmacologically active compound administered for treatment. In another preferred embodiment of the invention, the benzofuran derivatives of the invention may be used in combination with other therapeutic agents for the treatment or prevention of TRPM3-mediated disorders. Therefore, the present invention also provides - one or more compounds of the formulas and embodiments herein, and - one or more further therapeutic agents or prophylactics used as biologically active agents in the form of a combined preparation for simultaneous, separate or sequential use for the prophylaxis or treatment of TRPM3-mediated disorders; The use of a composition comprising:
[0132] The pharmaceutical compositions or complex preparations according to the invention can contain the benzofuran derivatives of the invention over a wide content range, depending on the intended use and the expected effect of the preparation. Generally, the content of the benzofuran derivative of the invention in the composite preparation is in the range of 0.1 to 99.9% by weight, preferably 1 to 99% by weight, more preferably 5 to 95% by weight.
[0133] When several active ingredients are used in combination, the corresponding compositions may also be used separately, taking into account the fact that they do not necessarily directly exert their joint therapeutic effect at the same time in the treated mammal. However, it may be in the form of a medical kit or package containing the two components in adjacent storage or compartments. Thus, in the latter context, each active ingredient may be formulated in a manner suitable for a different route of administration than that of the other ingredients, for example one of them may be in the form of an oral or parenteral formulation. While the other may be in the form of an ampoule or an aerosol for intravenous injection.
[0134] Those skilled in the art will also recognize that the benzofuran derivatives of the invention can exist in many different protonation states, depending, among other things, on the pH of their environment. Although the structural formulas provided herein depict compounds in only one of several possible protonation states, these structures are exemplary and the present invention It will be understood that, without being limited to the protonation state of , any and all protonated forms of the compounds are intended to fall within the scope of the present invention.
[0135] The term "pharmaceutically acceptable salt" as used herein refers to the therapeutically active, non-toxic salt forms that the compounds of the formulas herein are capable of forming. Accordingly, the compounds of the present invention optionally include salts of the compounds herein, particularly, for example, Na + , Li + ,K + , Ca 2+ , and Mg 2+ Contains pharmaceutically acceptable non-toxic salts containing. Such salts may include those derived from suitable cations, such as alkali and alkaline earth metal ions, or ammonium and quaternary amino ions, in combination with acidic anionic moieties, typically carboxylic acids. The benzofuran derivatives of the present invention may have multiple positive or negative charges. The net charge of the benzofuran derivatives of the invention can be either positive or negative. Any relevant counterions are typically determined by the synthetic and / or isolation methods by which the compound is obtained. Typical counterions include, but are not limited to, ammonium, sodium, potassium, lithium, halides, acetate, trifluoroacetate, etc., and mixtures thereof. It will be understood that the identity of any relevant counterion is not a critical feature of the invention, and the invention includes compounds that are associated with any type of counterion. Furthermore, as compounds can exist in a variety of different forms, the present invention encompasses not only forms of the compounds that are associated with counterions (e.g., dry salts), but also forms that are not associated with counterions (e.g., in aqueous or organic solutions). ) is also intended to be included. Metal salts are typically prepared by reacting metal hydroxides with compounds of the invention. An example of a metal salt prepared in such a way is Li + , Na + , and K + It is a salt containing. Less soluble metal salts can be precipitated from solutions of more soluble salts by addition of suitable metal compounds. Additionally, salts may be formed from the acid addition of certain organic and inorganic acids to basic centers, typically amines, or acidic groups. Examples of such suitable acids include, for example, hydrohalogen acids, e.g. hydrochloric or hydrobromic acid, inorganic acids such as sulfuric acid, nitric acid, phosphoric acid, or e.g. acetic acid, propanoic acid, hydroxyacetic acid, 2-hydroxypropane. acids, 2-oxopropanoic acid, lactic acid, pyruvic acid, oxalic acid (i.e., ethanedioic acid), malonic acid, succinic acid (i.e., butanedioic acid), maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, methanesulfonic acid. organic acids such as ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexanesulfamic acid, salicylic (ie, 2-hydroxybenzo) acid, p-aminosalicylic acid. Additionally, the term also includes the solvates that the compounds of the formulas herein as well as their salts can form, such as hydrates, alcoholates, and the like. Finally, it is understood that the compositions herein include the benzofuran derivatives of the invention in their unionized form, as well as in zwitterionic form, and in the case of hydrates, in combination with stoichiometric amounts of water. I want to be
[0136] Also included within the scope of this invention are salts of the parent compounds having one or more amino acids, particularly naturally occurring amino acids found as protein components. Amino acids typically have side chains with basic or acidic groups, such as lysine, arginine or glutamic acid, or neutral groups such as glycine, serine, threonine, alanine, isoleucine, or leucine.
[0137] The benzofuran derivatives of the present invention also include their physiologically acceptable salts. Examples of physiologically acceptable salts of the benzofuran derivatives of the invention include alkali metal (e.g. sodium), alkaline earth (e.g. magnesium), ammonium and NX4 + (In the formula, X is -C 1-6 -alkyl). Physiologically acceptable salts of hydrogen atoms or amino groups include organic carboxylic acids such as acetic acid, benzoic acid, lactic acid, fumaric acid, tartaric acid, maleic acid, malonic acid, malic acid, isethionic acid, lactobionic acid, and succinic acid. Salts of acids include organic sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid, and inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, and sulfamic acid. Physiologically acceptable salts of compounds containing hydroxy groups include Na + and NX4 + (wherein X is typically independently -H or -C 1-4 -alkyl group). However, salts of acids and bases that are not physiologically acceptable may also find use, for example, in the preparation or purification of physiologically acceptable compounds. All salts, whether or not they form physiologically acceptable acids or bases, are within the scope of the invention.
[0138] As used herein, and unless otherwise specified, the term "enantiomer" means at least 80% (i.e., at least 90% of one enantiomer and up to 10% of the other enantiomer), preferably It refers to each individual optically active form of a benzofuran derivative of the invention having an optical purity or enantiomeric excess (as determined by standard methods in the art) of at least 90%, more preferably at least 98%.
[0139] As used herein, the term "isomer" refers to all possible forms that a compound of the formulas herein may have, including tautomeric and stereochemical forms, but not including positional isomers. means the isomeric form. Typically, the structures shown herein exemplify only one tautomeric or resonant form of the compound, although corresponding alternative configurations are contemplated as well. Unless otherwise specified, the chemical names of compounds refer to the mixture of all possible stereochemically isomeric forms, which include all diastereomers and enantiomers (as defined herein) of the basic molecular structure. Compounds of the formula may have at least one chiral center) as well as stereochemically pure or enriched compounds. More specifically, the stereocenter may have either the R or S conformation, and the bonds may have either the cis or trans conformation.
[0140] A pure isomeric form of a compound is defined as an isomer substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure. Specifically, the terms "stereomerically pure" or "chirally pure" mean at least about 80% (i.e., at least 90% of one isomer and up to 10% of the other possible isomer) ), preferably having a stereoisomeric excess of at least 90%, more preferably at least 94%, and most preferably at least 97%. The terms "enantiomerically pure" and "diastereoselectively pure" are to be understood in a similar manner, taking into account the enantiomeric excess, respectively diastereomeric excess, of the mixture in question. be.
[0141] Separation of stereoisomers is accomplished by standard methods known to those skilled in the art. One enantiomer of the benzofuran derivatives of the present invention can be separated substantially free of its opposite enantiomer by methods such as formation of diastereomers using optically active resolving agents (“Stereochemistry of Carbon Compounds,” (1962) by E.L. Eliel, McGraw Hill, Lochmuller, C.H., (1975) J. Chromatogr., 113: (3) 283-302). Separation of isomers in a mixture can be accomplished by (1) formation of ionic diastereomeric salts by chiral compounds and separation by fractional crystallization or other methods; (2) formation of diastereomeric compounds by chiral derivatizing reagents; This can be accomplished by any suitable method, including (3) separation of the mer and conversion to pure enantiomers, or (3) the enantiomers can be directly separated under chiral conditions. In method (1), diastereomeric salts are formed by combining enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, a-methyl-b-phenylethylamine (amphetamine) and carboxylic acids and sulfonic acids. They can be formed by reaction with asymmetric compounds having acidic functionality. Diastereomeric salts can be derived to be separated by fractional crystallization or ion chromatography. For separation of optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in the formation of diastereomeric salts. Alternatively, by method (2), the substrate to be resolved may be reacted with one enantiomer of a chiral compound to form a diastereomeric pair (Eliel, E. and Wilen, S. (1994) Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., p. 322). Diastereomeric compounds are formed by reacting an asymmetric compound with an enantiomerically pure chiral derivatization reagent such as a menthyl derivative, followed by separation and hydrolysis of the diastereomers to form the free enantiomerically enriched Compounds can be obtained. Methods for determining optical purity include chiral esters of racemic mixtures, such as menthyl esters or Mosher esters, a-methoxy-a-(trifluoromethyl)phenylacetate (Jacob III. (1982) J.Org.Chem.47: 4165) and analyzing the NMR spectrum for the presence of two atropisomeric diastereomers. Stable diastereomers can be separated and isolated by normal phase and reverse phase chromatography according to the method for the separation of atropisomeric naphthyl-isoquinolines (Hoye, T., WO96 / 15111). Under method (3), racemic mixtures of two asymmetric enantiomers are separated by chromatography using a chiral stationary phase. Suitable chiral stationary phases are, for example, polysaccharides, especially cellulose or amylose derivatives. Commercially available polysaccharide-based chiral stationary phases include ChiralCel® CA, OA, OB5, OC5, OD, OF, OG, OJ, and OK, and Chiralpak® AD, AS, OP(+) and It is OT(+). A suitable eluent or mobile phase for use in combination with the polysaccharide chiral stationary phase is hexane, etc., modified with an alcohol such as ethanol, isopropanol, etc. (“Chiral Liquid Chromatography” (1989) W.J. Lough, Ed. Chapman and Hall, New York, Okamoto, (1990) “Optical resolution of dihydropyridine enantiomers by High-performance liquid chromatography using phenylcarbamates of polysaccharides as a chiral stationary phase”, J .of Chromatogr.513:375-378).
[0142] The terms cis and trans are used herein in accordance with chemical information retrieval nomenclature and include reference to the positions of substituents on cyclic moieties. The absolute stereochemical configuration of compounds of the formulas described herein can be readily determined by one of skill in the art using well-known methods such as, for example, X-ray diffraction.
[0143] When a compound is crystallized from a solution or slurry, it can crystallize in different spatial lattice arrangements (this property is called "polymorphism"), forming crystals with different crystal forms; Each of these is known as a "polymorph." Thus, the term "polymorph" as used herein refers to a crystalline form of a compound of formula (I) in which the molecule is localized in three-dimensional lattice sites. Different polymorphs of a compound of formula (I) differ from each other in one or more physical properties such as solubility and dissolution rate, true specific gravity, crystalline form, accumulation mode, fluidity, and / or solid state stability. It can be different.
[0144] The benzofuran derivatives and their physiologically acceptable salts (hereinafter collectively referred to as active ingredients) of the present invention can be used to treat the disease state being treated, including oral, rectal, nasal, topical (including ophthalmic, buccal, and sublingual). ), vaginal and parenteral (including subcutaneous, intramuscular, intranasal, intravenous, intraarterial, intradermal, intrathecal, and epidural). . The preferred route of administration may vary depending on, for example, the condition of the recipient.
[0145] In particular, a therapeutically effective amount of a compound preparation for the treatment of TRPM3-mediated disorders in humans and other mammals or animals is preferably a TRPM3 ion channel inhibiting amount of a compound as defined herein. , 1 μg / ml to 100 mg / ml, optionally corresponding to an amount that ensures a plasma level of 10 mg / ml.
[0146] A suitable dose of a compound or composition of the invention should be used to treat or prevent a TRPM3-mediated disorder in a subject. Depending on the pathological condition being treated and the condition of the patient, the effective amount may be divided into several subunits per day or administered at intervals of more than one day.
[0147] The present invention further relates to one or more benzofuran derivatives of the present invention, more particularly all formula (I) and other formulas and embodiments described herein, as well as more specific aspects or embodiments thereof. (Pharmaceutical) compositions comprising embodiments are provided. Furthermore, the present invention relates to the compounds or (pharmaceutical) compositions of the present invention, more particularly all formula (I) and other formulas and embodiments described herein, and more specifically These aspects or embodiments are provided for use as a medicament, and more particularly for use in the treatment of pain. TRPM3-mediated disorders are selected from pain and inflammatory hypersensitivity conditions.
[0148] The benzofuran derivatives of the invention may be formulated with conventional carriers and excipients, which are selected according to common practice. Tablets contain excipients, flow agents, fillers, binders, and the like. Aqueous formulations are prepared in sterile form and generally will be isotonic if intended for delivery by other than oral administration. The formulation optionally contains excipients as described in the "Handbook of Pharmaceutical Excipients" (1986).
[0149] Thereafter, the term "pharmaceutically acceptable carrier" as used herein refers to its application or dissemination to the locus to be treated, e.g., by dissolving, dispersing, or diffusing the composition. means any material or substance with which an active ingredient is formulated to facilitate its storage, transport, or handling without compromising its effectiveness. A pharmaceutically acceptable carrier can be a solid or liquid, or a gas compressed to form a liquid, i.e., the compositions of the invention can be prepared as concentrates, emulsions, solutions, granules, dusts, sprays, It can be suitably used as an aerosol, suspension, ointment, cream, tablet, pellet or powder.
[0150] Suitable pharmaceutical carriers for use in such pharmaceutical compositions and their formulations are well known to those skilled in the art, and there is no particular restriction on their selection within the present invention. These also include wetting agents, dispersants, stickers, adhesives, emulsifiers, provided that the same is consistent with pharmaceutical practice, i.e. with carriers and additives that do not cause permanent damage to mammals. , surfactants, solvents, coatings, antibacterial and antifungal agents, isotonic agents, and other additives. The pharmaceutical compositions of the invention can be prepared in any known manner, e.g. in a one-step or multi-step procedure, with the selected carrier material and optionally with other additives such as surfactants. It can be prepared by uniformly mixing, coating, and / or milling the active ingredients. They can also be prepared by micronization, for example to obtain them in the form of microspheres, usually with a diameter of about 1 to 10 gm, for the production of microcapsules for controlled or sustained release of active ingredients.
[0151] While it is possible for the benzofuran derivatives to be administered alone, it is preferable to present them as a pharmaceutical formulation. Both veterinary and human formulations of the invention contain at least one active ingredient, as described above, together with one or more pharmaceutically acceptable carriers, and optionally other therapeutic ingredients. A carrier is optimally "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to its recipient. The formulation is suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal, and epidural) administration. including things. The formulations may conveniently be presented in unit dosage form and prepared by any of the methods well known in the pharmaceutical art. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with liquid carriers or finely divided solid carriers, or both, and optionally shaping the product.
[0152] Formulations of the invention suitable for oral administration may be prepared either as separate units (e.g., capsules, cachets, or tablets containing a predetermined amount of the active ingredient), as powders or granules, or as solutions in aqueous or non-aqueous liquids. or may be presented as a suspension, or an oil-in-water or water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, lozenge, or paste.
[0153] A tablet can be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets are prepared by preparing the active ingredient in a suitable machine in free-flowing form, such as a powder or granules, optionally mixed with binders, lubricants, inert diluents, preservatives, surfactants, or dispersants. It can be prepared by compressing. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. Tablets may optionally be coated or scored and may be formulated to provide sustained or controlled release of the active ingredient therein. For infections of the eye or other external tissues, e.g. mouth and skin, the formulation may contain, e.g. optionally as a topical ointment or cream containing the active ingredient in an amount ranging from 0.1% to 20% active ingredient), preferably from 0.2 to 15% w / w, most preferably from 0.5 to 10% w / w. Applicable. When formulated in an ointment, the active ingredient may be used with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may contain, for example, at least 30% w / w of polyhydric alcohols, namely propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol, and polyethylene glycols (including PEG400). ), and mixtures thereof. Topical formulations may desirably contain compounds that enhance absorption or penetration of the active ingredient through the skin or other affected area. Examples of such skin penetration enhancers include dimethyl sulfoxide and related analogs.
[0154] The oily phase of the emulsion according to the invention may be constituted from known ingredients in a known manner. The phase may simply contain an emulsifier (otherwise known as a diuretic), but desirably contains a mixture of at least one emulsifier and a fat or oil, or a mixture of both a fat and an oil. Optionally, a hydrophilic emulsifier is included along with a lipophilic emulsifier that acts as a stabilizer. It is also preferred to contain both oil and fat. Together, the emulsifiers, with or without stabilizers, constitute the so-called emulsifying waxes, which together with oils and fats constitute the so-called emulsifying ointment base, which forms the oily dispersed phase of the cream formulation.
[0155] The selection of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compounds in most oils likely to be used in pharmaceutical emulsion formulations is very low. Therefore, the cream should be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. of branched chain esters of coconut fatty acids known as diisoadipate, isocetyl stearate, propylene glycol diester, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate, or Crodamol CAP. Linear or branched, mono- or dibasic alkyl esters such as blends may be used, the last three being the preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and / or liquid paraffin or other mineral oils may be used.
[0156] Formulations suitable for topical administration to the eye include eye drops in which the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is optionally present in such formulations in a concentration of 0.5-20%, advantageously 0.5-10%, especially about 1.5% w / w. Formulations suitable for topical administration in the mouth include lozenges containing the active ingredient in a flavored base, usually sucrose and acacia or tragacanth, ceratin and glycerin, or the active ingredient in an inert base such as sucrose and acacia. as well as mouthwashes containing an active ingredient in a suitable liquid carrier.
[0157] Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate. Formulations suitable for nasal administration, where the carrier is a solid, are administered in a sniffed manner, i.e. by rapid inhalation via the nasal route from a container of powder held close to the nose, e.g. , including coarse powders with particle sizes ranging from 20 to 500 microns (having particle sizes ranging from 20 to 500 microns in 5 micron increments such as 30 microns, 35 microns, etc.). Suitable formulations in which the carrier is liquid include, for example, aqueous or oily solutions of the active ingredient for administration as a nasal spray or nasal drops. Formulations suitable for aerosol administration can be prepared according to conventional methods and delivered with other therapeutic agents.
[0158] Formulations suitable for vaginal administration are as pessaries, tampons, creams, gels, pastes, foams, or spray formulations containing, in addition to the active ingredient, such carriers as are known in the art to be suitable. It can exist.
[0159] Compositions suitable for parenteral administration include aqueous and non-aqueous sterile injectable solutions that may contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient. Injectable solutions include aqueous and non-aqueous sterile suspensions that may contain suspending agents and thickening agents. The formulations can be presented in unit-dose or multi-dose containers (e.g., sealed ampoules and vials) and can be freeze-dried (i.e., lyophilized) requiring only the addition of a sterile liquid carrier (e.g., water) immediately before use. ) can be preserved. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the type previously described.
[0160] Preferred unit dose formulations are those containing a daily dose or daily subdose of the active ingredient, or an appropriate fraction thereof, as described herein.
[0161] In particular, in addition to the above-mentioned ingredients, the formulations of the invention may contain other agents conventional in the art, taking into account the type of formulation in question (e.g. those suitable for oral administration include flavoring agents). I would like you to understand (obtaining).
[0162] The benzofuran derivatives of the present invention can be used to provide controlled release pharmaceutical formulations (“controlled release formulations”) containing one or more benzofuran derivatives of the present invention as an active ingredient, wherein the release of the active ingredient is It can be controlled and adjusted to allow for less frequent administration or to improve the pharmacokinetic or toxicity profile of a given compound of the invention. Controlled release formulations adapted for oral administration, in which discrete units contain one or more benzofuran derivatives of the invention, may be prepared according to conventional methods.
[0163] Another embodiment of the invention relates to various precursor or "prodrug" forms of the benzofuran derivatives of the invention. Although the benzofuran derivatives of the present invention are not themselves significantly biologically active, when delivered to an animal, mammal, or human, they may undergo chemical reactions catalyzed by the body's normal functions, particularly in the stomach or serum. It may be desirable to formulate the compound in the form of a chemical species that undergoes a chemical reaction catalyzed by an enzyme present in the compound, which chemical reaction has the effect of releasing a compound as defined herein. Accordingly, the term "prodrug" refers to those species that are converted in vivo to the active pharmaceutical ingredient.
[0164] Prodrugs of benzofuran derivatives of the present invention may have any form suitable for formulation agents, for example, esters are non-limiting common prodrug forms. However, in this case, the prodrug may necessarily exist in a form in which the covalent bond is cleaved by the action of an enzyme present at the target locus. For example, a C-C covalent bond can be selectively cleaved by one or more enzymes at the target locus, and thus easily hydrolyzable precursors, especially prodrugs in forms other than esters, amides, etc., are used. can be done. The counterpart of the active pharmaceutical ingredient in a prodrug can have different structures such as amino acid or peptide structures, alkyl chains, sugar moieties, etc. known in the art.
[0165] For the purposes of the present invention, the term "therapeutically suitable prodrug" means "contact with the tissue of the animal, mammal, or human to which the prodrug has been administered, by single or multiple biological transformations". Defined herein as "a compound that is modified to be converted in vivo to a therapeutically active form to achieve its intended therapeutic outcome without undue toxicity, irritation, or allergic reactions."
[0166] More specifically, the term "prodrug" as used herein refers to a compound that undergoes a spontaneous or enzymatic conversion reaction in the body to release the pharmacologically active form of the compound. relates to inactive or significantly less active derivatives of compounds such as those represented by the structural formulas set forth in . For a comprehensive review, see Rautio J. et al. (“Prodrugs: design and clinical applications” Nature Reviews Drug Discovery, 2008, doi:10.1038 / nrd2468).
[0167] Representative benzofuran derivatives of the present invention can be synthesized according to the general synthetic methods described below, and are exemplified in the schemes below. Because the schemes are illustrative, the invention should not be construed as limited by the specific chemistry and specific conditions described in the schemes and examples. The various starting materials used in the schemes are commercially available or can be prepared by methods familiar to those skilled in the art. Variables are as defined herein and are within the skill of one of ordinary skill in the art.
[0168] Preferred embodiments of the invention are summarized in Clauses 1-42 below. 1. Compounds of formula (I), stereoisomers, physiologically acceptable salts, solvates and / or polymorphs thereof, [ka] Preferably, a compound of formula (I), stereoisomers, physiologically acceptable salts, solvates and / or polymorphs thereof for use in the treatment of pain, comprising: During the ceremony, R 1 is -F, -Cl, -Br, -I, -CN, -R W ,-OR W , -OC(=O)R W ,-NR W R X ,-NR W C(=O)R X ,-SR W , -S(=O)R W , -S(=O) 2 R W , -C(=O)R W , -C(=O)OR W , or -C(=O)NR W R X represents, Q is -OR 2 or -NR 3 R 4 represents, R 2 But -R Y represents, R 3 is -OH or -R Y represents, R 4 But -R Y or -S(=O) 2 R Y or Alternatively, R 3 and R 4 together contain 1 to 3 heteroatoms selected from N, O, and S, saturated or unsaturated, unsubstituted, or mono- or polysubstituted 4, 5, 6, Forms a 7- or 8-membered heterocycle, T represents -O- and U represents -CR 5 R 5 ’- or T is -CR 5 R 5 '-, U represents -O-, R 5 and R 5 ’, independently of each other, -R Y or Alternatively, T represents -O- and U represents -CR 5 R 5 ’-, and alternatively, R 5 and R 9 are together a saturated or unsaturated, unsubstituted or monosubstituted or polysubstituted 4- to 8-membered carbocyclic ring, or containing 1 to 3 heteroatoms selected from N, O, and S, or forming an unsaturated, unsubstituted, monosubstituted or polysubstituted 4- to 8-membered heterocycle, R 6 ,R 7 , and R 8 are, independently of each other, -F, -Cl, -Br, -I, -CN, -NO 2 ,-SCIENCE FICTION 5 ,-R W ,-OR W , -OC(=O)R W ,-NR W R X ,-NR W C(=O)R X ,-SR W , -S(=O)R W , -S(=O) 2 R W , -C(=O)R W , -C(=O)OR W , or -C(=O)NR W R X represents, R 9 ,R 10 ,R 11 ,R 12 , and R 13 are, independently of each other, -F, -Cl, -Br, -I, -CN, -NO, -NO 2 , =O, =S, -SF 5 ,-R Y ,-OR Y , -OC(=O)R Y ,-NR Y R Z ,-NR Y C(=O)R Z ,-SR Y , -S(=O)R Y , -S(=O) 2 R Y , -C(=O)R Y , -C(=O)OR Y , or -C(=O)NR Y R Z represents, During the ceremony, R W and R X but independently of each other, in each case independently, -H, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -heteroalkyl, a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl; a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered heterocycloalkyl, wherein the 3- to 14-membered heterocycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 -represents a saturated or unsaturated, unsubstituted, mono- or polysubstituted, 3- to 14-membered heterocycloalkyl, optionally connected through -heteroalkylene-, R Y and R Z but independently of each other, in each case independently, -H, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -heteroalkyl, a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, optionally connected through -heteroalkylene-, in each case saturated or unsaturated; a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered heterocycloalkyl, wherein the 3- to 14-membered heterocycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl, optionally connected through -heteroalkylene-, in each case saturated or unsaturated, An unsubstituted, monosubstituted or polysubstituted 6- to 14-membered aryl, wherein the 6- to 14-membered aryl is -C 1 -C 6 -alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 6- to 14-membered aryl; an unsubstituted, monosubstituted or polysubstituted 5- to 14-membered heteroaryl, wherein the 5- to 14-membered heteroaryl is -C 1 -C 6 -alkylene- or -C 1 -C 6 optionally connected through -heteroalkylene-, in each case representing a saturated or unsaturated, unsubstituted, mono- or polysubstituted 5- to 14-membered heteroaryl; "Monosubstituted or polysubstituted" in each case independently, independently of each other, -F, -Cl, -Br, -I, -CN, -C 1-6 -alkyl, -CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-6 -Alkylene-CF 3 ,-C 1-6 -Alkylene-CF 2 H, -C 1-6 -alkylene-CFH 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 ,-C 1-6 -alkylene-N(C 1-6 -alkyl)-C 1-6 -Alkylene-CF 3 , -C(=O)-C 1-6 -alkyl, -C 1-6 -alkylene-C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C 1-6 -alkylene-C(=O)-OH, -C(=O)-OC 1-6 -alkyl, -C 1-6 -alkylene-C(=O)-OC 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)-NH 2 ,-C 1-6 -alkylene-C(=O)-NH 2 , -C(=O)-NH(C 1-6 -alkyl), -C 1-6 -alkylene-C(=O)-NH(C 1-6 -alkyl), -C(=O)-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-C(=O)-N(C 1-6 -alkyl) 2 , -C(=O)-NH(OH), -C 1-6 -Alkylene-C(=O)-NH(OH), -OH, -C 1-6 -alkylene-OH, =O, -OCF 3 ,-OCF 2 H, -OCFH 2 ,-OCF 2 Cl, -OCFCl 2 ,-O-C 1-6 -alkyl, -C 1-6 -alkylene-O-C 1-6 -alkyl, -O-C 1-6 -alkylene-O-C 1-6 -alkyl, -O-C 1-6 -alkylene-NH 2 ,-O-C 1-6 -alkylene-NH-C 1-6 -alkyl, -O-C 1-6 -alkylene-N(C 1-6 -alkyl) 2 , -O-C(=O)-C 1-6 -alkyl, -C 1-6 -alkylene-O-C(=O)-C 1-6 -Alkyl, -O-C(=O)-O-C 1-6 -alkyl, -C 1-6 -Alkylene-O-C(=O)-O-C 1-6 -Alkyl, -O-C(=O)-NH(C 1-6 -alkyl), -C 1-6 -alkylene-O-C(=O)-NH(C 1-6 -Alkyl), -O-C(=O)-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-O-C(=O)-N(C 1-6 -alkyl) 2 , -O-S(=O) 2 -NH 2 ,-C 1-6 -alkylene-O-S(=O) 2 -NH 2 , -O-S(=O) 2 -NH(C 1-6 -alkyl), -C 1-6 -alkylene-O-S(=O) 2 -NH(C 1-6 -alkyl), -O-S(=O) 2 -N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-O-S(=O) 2 -N(C 1-6 -alkyl) 2 , -NH 2 ,-NO,-NO 2 ,-C 1-6 -alkylene-NH 2 , -NH(C 1-6 -alkyl), -C 1-6 -alkylene-NH(C 1-6 -alkyl), -N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-N(C 1-6 -alkyl) 2 , -NH-C(=O)-C 1-6 -alkyl, -C 1-6 -alkylene-NH-C(=O)-C 1-6 -Alkyl, -NH-C(=O)-O-C 1-6 -alkyl, -C 1-6 -alkylene-NH-C(=O)-O-C 1-6 -Alkyl, -NH-C(=O)-NH 2 ,-C 1-6 -alkylene-NH-C(=O)-NH 2 , -NH-C(=O)-NH(C 1-6 -alkyl), -C 1-6 -alkylene-NH-C(=O)-NH(C 1-6 -alkyl), -NH-C(=O)-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-C(=O)-N(C 1-6 -alkyl) 2 , -N(C 1-6 -Alkyl)-C(=O)-C 1-6 -alkyl, -C 1-6-alkylene-N(C 1-6 -Alkyl)-C(=O)-C 1-6 -Alkyl, -N(C 1-6 -Alkyl)-C(=O)-O-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -Alkyl)-C(=O)-O-C 1-6 -Alkyl, -N(C 1-6 -Alkyl)-C(=O)-NH 2 ,-C 1-6 -alkylene-N(C 1-6 -Alkyl)-C(=O)-NH 2 , -N(C 1-6 -alkyl)-C(=O)-NH(C 1-6 -alkyl), -C 1-6 -alkylene-N(C 1-6 -alkyl)-C(=O)-NH(C 1-6 -alkyl), -N(C 1-6 -Alkyl)-C(=O)-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-N(C 1-6 -Alkyl)-C(=O)-N(C 1-6 -alkyl) 2 , -NH-S(=O) 2 OH, -C 1-6 -alkylene-NH-S(=O) 2 OH, -NH-S(=O) 2 -C 1-6 -alkyl, -C 1-6 -alkylene-NH-S(=O) 2 -C 1-6 -Alkyl, -NH-S(=O) 2 -O-C 1-6 -alkyl, -C 1-6 -alkylene-NH-S(=O) 2 -O-C 1-6 -Alkyl, -NH-S(=O) 2 -NH 2 ,-C 1-6 -alkylene-NH-S(=O) 2 -NH 2 , -NH-S(=O) 2 -NH(C 1-6 -alkyl), -C 1-6 -alkylene-NH-S(=O) 2 -NH(C 1-6 -alkyl), -NH-S(=O) 2 N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-S(=O) 2 N(C 1-6 -alkyl) 2 , -N(C 1-6 -Alkyl)-S(=O) 2 -OH, -C 1-6 -alkylene-N(C 1-6 -Alkyl)-S(=O) 2 -OH, -N(C 1-6 -Alkyl)-S(=O) 2 -C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -Alkyl)-S(=O) 2 -C 1-6 -Alkyl, -N(C 1-6 -Alkyl)-S(=O) 2 -O-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -Alkyl)-S(=O) 2 -O-C 1-6 -Alkyl, -N(C 1-6 -Alkyl)-S(=O) 2 -NH 2 ,-C 1-6 -alkylene-N(C 1-6 -Alkyl)-S(=O) 2 -NH 2 , -N(C 1-6 -Alkyl)-S(=O) 2 -NH(C 1-6 -alkyl), -C 1-6 -alkylene-N(C 1-6 -Alkyl)-S(=O) 2 -NH(C 1-6 -alkyl), -N(C 1-6 -Alkyl)-S(=O) 2 -N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-N(C 1-6 -Alkyl)-S(=O) 2 -N(C 1-6 -alkyl) 2 , -SH, =S, -SF 5 ,-SCF 3 ,-SCF 2 H, -SCFH 2 ,-S-C 1-6 -alkyl, -C 1-6 -Alkylene-S-C 1-6 -Alkyl, -S(=O)-C 1-6 -alkyl, -C 1-6 -alkylene-S(=O)-C 1-6 -Alkyl, -S(=O) 2 -C 1-6 -alkyl, -C 1-6 -alkylene-S(=O) 2 -C 1-6 -Alkyl, -S(=O) 2 -OH, -C 1-6 -alkylene-S(=O) 2 -OH, -S(=O) 2 -O-C 1-6 -alkyl, -C 1-6 -alkylene-S(=O) 2 -O-C 1-6 -Alkyl, -S(=O) 2 -NH 2 ,-C 1-6 -alkylene-S(=O) 2 -NH 2 , -S(=O) 2 -NH(C 1-6 -alkyl), -C 1-6 -alkylene-S(=O) 2 -NH(C 1-6 -Alkyl), -S(=O) 2 -N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-S(=O) 2 -N(C 1-6 -alkyl) 2 , 3-14 membered cycloalkyl, -C 1-6 -Alkylene-(3-14 membered cycloalkyl), 3-14 membered heterocycloalkyl, -C 1-6 -alkylene-(3-14 membered heterocycloalkyl), -phenyl, -C 1-6 -alkylene-phenyl, 5-14 membered heteroaryl, -C 1-6 -Alkylene-(5-14 membered heteroaryl), -O-(3-14 membered cycloalkyl), -O-(3-14 membered heterocycloalkyl), -O-phenyl, -O-(5-14 membered heteroaryl), -C(=O)-(3-14 membered cycloalkyl), -C(=O)-(3-14 membered heterocycloalkyl), -C(=O)-phenyl, -C(= O)-(5-14 membered heteroaryl), -S(=O) 2 -(3-14 membered cycloalkyl), -S(=O) 2 -(3-14 membered heterocycloalkyl), -S(=O) 2 -Phenyl, -S(=O) 2 Compounds, stereoisomers, physiologically acceptable salts, solvates, and / or stereoisomers thereof, meaning substituted with one or more substituents selected from -(5-14 membered heteroaryl) or polymorphs. 2. Q is -NR 3 R 4 represents, T represents -O- and U represents -CR 5 R 5 ’-represents R 9 ,R 10 ,R 11 ,R 12 , and R 13 at least one of them does not represent -H, A compound as such or for use in clause 1, provided that it does not include: [ka] 3.T represents -O- and U represents -CR 5 R 5 A compound as such or for use according to clause 1 or 2, representing '-. 4.Q is -NR 3 R 4 The compound itself or a compound for use according to any one of clauses 1 to 3, which is 5.Q is -OR 2 The compound itself or a compound for use according to any one of clauses 1 to 3, which is 6.R 1 but, -H, -F, -Cl, -Br, -I, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 - 6 -Alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted -O-C 1 - 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C(=O)C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C(=O)OC 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C(=O)NHC 1-6 -alkyl, Saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted -C(=O)N(C 1-6 -alkyl) 2 , Saturated or unsaturated, unsubstituted, mono- or polysubstituted -S(=O)C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -S(=O) 2 -C 1 - 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -heteroalkyl, or a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, optionally connected through -heteroalkylene-; The compound itself or the compound for use. 7.R 1 is -H, -F, -Cl, -Br, -I, -C 1-6 -Alkyl, -O-C 1-6 -alkyl, -C 1-6 -alkylene-O-C 1-6 -alkyl, -C 1-6 -alkylene-NH(C 1-6 -alkyl), -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-6 -Alkylene-CF 3 ,-C 1-6 -Alkylene-CF 2 H, -C 1-6 -alkylene-CFH 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 ,-C 1-6 -alkylene-N(C 1-6 -alkylene)-C 1-6 -Alkylene-CF 3 , -C(=O)C 1-6 -Alkyl, -C(=O)OC 1-6 -Alkyl, -C(=O)NHC 1-6 -Alkyl, -C(=O)N(C 1-6 -alkyl) 2 , -S(=O)-C 1-6 -Alkyl, -S(=O) 2 -C 1-6 -Alkyl, -O-C 1-6 -Alkyl, unsubstituted-cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl or unsubstituted cyclohexyl, as such, or for use as a compound according to any one of the preceding clauses. 8.R 1 , -H, -C 1-6 -alkyl, -C 1-6 -alkylene-O-C 1-6 -alkyl, -CHF 2 ,-CF 3 , or unsubstituted-cyclopentyl, as such, or for use as a compound according to any one of the preceding clauses. 9.R 2 but, -H, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -heteroalkyl, a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl; a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered heterocycloalkyl, wherein the 3- to 14-membered heterocycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 as described in any one of the preceding clauses, optionally connected through -heteroalkylene-, in each case representing a saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl; The compound itself or the compound for use. 10.R 2 , -H, -C 1-6 -alkyl, -C 1-6 -alkylene-O-C 1-6 -alkyl, -C 1-6 -alkylene-NH(C 1-6 -alkyl), -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-6 -Alkylene-CF 3 ,-C 1-6 -Alkylene-CF 2 H, -C 1-6 -alkylene-CFH 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , or -C 1-6 -alkylene-N(C 1-6 -alkyl)-C 1-6 -Alkylene-CF 3 A compound as such, or for use in any one of the preceding clauses, representing 11.R 2 is -H or -C 1-6 - A compound as such or for use in any one of the preceding clauses, representing alkyl. 12.R 3 but, -H, -OH, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -alkyl, or Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -heteroalkyl, as such, or for use in a compound according to any one of the preceding clauses. 13.R 3 is -H, -OH, -C 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH(C 1-6 -alkyl), -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-CF 3 ,-CF 2 H, -CFH 2 ,-CF 2 Cl, -CFCl 2 ,-C 1-6 -Alkylene-CF 3 ,-C 1-6 -Alkylene-CF 2 H, -C 1-6 -alkylene-CFH 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , or -C 1-6 -alkylene-N(C 1-6 -alkyl)-C 1-6 -Alkylene-CF 3 A compound as such, or for use in any one of the preceding clauses, representing 14.R 3 is -H, -OH, or saturated, unsubstituted, or -C monosubstituted with -OH 1-6 - A compound as such or for use in any one of the preceding clauses, representing alkyl. 15.R 4 but, -H, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -S(=O)C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -S(=O) 2 -C 1 - 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -heteroalkyl, a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C6 -alkylene- or -C 1 -C 6 unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, optionally connected through -heteroalkylene-, in each case saturated or unsaturated; a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered heterocycloalkyl, wherein the 3- to 14-membered heterocycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl, optionally connected through -heteroalkylene-, in each case saturated or unsaturated, An unsubstituted, monosubstituted or polysubstituted 6- to 14-membered aryl, wherein the 6- to 14-membered aryl is -C 1 -C 6 -alkylene- or -C 1 -C 6 optionally connected through -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted, 6- to 14-membered aryl; an unsubstituted, monosubstituted or polysubstituted 5- to 14-membered heteroaryl, wherein the 5- to 14-membered heteroaryl is -C 1 -C 6 -alkylene- or -C 1 -C 6 as defined in any one of the preceding clauses, optionally connected through -heteroalkylene- and in each case representing a saturated or unsaturated, unsubstituted, mono- or polysubstituted 5- to 14-membered heteroaryl; The compound itself or the compound for use. 16.R 4 but, Saturated or unsaturated, unsubstituted, independently of each other, -F, -Cl, -C 1-6 -alkyl, -C 1-6 -Alkylene-CF 3 , -OH, =O, -OC 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -NH 2 ,-NHC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 , -NHC(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl)C(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NHC(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -alkyl), -C(=O)N(C 1-6 -alkyl) 2 , -S(=O) 2 C 1-6 -alkyl, -phenyl, -C 1-6 -alkylene-phenyl, saturated or unsaturated, unsubstituted 3- to 14-membered heterocycloalkyl, and unsubstituted 5- to 14-membered heteroaryl, mono- or polysubstituted; Yes, -S(=O) 2 C 1-6 -alkyl, -S(=O) 2 (3-14 membered cycloalkyl), wherein the 3-14 membered cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, in each case saturated or unsaturated; Unsubstituted, independently of each other, -F, -Cl, -C 1-6 -alkyl, -C 1-6 -Alkylene-CF 3 , -OH, =O, -OC 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -NH 2 ,-NHC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 , -NHC(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl)C(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NHC(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -alkyl), -C(=O)N(C 1-6 -alkyl) 2 ,S(=O) 2 C 1-6 -alkyl, -phenyl, -C 1-6 -alkylene-phenyl, saturated or unsaturated, unsubstituted 3- to 14-membered heterocycloalkyl, and unsubstituted 5- to 14-membered heteroaryl, mono- or polysubstituted; Yes, -S(=O) 2 (3-14 membered cycloalkyl), Saturated or unsaturated, unsubstituted, independently of each other, -F, -Cl, -C 1-6 -alkyl, -C 1-6 -Alkylene-CF 3 , -OH, =O, -OC 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -NH 2 ,-NHC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 , -NHC(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl)C(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NHC(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -alkyl), -C(=O)N(C 1-6 -alkyl) 2 , -S(=O) 2 C 1-6 -alkyl, -phenyl, -C 1-6 -alkylene-phenyl, saturated or unsaturated, unsubstituted 3- to 14-membered heterocycloalkyl, and unsubstituted 5- to 14-membered heteroaryl, mono- or polysubstituted; Yes, -C 1-6 -alkyl, 3-14 membered cycloalkyl or -C 1-6 -alkylene-(3-14 membered cycloalkyl), -C 1-6 -alkylene- is unsubstituted or monosubstituted with -OH, and the 3- to 14-membered cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, in each case saturated or unsaturated, in each case unsubstituted, independently of each other, -F, -Cl, -C 1-6 -alkyl, -C 1-6 -Alkylene-CF 3 , -OH, =O, -OC 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -NH 2 ,-NHC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 , -NHC(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl)C(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NHC(=O)O-C 1-6-alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -alkyl), -C(=O)N(C 1-6 -alkyl) 2 , -S(=O) 2 C 1-6 -alkyl, -phenyl, -C 1-6 -alkylene-phenyl, saturated or unsaturated, unsubstituted 3- to 14-membered heterocycloalkyl, and unsubstituted 5- to 14-membered heteroaryl, mono- or polysubstituted; 3-14 membered cycloalkyl or -C 1-6 -alkylene-(3-14 membered cycloalkyl), 3-14 membered heterocycloalkyl or -C 1-6 -alkylene-(3-14 membered heterocycloalkyl), -C 1-6 -alkylene- is unsubstituted or monosubstituted with -OH, and the 3- to 14-membered heterocycloalkyl is in each case azepane, 1,4-oxazepane, azetane, azetidine, aziridine, azocane. , diazepane, dioxane, dioxolane, dithiane, dithiolane, imidazolidine, isothiazolidine, isoxalidine, morpholine, oxazolidine, oxepane, oxetane, oxirane, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiopyran, thiazolidine, Thietane, thiirane, thiolane, thiomorpholine, indoline, dihydrobenzofuran, dihydrobenzothiophene, 1,1-dioxothiacyclohexane, 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, 7-azaspiro[3.5] Nonane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, hexahydro-1H-pyrrolidine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, and octahydropyrrolo selected from the group consisting of [1,2-a]pyrazine, in each case unsubstituted, independently of each other, -F, -Cl, -C 1-6 -alkyl, -C 1-6 -Alkylene-CF 3 , -OH, =O, -OC 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -NH 2 ,-NHC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 , -NHC(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl)C(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NHC(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -alkyl), -C(=O)N(C 1-6 -alkyl) 2 , -S(=O) 2 C 1-6 -alkyl, -phenyl, -C 1-6 -alkylene-phenyl, saturated or unsaturated, unsubstituted 3- to 14-membered heterocycloalkyl, and unsubstituted 5- to 14-membered heteroaryl, mono- or polysubstituted; 3-14 membered heterocycloalkyl or -C 1-6 -alkylene-(3-14 membered heterocycloalkyl), Unsubstituted, independently of each other, -F, -Cl, -CN, -C 1-6 -alkyl, -C 1-6 -Alkylene-CF 3 , -OH, =O, -OC 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -NH 2 ,-NHC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 , -NHC(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl)C(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NHC(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -alkyl), -C(=O)N(C 1-6 -alkyl) 2 , -S(=O) 2 C 1-6 -alkyl, -phenyl, -C 1-6 -alkylene-phenyl, saturated or unsaturated, unsubstituted 3- to 14-membered heterocycloalkyl, and unsubstituted 5- to 14-membered heteroaryl, mono- or polysubstituted; There, -phenyl, 5-14 membered heteroaryl or -C 1-6 -alkylene-(5-14 membered heteroaryl), -C 1-6 -alkylene- is unsubstituted or monosubstituted with -OH, and the 5- to 14-membered heteroaryl is, in each case, benzimidazole, benzisoxazole, benzazole, benzodioxole, benzofuran, benzothiadiazole , benzothiazole, benzothiophene, carbazole, shinoline, dibenzofuran, furan, furazane, imidazole, imidazopyridine, indazole, indole, indolizine, isobenzofuran, isoindole, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, Oxindole, phthalazine, purine, pyrazine, pyrazole, pyridazine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazine, triazole, and [1,2,4]triazolo[4,3-a] ]pyrimidine, in each case unsubstituted, independently of each other, -F, -Cl, -CN, -C 1-6 -alkyl, -C 1-6 -Alkylene-CF 3 , -OH, =O, -OC 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -NH 2 ,-NHC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 , -NHC(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl)C(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NHC(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -alkyl, -C 1-6 -alkylene-N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -alkyl), -C(=O)N(C 1-6 -alkyl) 2 , -S(=O) 2 C 1-6-alkyl, -phenyl, -C 1-6 -alkylene-phenyl, saturated or unsaturated, unsubstituted 3- to 14-membered heterocycloalkyl, and unsubstituted 5- to 14-membered heteroaryl, mono- or polysubstituted; 5-14 membered heteroaryl or -C 1-6 -Alkylene-(5- to 14-membered heteroaryl), as such, or for use in a compound according to any one of the preceding clauses. 17.R 4 but, -H, Saturated, unsubstituted, mono- or polysubstituted with -F, -S(=O) 2 C 1-6 -alkyl, Saturated, unsubstituted -S(=O) 2 (3-14 membered cycloalkyl), Saturated, unsubstituted, independently of each other, -OH, -OC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 mono- or di-substituted with a substituent selected from the group consisting of -alkyl, unsubstituted -phenyl, -C 1-6 -alkyl, 3-14 membered cycloalkyl or -C 1-6 -alkylene-(3-14 membered cycloalkyl), -C 1-6 -alkylene- is unsubstituted or monosubstituted with -OH, and the 3- to 14-membered cycloalkyl is saturated, unsubstituted, independently of each other, -C 1-6 -alkyl, -C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NH-C 1-6 -Alkylene-CF 3 ,-C 1-6 -alkylene-OH, -C 1-6 -alkylene-NHC(=O)O-C 1-6 -alkyl, -OH, -OC 1-6 -alkyl, -NH 2 , -N(C 1-6 -alkyl) 2 , -NHC(=O)O-C 1-6 -3- to 14-membered cycloalkyl or -C mono- or di-substituted with a substituent selected from the group consisting of -alkyl 1-6 -alkylene-(3-14 membered cycloalkyl), 3-14 membered heterocycloalkyl or -C 1-6 -alkylene-(3-14 membered heterocycloalkyl), -C 1-6 -alkylene- is unsubstituted or monosubstituted with -OH, and the 3- to 14-membered heterocycloalkyl is in each case azetane, 1,4-oxazepane, pyrrolidine, piperidine, azepane, diazepane. , tetrahydrofuran, tetrahydropyran, oxetane, morpholine, piperazine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, octahydropyrrolo[1,2-a]pyrazine, 8-azabicyclo[3.2.1] Octane, 9-azabicyclo[3.3.1]nonane, quinuclidine, hexahydro-1H-pyrrolidine, 2-oxaspiro[3.3]heptane, 2-azaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 1,1-dioxo selected from thiacyclohexane, in each case unsubstituted, independently of each other, -F, -OH, =O, -C 1-6 -alkyl, -C 1-6 -Alkylene-CF 3 ,-C 1-6 -alkylene-OH, -C 1-6 -alkylene-O-C 1-6 -alkyl, -NH 2 , -N(C 1-6 -alkyl) 2 ,-C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-N(C 1-6 -alkyl) 2 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -Alkyl), -S(=O) 2 C 1-6 -alkyl, oxetanyl, pyrimidinyl, -C 1-6 3- to 14-membered heterocycloalkyl or -C mono- or polysubstituted with a substituent selected from the group consisting of -alkylene-phenyl 1-6 -alkylene-(3-14 membered heterocycloalkyl), unsubstituted phenyl, 5-14 membered heteroaryl or -C 1-6 -alkylene-(5-14 membered heteroaryl), -C 1-6 -alkylene- is unsubstituted or monosubstituted with -OH, and the 5- to 14-membered heteroaryl is in each case pyridine, pyridazine, pyrazine, pyrazole, isoxazole, triazole, and [1, 2,4]triazolo[4,3-a]pyrimidine, in each case unsubstituted, independently of each other, -C 1-6 5- to 14-membered heteroaryl or -C mono- or di-substituted with a substituent selected from the group consisting of -alkyl, -OH 1-6 -Alkylene-(5- to 14-membered heteroaryl), as such, or for use in a compound according to any one of the preceding clauses. 18.R 3 and R 4 5- or 6-membered, saturated or unsaturated, unsubstituted, or mono- or polysubstituted, together containing 1 or 2 heteroatoms selected from N, O, and S A compound according to any one of the preceding clauses, by itself or for use, forming a membered heterocycle. 19.R 3 and R 4 are taken together to form a heterocycle selected from the group consisting of pyrrolidine, piperidine, morpholine, and piperazine, in each case unsubstituted or independently of each other, -C 1-6 -alkyl, -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(=O)NH-C 1-6 -Alkyl, -C(=O)N(C 1-6 -alkyl) 2 , -C(=O)O-C 1-6 -Alkyl, -NHC(=O)O-C 1-6 -alkyl, unsubstituted -pyridyl, and unsubstituted or -C 1-6 - a compound according to any one of the preceding clauses, as such, mono- or polysubstituted with a substituent selected from the group consisting of 1,2,4-oxadiazole monosubstituted with alkyl; or compounds for use. 20.R 3 and R 4 But together, Unsubstituted, or -N(CH 3 ) 2 a pyrrolidine ring, monosubstituted with unsubstituted or -C 1-6 -alkyl, -NH 2 , -N(CH 3 ) 2 , -C(=O)NH-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkyl, -NHC(=O)O-C 1-6 -alkyl, and unsubstituted or -C 1-6 - a piperidine ring monosubstituted with a substituent selected from the group consisting of 1,2,4-oxadiazole monosubstituted with alkyl, an unsubstituted morpholine ring, or unsubstituted or -C 1-6 A compound as defined in any one of the preceding clauses, as such, or for use, forming a piperidine ring, N-substituted with a substituent selected from the group consisting of -alkyl and unsubstituted -pyridyl. Compound. 21.R 5 and R 5 ’, independently of each other, -H, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -heteroalkyl, a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, optionally connected through -heteroalkylene-; The compound itself or the compound for use. 22.R 5 and R 5 ’, independently of each other, -H, -C 1 -C 6 -alkyl or -C 1 -C 6 -alkylene-N(C 1 -C 6 -alkyl) 2 , as such, or for use in any one of the preceding clauses. 23.R 5 and R 9 are taken together to form an unsubstituted 5- to 6-membered carbocyclic ring, or R 5 and R 9 are taken together to form a 5- to 6-membered heterocycle containing one unsubstituted heteroatom O, as such, or for use. 24.R 6 ,R 7 , and R 8 but independently of each other, -H, -F, -Cl, -Br, -I, -OH, -SH, -SF 5 , -CN, -NO 2 , -C(=O)OH, -NH 2 , Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -O-C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -NHC 1-6 -alkyl, Saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted -N(C 1-6 -alkyl) 2 , Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C(=O)OC 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -OC(=O)C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1-6 -heteroalkyl, as such, or for use in a compound according to any one of the preceding clauses. 25.R 6 ,R 7 , and R 8 but independently of each other, -H, -F, -Cl, -Br, -I, -OH, -SH, -SF 5 , -CN, -NO 2 , -C(=O)OH, -NH 2 , -C 1-6 -alkyl, -CF 3 ,-CHF 2 ,-CH 2 F, -O-C 1-6 -alkyl, -OCF 3 ,-OCHF 2 ,-OCH 2 F, Unsubstituted or independently of each other, -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 , and -C(=O)NH 2 -NHC substituted with one or more substituents selected from 1-6 -alkyl, Unsubstituted or independently of each other, -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 , and -C(=O)NH 2 -N(C 1-6 -alkyl) 2 , Unsubstituted or independently of each other, -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 , and -C(=O)NH 2 -C(=O)OC substituted with one or more substituents selected from 1-6 -alkyl, Unsubstituted or independently of each other, -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 , and -C(=O)NH 2 -OC(=O)C substituted with one or more substituents selected from 1-6 -alkyl, Unsubstituted or independently of each other, -OH, =O, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 , and -C(=O)NH 2 -C substituted with one or more substituents selected from 1-6 -heteroalkyl, as such, or for use in a compound according to any one of the preceding clauses. 26.R 6 is -H, -F, -Cl, -CN, or -C 1 -C 6 - A compound as such or for use in any one of the preceding clauses, representing alkyl. 27.R 6 does not represent -H, as such, or for use in a compound according to any one of the preceding clauses. 28.R 7 is -H, -F, -Cl, -CN, or -C 1 -C 6 - A compound as such or for use in any one of the preceding clauses, representing alkyl. 29.R 7 does not represent -H, as such, or for use in a compound according to any one of the preceding clauses. 30.R 8 is -H, -F, -Cl, -CN, or -C 1 -C 6 - A compound as such or for use in any one of the preceding clauses, representing alkyl. 31.R 8 does not represent -H, as such, or for use in a compound according to any one of the preceding clauses. 32. (i)R 6 ,R 7 , and R 8 each represents -H, (ii)R 6 ,R 7 , and R 8 Two of them represent -H and R 6 ,R 7 , and R 8 the other of which is -F, -Cl, -CN, or -CH 3 represents, (iii)R 6 ,R 7 , and R 8 One of them represents -H and R 6 ,R 7 , and R 8 the other independently of each other is -F, -Cl, -CN, or -CH 3 A compound as such, or for use in any one of the preceding clauses, representing 33.R 9 ,R 10 ,R 11 ,R 12 , and R 13 but independently of each other, -H, -F, -Cl, -Br, -I, -CN, -C(=O)OH, -NH 2 ,-NO 2 , -OH, =O, -SF 5 , Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C(=O)O-C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -NHC 1-6 -alkyl, Saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted -N(C 1-6 -alkyl) 2 , Saturated or unsaturated, unsubstituted, mono- or polysubstituted -O-C 1-6 -alkyl, Saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted, -S(=O) 2 -C 1 - 6 -alkyl, a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl; a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered heterocycloalkyl, wherein the 3- to 14-membered heterocycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 as described in any one of the preceding clauses, optionally connected through -heteroalkylene-, in each case representing a saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl; The compound itself or the compound for use. 34.R 9 ,R 10 ,R 11 ,R 12 , and R 13 but independently of each other, -H, -OH, -F, -Cl, -Br, -I, -SH, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 , -CN, -NO 2 , -C(=O)OH, -NH 2 , or -N(CH 3 ) 2 , Saturated or unsaturated, unsubstituted, independently of each other, -F, -Cl, -Br, -I, -C 1-6 -Alkyl, C 2-6 -alkenyl, -C 2-6 -alkynyl, -OH, =O, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 ,C(=O)CHF 2 , and -C(=O)NH 2 -C mono- or polysubstituted with a substituent selected from the group consisting of 1-6 -alkyl, Saturated or unsaturated, unsubstituted, independently of each other, -F, -Cl, -Br, -I, -C 1-6 -Alkyl, C 2-6 -alkenyl, -C 2-6 -alkynyl, -OH, =O, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 ,C(=O)CHF 2 , and -C(=O)NH 2 -C mono- or polysubstituted with a substituent selected from the group consisting of 1-6 -heteroalkyl, Unsubstituted, independently of each other, -F, -Cl, -Br, -I, -C 1-6 -Alkyl, C 2-6 -alkenyl, -C 2-6 -alkynyl, -OH, =O, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 ,C(=O)CHF 2 , and -C(=O)NH 2 -OC mono- or polysubstituted with a substituent selected from the group consisting of 1-6 -alkyl, Unsubstituted, independently of each other, -F, -Cl, -Br, -I, -C 1-6 -Alkyl, C 2-6 -alkenyl, -C 2-6 -alkynyl, -OH, =O, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 ,C(=O)CHF 2 , and -C(=O)NH 2 -O(C=O)C mono- or polysubstituted with a substituent selected from the group consisting of 1-6 -alkyl, Unsubstituted, independently of each other, -F, -Cl, -Br, -I, -C 1-6 -Alkyl, C 2-6 -alkenyl, -C 2-6 -alkynyl, -OH, =O, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 ,C(=O)CHF 2 , and -C(=O)NH 2 -C(=O)OC mono- or polysubstituted with a substituent selected from the group consisting of 1-6 -alkyl, 3- to 14-membered cycloalkyl selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, in each case unsubstituted and independently of each other -F, -Cl, -Br, -I C 1-6 -Alkyl, C 2-6 -alkenyl, -C 2-6 -alkynyl, -OH, =O, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 ,C(=O)CHF 2 , and -C(=O)NH 2 3- to 14-membered cycloalkyl, mono- or polysubstituted with a substituent selected from the group consisting of; Azepane, 1,4-oxazepane, azetane, azetidine, aziridine, azocane, diazepane, dioxane, dioxolane, dithiane, dithiolane, imidazolidine, isothiazolidine, isoxalidine, morpholine, oxazolidine, oxepane, oxetane, oxirane, piperazine, piperidine, pyrazolidine, Pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiopyran, thiazolidine, thietane, thiirane, thiolane, thiomorpholine, indoline, dihydrobenzofuran, dihydrobenzothiophene, 1,1-dioxothiacyclohexane, 2-azaspiro[3.3]heptane , 2-oxaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, hexahydro-1H-pyrrolidine, hexahydrocyclopenta[c] pyrrole, octahydrocyclopenta[c]pyrrole, and octahydropyrrolo[1,2-a]pyrazine, in each case unsubstituted, independently of each other, -F, -Cl, -Br ,-I C 1-6 -Alkyl, C 2-6 -alkenyl, -C 2-6 -alkynyl, -OH, =O, -SH, =S, -CN, -CF 3 ,-CHF 2 ,-CH 2 F,-OCF 3 ,-OCHF 2 ,-OCH 2 F, S.F. 5 ,-NO 2 , -C(=O)OH, -NH 2 ,C(=O)CHF 2 , and -C(=O)NH 2 3-14 membered heterocycloalkyl, mono- or polysubstituted with substituents selected from the group consisting of , as such, or for use as a compound according to any one of the preceding clauses. 35.R 9 ,R 10 ,R 11 ,R 12 , and R 13 are, independently of each other, -H, -F, -Cl, -CN, -OH, =O, -C 1-6 -alkyl, -CHF 2 ,-CF 3 ,-C 1-6 -alkylene-NH 2 ,-C 1-6 -alkylene-NHC(=O)O-C 1-6 -alkyl, -C 1-6 -alkylene-OH, -C 1-6 -alkylene-NHC(=O)-O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 ,-OC 1-6-alkyl, -OCF 3 ,-O-C 1-6 -alkylene-N(C 1-6 -alkyl) 2 , -S(=O) 2 -C 1-6 -alkyl, -azetidine, -C 1-6 -alkylene-O-tetrahydropyran, or -C 1-6 A compound as such or for use according to any one of the preceding clauses, representing -alkyl-substituted-piperazine. 36. (i)R 9 ,R 10 ,R 11 ,R 12 , and R 13 represents -H, (ii)R 9 ,R 10 ,R 11 ,R 12 , and R 13 Four of them represent -H and R 9 ,R 10 ,R 11 ,R 12 , and R 13 the other two of which represent substituents other than -H, or (iii)R 9 ,R 10 ,R 11 ,R 12 , and R 13 Three of them represent -H and R 9 ,R 10 ,R 11 ,R 12 , and R 13 A compound as such, or a compound for use, according to any one of the preceding clauses, the other of which represents a substituent other than -H. 37. A compound as such or a compound for use as defined in any one of the preceding clauses, selected from the group consisting of compounds 001 to 308 above, and physiologically acceptable salts thereof. 38. A compound per se or for use according to any one of the preceding clauses, wherein the pain is selected from nociceptive pain, inflammatory pain and neuropathic pain. 39. A compound per se or for use according to any one of the preceding clauses, wherein the pain is post-surgical pain. 40. (a)Q is -OR 2 represents, (a-1)R 1 But -CH 2 F, -CHF 2 , or -CF 3 represents and / or (a-2)R 5 and R 5 ’ does not represent -H and R 9 ,R 10 ,R 11 ,R 12 , and R 13 at least one of them does not represent -H and / or (a-3)R 8 does not represent -H, or (b) Q is -NR 3 R 4 represents, (b-1)R 1 But -CH 2 F, -CHF 2 , or -CF 3 represents and / or (b-2)R 9 ,R 10 ,R 11 ,R 12 , and R 13 provided that at least one of them does not represent -H and the following compounds are excluded: [ka] and / or (b-3)R 5 and R 5 ’ does not represent -H and / or (b-4)R 6 ,R 7 , and R 8 provided that at least one of them does not represent -H and the following compounds are excluded: [ka] and / or (b-5)R 3 represents -H and R 9 ,R 10 ,R 11 ,R 12 , and R 13 at least one of them does not represent -H and R 4 but, Saturated or unsaturated, unsubstituted, mono- or polysubstituted -C 1 -C 6 -alkyl, a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl, wherein the 3- to 14-membered cycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, optionally connected through -heteroalkylene-, in each case saturated or unsaturated; a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered heterocycloalkyl, wherein the 3- to 14-membered heterocycloalkyl is -C 1 -C 6 -alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl, An unsubstituted, monosubstituted or polysubstituted 6- to 14-membered aryl, wherein the 6- to 14-membered aryl is -C 1 -C 6 -alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 6- to 14-membered aryl; an unsubstituted, monosubstituted or polysubstituted 5- to 14-membered heteroaryl, wherein the 5- to 14-membered heteroaryl is -C 1 -C 6 -alkylene- or -C 1 -C 6 as defined in any one of the preceding clauses, optionally connected through -heteroalkylene- and in each case representing a saturated or unsaturated, unsubstituted, mono- or polysubstituted 5- to 14-membered heteroaryl; Compounds of formula (I), stereoisomers thereof, physiologically acceptable salts, solvates and / or polymorphs thereof. 41.Q is -NR 3 R 4 represents R 9 ,R 10 ,R 11 ,R 12 , and R 13 Compounds according to clause 40, provided that at least one of them does not represent -H, -F or -Cl. 42. A pharmaceutical composition or medicament comprising a compound according to any one of the preceding clauses.
Example
[0169] The following examples are provided to further illustrate the invention and are not intended to limit the scope of the invention in any way.
[0170] Representative compounds of the present invention can be synthesized according to the general synthetic methods described below and are exemplified in the schemes below. Because the schemes are illustrative, the invention should not be construed as limited by the specific chemistry and specific conditions described in the schemes and examples. The various starting materials used in the schemes are commercially available or can be prepared by methods familiar to those skilled in the art. Variables are as defined herein and are within the skill of one of ordinary skill in the art.
[0171] Abbreviations used herein, particularly in the schemes and examples, are as follows. AcOH-acetic acid, ADDP-1,1'-(azodicarbonyl)dipiperidide, aq.-aqueous, COMU-(1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylamino-morpholino-carbenium hexafluoro Phosphate, DBU-1,8-diazabicyclo[5.4.0]undec-7-ene, DCC-N,N'-dicyclohexylcarbodiimide, DCM-dichloromethane, DEAD-diethyl azodicarboxylate, DEA-diethylamine, DIPEA-diisopropyl- Ethylamine, DIA-diastereomer, DIAD-diisopropylazodicarboxylate, DME-1,2-dimethoxyethane, DMF-N,N-dimethylformamide, DMSO-dimethylsulfoxide, DTBAD-tert-butyl azodicarboxylate, EDCI -1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, En-enantiomer, Et2O-diethyl ether, EtOAc-ethyl acetate, EtOH-ethanol, Eq.-equivalent, FA-formic acid, FCC-flash column chromatography, h-time, HATU-O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate, HPLC-high performance liquid chromatography, IPA-isopropyl alcohol , LG-leaving group, MgSO4-magnesium sulfate, min.-min, Na2SO4-sodium sulfate, NBS-N-bromosuccinimide, NMP-1-methyl-2-pyrrolidinone, Pd(PPh3)4-tetrakis-(triphenylphosphine )-palladium(0), Pd2(dba)3-tris(dibenzylideneacetone)dipalladium, PPh3-triphenylphospine, PS-DIEA polystyrene-supported diisopropyl-ethylamine, PS-PPh3-polystyrene-supported triphenylphospine, PyBop -benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, RP - reversed phase, RT - room temperature, RM - reaction mixture, sat. - saturated, SFC - supercritical fluid chromatography, SPE - solid phase Extraction, TBAI-tetrabutylammonium iodide, TEA-triethylamine, THF-tetrahydrofuran, TFA-trifluoroacetic acid.
[0172] The compounds of interest have structures according to general formula (A), and all other formulas and embodiments thereof described herein can be prepared as outlined in General Chemical Scheme 1. . [ka] Scheme 1: All R1, R2, R3, R4, and R5 are as described for the compounds of the invention.
[0173] Para-benzoquinones of formula 1 are ketoesters of formula 2 (commercially available or synthesized by procedures known to those skilled in the art), where R 2 The ester protection is carried out in the presence of Lewis acids (e.g., titanium(IV) chloride, zinc(II) chloride, etc.) in polar solvents (e.g., DCM, MeOH, EtOH, etc.) at temperatures ranging from 0 to 100 °C. (eg, methyl, ethyl, t-Bu, etc.) to yield intermediates of formula 4. More detailed information can be found in the following references (Bioorg.Med.Chem.2012,20,4237-4244 and FR1319594). Alternatively, the para-benzoquinone of formula 1 can be reacted with an enamine of formula 3 (commercially available or synthesized by procedures known to those skilled in the art) in a polar solvent at a temperature range of 0 to 100 °C. In the presence of a protic acid (eg, trifluoroacetic acid, para-toluenesulfonic acid, etc.) in (eg, DCM, MeOH, EtOH, etc.) intermediates of formula 4 can be obtained. More detailed information can be found in the following reference (J. Heterocyclic Chem. 2006, 43, 873). The intermediate of formula 4 is then converted to the desired compound of formula 7 via nucleophilic substitution using an intermediate of formula 5 (commercially available or synthesized), where LG is a polar solvent (e.g., base (e.g. DIPEA, DBU, triethylamine, Cs in acetonitrile, DMF, NMP, etc.) 2 C.O. 3 etc.), it is a leaving group. Alternatively, intermediates of formula 4 can also be combined with azodicarboxylate reagents (e.g., DEAD, DIAD, ADDP, etc.) and phosphines (e.g., DEAD, DIAD, ADDP, etc.) in a solvent (e.g., THF, toluene, etc.) at a temperature range of 0-100°C. For example, tributylphosine, triphenylphosphine, etc.) can also be reacted with an intermediate of formula 6 (commercially available or synthesized) to give the desired compound of formula 7. Ester derivative 7 can then be converted to the desired compound of formula 8 by standard saponification reactions. The desired compound of formula 10 can be synthesized with an amine derivative of formula 9 ( are commercially available or can be obtained from acid derivatives of formula 8 by reaction by procedures known in the art or synthesized as described in the Examples below. Alternatively, carboxylic acid derivatives of formula 8 are converted to acid chloride derivatives by procedures known to those skilled in the art or as described in the examples below, and then reacted with amines of formula 9. The desired compounds of formula 10 can be obtained by procedures known to those skilled in the art, or as described in the Examples below.
[0174] In a more specific embodiment, compounds of the invention can be synthesized as shown in Scheme 2. [ka] Scheme 2: All R1, R2, R3, R4, and R5 are as described for the compounds of the invention.
[0175] 5-Hydroxy-benzofuran-3-carboxylic acid derivative 11 (commercially available or synthesized by procedures known in the art or as described in the Examples below) is prepared in a polar aprotic solvent. Amine derivatives of formula 9 (commercially available or procedures known in the art) under standard peptide binding conditions (e.g., DCC, EDCI, HATU, PyBop, etc.) in (e.g., DCM, DMF, etc.) or as synthesized as described in the Examples below) to provide intermediates of formula 12. Alternatively, compounds of formula 13 (synthesized as described in Scheme 1) can be reduced using a catalyst (more preferably Pd or Pt) in a solvent (e.g. THF, EtOH, etc.). It can be converted to intermediates of formula 12 by hydrogenation reaction with agents (eg, hydrogen gas, ammonium formate, cyclohexadiene, etc.). The intermediate of formula 12 is then converted to the desired compound of formula 10 (where LG is 0 Polar solvents (e.g. acetonitrile, DMF , NMP, etc.) in base materials (e.g., DIPEA, DBU, triethylamine, Cs 2 C.O. 3 ), which is a leaving group. Alternatively, intermediates of formula 12 can also be synthesized with azodicarboxylate reagents (e.g. DEAD, ADDP, DIAD, tert-butylazo dicarboxylate) and a phosphine (e.g., tributylphosine, triphenylphosphine, etc.) to form the desired compound of formula 10. It is also possible to obtain a compound of
[0176] In a more specific embodiment, compounds of the invention can be synthesized as shown in Scheme 3. [ka] Scheme 3: All R1, R2, R3, R4, R5, R7, and R8 are as described for the compounds of the invention.
[0177] Substituted para-benzoquinone derivatives of formula 14 are ketoesters of formula 2 (commercially available or synthesized by procedures known to those skilled in the art) (wherein R 2 The ester protection is carried out in the presence of Lewis acids (e.g., titanium(IV) chloride, zinc(II) chloride, etc.) in polar solvents (e.g., DCM, MeOH, EtOH, etc.) at temperatures ranging from 0 to 100 °C. (eg, methyl, ethyl, t-Bu, etc.) to yield a mixture of substituted intermediates of formulas 15 and 16. More detailed information can be found in the following references (Bioorg.Med.Chem.2012,20,4237-4244 and FR1319594). Intermediates of formula 15 and / or 16 are then converted to desired compounds of formula 17 and / or 18 via nucleophilic substitution using intermediates of formula 5 (commercially available or synthesized). (In the formula, LG is a compound with or without a chelating agent (e.g., 18-crown-6, cis-anti-cis-dicyclohexano-18-crown-6, etc.) at a temperature range of 0 to 100°C. Base (e.g. DIPEA, DBU, triethylamine, Cs 2 C.O. 3), which is a leaving group. Alternatively, intermediates of formula 15 and / or 16 can also be prepared using azodicarboxylate reagents (e.g., DEAD, DIAD, ADDP, etc.) in a solvent (e.g., THF, toluene, etc.) at a temperature range of 0-100°C. ) and a phosphine (e.g., tributylphosine, triphenylphosphine, etc.) with an intermediate of formula 6 (commercially available or synthesized) to form the desired compound of formula 17 and / or 18. It is also possible to obtain a compound of Ester derivatives 17 and / or 18 can then be converted to the desired carboxylic acids of formulas 19 and / or 20 by standard saponification reactions. Desired compounds of formula 21 and / or 22 can be synthesized from formula 9 under standard peptide coupling conditions (e.g., DCC, EDCI, HATU, PyBop, etc.) in polar aprotic solvents (e.g., DCM, DMF, etc.). from acid derivatives of formula 19 and / or 20 by reaction with amine derivatives of (commercially available or synthesized by procedures known in the art or as described in the Examples below) I can do it. A mixture of compounds 21 and 22 can be separated (eg, silica gel, HPLC, SFC or preparative CFC) to yield the desired compound of formula 21 or 22.
[0178] In a more specific embodiment, compounds of the invention can be synthesized as shown in Scheme 4. [ka] Scheme 4: All R1, R2, R3, R4, R5, R7, and R8 are as described for the compounds of the invention.
[0179] Intermediates of formula 4 can be halogenated with a suitable halogenating agent (eg, bromine, N-bromosuccinimide, etc.) in a solvent (eg, chloroform, water, etc.) to provide the desired intermediate 23. The desired compound of formula 26 can be obtained by an Ullmann type reaction with CuCN followed by a Mitsunobu type reaction with intermediates of formula 6 (commercially available or synthesized). Alternatively, the desired compound of formula 26 can be obtained by a Mitsunobu type reaction with an intermediate of formula 6 (commercially available or synthesized) followed by a Suzuki reaction. Ester derivative 26 can then be converted to the desired compound of formula 27 by standard saponification reactions. The desired compound of formula 28 can be synthesized with an amine derivative of formula 9 ( are commercially available or can be obtained from acid derivatives of formula 27 by reaction by procedures known in the art or synthesized as described in the Examples below.
[0180] In a more specific embodiment, compounds of the invention can be synthesized as shown in Scheme 5. [ka] Scheme 5: All R1, R2, R3, and R4 are as described for the compounds of the invention.
[0181] Intermediates of formula 4 can be halogenated with a suitable halogenating agent (eg, select fluor, etc.) in a solvent (eg, chloroform, acetonitrile, etc.) to provide the desired intermediates 29 and 30. Intermediates of formula 29 and / or 30 can be prepared using azodicarboxylate reagents (e.g. DEAD, DIAD, ADDP, etc.) and phosphines (e.g. , triphenylphosphine, etc.) to give the desired compounds of formula 31 and / or 32. Ester derivatives 31 and / or 32 can then be converted to the corresponding carboxylic acids of formula 33 and / or 34 by standard saponification reactions. Desired compounds of formula 35 and / or 36 can be synthesized by formula 9 under standard peptide coupling conditions (e.g., DCC, EDCI, HATU, PyBop, etc.) in polar aprotic solvents (e.g., DCM, DMF, etc.). from acid derivatives of formula 33 and / or 34 by reaction with amine derivatives of (commercially available or synthesized by procedures known in the art or as described in the Examples below) I can do it. A mixture of compounds 35 and 36 can be separated (eg, silica gel, HPLC, SFC or preparative CFC) to yield the desired compound of formula 35 or 36.
[0182] Example [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7] [Table 3-8] [Table 3-9] [Table 3-10] [Table 3-11] [Table 3-12] [Table 3-13]
[0183] The above examples are provided for the purpose of illustrating the invention and should not be construed as limiting the scope of the invention in any way.
[0184] Part A represents compound preparation and Part B represents pharmacological examples.
[0185] Part A All starting materials not explicitly mentioned are commercially available (e.g. Acros, Avocado, Aldrich, Fluka, FluoroChem, MatrixScientific, Maybridge, Merck, Sigma, etc.). trademark) database), or their synthesis has already been precisely described in the specialized literature (e.g. experimental guidelines can be found in the Reaxys® database or the SciFinder® database, respectively) ) or prepared using conventional methods known to those skilled in the art.
[0186] The reaction is carried out under an inert atmosphere (mainly argon and N 2 ) was carried out under The number of equivalents of reagents, the amount of solvent used, and the reaction temperature and time may vary slightly between different reactions carried out by similar methods. Processing and purification methods are adapted according to the characteristic properties of each compound and may vary slightly for similar methods. The yield of the prepared compounds has not been optimized.
[0187] The expression "equivalent" ("eq." or "eq" or "equiv.") means molar equivalent; "RT" or "rt" means room temperature T (23±7°C); "M" is the expression of concentration in mol / l, "sol." means solution and "conc." means concentration. The mixing ratio of solvents is usually expressed as a volume / volume ratio.
[0188] Key analytical characterizations were performed for all exemplary compounds and selected intermediates. 1 H-NMR spectroscopy and / or mass spectrometry (MS, [M+H] + and / or [M-H] - m / z). In certain cases, e.g. where positional isomers and / or diastereomers may be formed, e.g. 13 Additional analyzes such as C NMR and NOE (nuclear Overhauser effect) NMR experiments were performed in some cases.
[0189] The analytical equipment used was, for example, a BRUKER 400MHz or BRUKER 500MHz machine (Software Topspin) for NMR analysis; alternatively, a BRUKER AVANCE 300MHz and 400Mhz were used. For LC / MS analysis, for example, Agilent 1290 infinity, Mass: 6150 SQD (ESI / APCI) or Agilent 1200 SERIES, Mass: 6130 SQD (ESI / APCI) (Software Chemistation) was used. Analytical HPLC was measured using, for example, Waters (Software Empower), Agilent-1200-ELSD (Software Chemisation), or Agilent-1260 (Software OpenLAB). Analytical SFC was performed, for example, in PIC solution (Software: SFC PICLAB ONLINE), WATERS-X5 (Software MASSLYNX), or WATERS-UPC2 (Empower).
[0190] Preparative HPLC was performed, for example, on a Waters 2998 (Software Empower) or YMC (Software K-Prep). Preparative SFC was performed on, for example, a Waters, SFC-200 (Software Chromscope or Super chrome), a Waters, SFC-80 (Super chrome), or a PIC, PIC-175 (Software S10-100).
[0191] Exemplary compound structures containing stereocenters are drawn and named in absolute stereochemistry, where known. In the case of unknown absolute stereochemistry, the compound can be either racemic, a mixture of diastereomers, a pure diastereomer of unknown stereochemistry, or a pure enantiomer of unknown stereochemistry. Dia1 and Dia2 mean that the diastereosomes are separated but the stereochemistry is unknown. En1 and En2 mean that both enantiomers have been separated but the absolute configuration is unknown. Unless the chemical name of the compound specifies the exact stereochemistry, a suffix after the compound code means that the compound containing the stereocenter was obtained as a racemic mixture or a mixture of diastereomers, respectively.
[0192] LC / MS analysis was also performed using a Dionex Ultimate 3000 HPLC system (equipped with a PDA detector) connected to a mass spectrometer Brucker Esquire 6000 (equipped with a multimode source, ESI / APCI) (method L in the table below) But it was implemented. Alternatively, the LC / MS analysis described in the experimental part was performed on a Waters system (Method U in the table below), combined with an Acquity UPLC H class equipped with an Acquity UPLC PDA detector and an Acquity TQ detector (ESI).
[0193] Separations can be performed using e.g. SunFire C18, a 3.5 μm 3.0x100 mm column equipped with a SunFire C18, a 3.5 μm 3.0x20 mm guard column, or an X-Bridge C18 100x3.0 mm column equipped with an X-Bridge C18, at 30 °C. It was carried out using a 3.5 μm, 3.0×20 mm guard column kept at constant temperature, and the DAD acquisition wavelength was set within the range of 190 to 420 nm (Method L in the table below). Alternatively, separation can be performed using an Acquity UPLC HSS C18, 2.1 x 50 mm, 1.8 μM column, equipped with a prefilter and incubated at 40°C, or an Acquity UPLC BEH C18, 2.1, equipped with a prefilter and incubated at 40°C. It was carried out using a ×50 mm, 1.7 μM column, and the PAD acquisition wavelength was set in the range of 210 to 420 nm (Method U in the table below). Elution was performed as described in the table below. [Table 4] [Table 5]
[0194] Preparative HPLC purification was also performed using a Waters 2489 UV / visible detector, a Waters 2545 Binary gradient module, a Waters Fraction Collector III, and a Waters Dual Flex syringe.
[0195] Separations were performed using an X-Bridge Prep C18 column, 100 x 19 mm; It was performed using a Prep C18 ODB column (5 μm; 19×100 mm).
[0196] Elution was performed as described in the table below, and detection wavelengths were fixed at 210 and 254 nm. [Table 6]
[0197] Methyl 2-ethyl-5-((3-fluorobenzyl)oxy)benzofuran-3-carboxylate (compound 030) and 2-ethyl-5-((3-fluorobenzyl)oxy)benzofuran-3-carboxylic acid (compound 015) synthesis [ka] Step 1: Methylamine (2M in THF, 2.9mL) was added dropwise to a solution of methyl 3-oxopentanoate (1.3M in MeOH, 2.9mL) at room temperature and the RM was stirred at room temperature for 3 hours. . The volatiles were removed under reduced pressure to give 550 mg (quantitative yield) of methyl 3-(methylamino)pent-2-enoate, which was used in the next step without further purification.
[0198] Step 2: A solution of methyl 3-(methylamino)pent-2-enoate (1.3M in DCM, 7.7mL) was combined with TFA (0.1mL, 1.31mmol) and p-benzoquinone (1.08M in DCM (7.5mL)). g, 9.99 mmol) dropwise over 10 minutes. The RM was stirred at -30°C for 6 hours and then kept at -25°C overnight without stirring. The RM was warmed to room temperature and volatiles were removed under reduced pressure to yield 2.14 g (90%) of the desired methyl 2-(2,5-dihydroxyphenyl)-3-(methylamino)pent-2-enoate. , which was used in the next step without further purification.
[0199] Step 3: Add TFA (1 mL, 13.06 mmol) to the suspension of methyl 2-(2,5-dihydroxyphenyl)-3-(methylamino)pent-2-enoate (0.55 g, 2.19 mmol) in toluene (25 mL). added to the suspension. The RM was stirred at 85° C. for 7 hours and at room temperature overnight. The volatiles were then removed under reduced pressure and the residue was purified by FCC on silica gel using a gradient of EtOAc in heptane (0% to 100%) to give 0.482 g (22% ) was obtained as methyl 2-ethyl-5-hydroxybenzofuran-3-carboxylate. 1 H NMR(CDCl 3 ,300 MHz):δ ppm 9.36(s,1H);7.40(d,1H);7.26(d,1H);6.75(dd,1H);3.87(s,3H);3.12(q,2H);1.26 (t,3H).
[0200] Step 4: Cesium carbonate (323 mg, 0.990 mmol) was added to a solution of methyl 2-ethyl-5-hydroxybenzofuran-3-carboxylate (109 mg, 0.495 mmol) in THF (3 mL). RM was stirred for 25 minutes at room temperature. 1-(Bromomethyl)-3-fluorobenzene (0.091 mL, 0.742 mmol) was then added and the solution was stirred at 95° C. for 18 hours. The mixture was cooled to room temperature, diluted with EtOAc, washed twice with water and brine. The organic layer was dried with magnesium sulfate and filtered. The solvent was removed under reduced pressure and the resulting oil was purified by FCC on silica gel using a gradient of EtOAc in heptane (0% to 100%) to give 110 mg (54%) of methyl 2-ethyl -5-((3-fluorobenzyl)oxy)benzofuran-3-carboxylate (compound 030) was obtained.
[0201] Step 5: In a sealed tube, add methyl 2-ethyl-5-((3 -fluorobenzyl)oxy)benzofuran-3-carboxylate (Compound 030) (110 mg, 0.335 mmol) and the RM was stirred at 85° C. overnight. The RM was cooled to room temperature, diluted with water, washed with EtOAc, acidified with 1N HCl solution, and extracted with EtOAc. The resulting organic layer was washed with water and water, dried over magnesium sulfate, and filtered. Solvent was removed under reduced pressure. The compound was purified by SPE on a C18 gel using a gradient of acetonitrile in water (0% to 80%) to yield 49.8 mg (46%) of 2-ethyl-5-((3-fluorobenzyl) Oxy)benzofuran-3-carboxylic acid (compound 015) was obtained.
[0202] Compound 007, Compound 020, and Compound 023 were prepared in a similar manner as Compound 030 and Compound 015 (using appropriate reagents and purification methods known to those skilled in the art).
[0203] Ethyl 5-((2-chloro-6-fluorobenzyl)oxy)-2-methylbenzofuran-3-carboxylate (Compound 033) and 5-((2-chloro-6-fluorobenzyl)oxy)-2-methyl Synthesis of benzofuran-3-carboxylic acid (compound 021). [ka] Step 1: To a solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (0.220 g, 1 mmol) in THF (8 mL) was added cesium carbonate (0.652 g, 2 mmol) to a RM of 10 at room temperature. Stir for a minute. 2-(bromomethyl)-1-chloro-3-fluorobenzene (0.338 mL, 2.5 mmol) was then added and the stirred solution was heated at 95 °C until consumption of 5-hydroxy-2-methylbenzofuran-3-carboxylate. heated with. The mixture was cooled to room temperature, poured into water and extracted twice with EtOAc. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient (0% to 100%) of DCM in heptane to give 0.282 g (78%) of ethyl 5-((2-chloro-6-fluorobenzyl) Oxy)-2-methylbenzofuran-3-carboxylate (compound 033) was obtained.
[0204] Step 2: Ethyl 5-((2-chloro-6-fluorobenzyl)oxy)-2-methylbenzofuran-3-carboxylate (Compound 033) (0.282 g) in a mixture of MeOH-EtOH (2:1, 23 mL) , 0.777 mmol) was added with an aqueous sodium hydroxide solution (1N, 23 mL) to convert RM to ethyl 5-((2-chloro-6-fluorobenzyl)oxy)-2-methylbenzofuran-3-carboxylate. Heated under reflux until consumption of (compound 033). After cooling, the volatiles were removed under reduced pressure and the remaining residue was dissolved in water. The mixture was acidified using aqueous hydrochloric acid (6N) until the pH was approximately 2. The white precipitate was washed with water and dried under reduced pressure to give 0.259 g (99%) of 5-((2-chloro-6-fluorobenzyl)oxy)-2-methylbenzofuran-3-carboxylic acid (compound 21) was obtained.
[0205] Compound 001, Compound 004, Compound 005, Compound 006, Compound 009, Compound 010, Compound 012, Compound 024, Compound 025, Compound 026, and Compound 028 were prepared in the same manner as Compound 33 and Compound 21 (as known to those skilled in the art). (using appropriate reagents and purification methods).
[0206] Ethyl 5-((2,3-dihydro-1H-inden-1-yl)oxy)-2-methylbenzofuran-3-carboxylate (Compound 032) and 5-((2,3-dihydro-1H-inden- Synthesis of 1-yl)oxy)-2-methylbenzofuran-3-carboxylic acid (compound 011). [ka] Step 1: Ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (100 mg, 0.454 mmol), 2,3-dihydro-1H-inden-1-ol (73.1 mg, 0.545 mmol) and PPh 3 (119 mg, 0.454 mmol) was dissolved in toluene (5 mL) and cooled to 0°C. A solution of DEAD (2M in THF, 1.2 eq.) was then added dropwise and the RM was stirred at room temperature for 18 hours. The volatiles were removed under reduced pressure and the residue was diluted with DCM and washed successively with aqueous NaOH (1N), water, and brine. The organic layer was dried over magnesium sulfate, filtered and the solvent was removed under reduced pressure. The compound was purified by SPE on a C18 gel using a gradient of acetonitrile in water (10% to 80%) to give 130 mg (77%) of ethyl 5-((2,3-dihydro-1H-indene). -1-yl)oxy)-2-methylbenzofuran-3-carboxylate (compound 032) was obtained.
[0207] Step 2: Add aqueous NaOH (1N, 7.83mL, 40mmol) to ethyl 5-((2,3-dihydro-1H-inden-1-yl)oxy)-2-methylbenzofuran-3- in MeOH (2mL). It was added to a solution of carboxylate (compound 032) (130 mg, 0.386 mmol) and the mixture was stirred at 80° C. for 4 hours. After cooling, the mixture was diluted with water and washed with DCM. The aqueous layer was acidified with aqueous HCl (6N) to pH=1 and extracted with EtOAc. The resulting organic layer was dried over magnesium sulfate, filtered, and the solvent was removed under reduced pressure. The crude material was purified by SPE on C18 gel using a gradient of acetonitrile in water (10% to 80%) to yield 26.6 mg (21%) of 5-((2,3-dihydro-1H- Inden-1-yl)oxy)-2-methylbenzofuran-3-carboxylic acid (compound 011) was obtained.
[0208] Compound 013 and Compound 014 were prepared in a similar manner as Compound 32 and Compound 11 (using appropriate reagents and purification methods known to those skilled in the art).
[0209] Synthesis of tert-butyl 3-(5-(benzyloxy)-2-methylbenzofuran-3-carboxamido)piperidine-1-carboxylate (compound 247). [ka] Step 1: HATU (121 mg, 0.319 mmol) was combined with 5-(benzyloxy)-2-methylbenzofuran-3-carboxylic acid (compound 002) (60 mg, 0.213 mmol) and DIPEA (82 mg, 0.638 mmol) in DCM (3 mL). mmol) solution. After 3 hours at room temperature, tert-butyl 3-aminopiperidine-1-carboxylate (53.2 mg, 0.266 mmol) was added and the RM was stirred overnight. The RM was then diluted with DCM and washed successively with saturated sodium bicarbonate solution and brine. The organic layer was dried with magnesium sulfate and filtered. The volatiles were removed under reduced pressure and the crude material was purified by FCC on silica gel using a gradient of EtOAc in heptane (10% to 100%) to yield 86.0 mg (84%) of tert-butyl 3 -(5-(benzyloxy)-2-methylbenzofuran-3-carboxamide)piperidine-1-carboxylate (Compound 247) was obtained.
[0210] The following compounds were prepared in a similar manner to compound 247 (using appropriate reagents and purification methods known to those skilled in the art): Compounds 035, 037, 038, 039, 040, 041, 043, 044, 045, 046, 047, 050, 051, 052, 053, 054, 055, 056, 057, 060, 064, 065, 066, 067, 068 , 071, 072, 076, 079, 080, 081, 086, 087, 088, 089, 090, 091, 092, 098, 099, 100, 101, 102, 104, 105, 106, 109, 111, 117, 118 , 122, 124, 125, 128, 132, 134, 138, 139, 142, 144, 148, 149, 150, 151, 152, 153, 154, 156, 165, 166, 168, 171, 172, 179, 182 , 183, 185, 186, 187, 189, 194, 196, 197, 198, 200, 205, 106, 107, 210, 212, 213, 214, 217, 218, 221, 222, 225, 228, 229, 230 , 232, 233, 234, 235, 236, 237, 238, 239, 241, 243, 244, 248, 249, 251, 252, 253, 258, 262, 264, 265, 266, 268, 269, 270, 271 , 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 309, 310, 312, 313, 315, 326, 328-En1(R), 328-En2(S), and 337.
[0211] Synthesis of tert-butyl((1-(5-(benzyloxy)-2-methylbenzofuran-3-carboxamido)cyclobutyl)methyl)carbamate (compound 246) [ka] Step 1: To a solution of 5-(benzyloxy)-2-methylbenzofuran-3-carboxylic acid (450 mg, 1.59 mmol) in toluene (30 mL) was added thionyl chloride (0.578 mL, 7.97 mmol) at room temperature. The RM was refluxed overnight, cooled to room temperature, and concentrated under reduced pressure to yield the desired acid chloride, which was used without further purification.
[0212] Step 2: Add 5-(benzyloxy)-2-methylbenzofuran-3-carbonyl chloride (200 mg, 0.66 mmol) in DCM (2 mL) to tert-butyl ((1-aminocyclobutyl) methyl)carbamate (160 mg, 0.8 mmol) and DIPEA (0.5 mL, 2.7 mmol). RM was stirred at room temperature for 36 hours. RM was concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of EtOAc in heptane (4% to 40%) to give 208 mg (67%) of tert-butyl ((1-(5-(benzyloxy)- 2-Methylbenzofuran-3-carboxamido)cyclobutyl)-methyl)carbamate (compound 246) was obtained.
[0213] The following compounds were prepared in a similar manner to compound 246 (using appropriate reagents and purification methods known to those skilled in the art): Compounds 036, 058, 059, 061, 062, 069, 070, 107, 108, 110, 112, 112, 123, 129, 146, 155, 159, 164, 167, 174, 178, 181, 208, 209, 216 , 219, 254, 259 and 263, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291 and 292.
[0214] Synthesis of tert-butyl (S)-3-(5-((2,3-difluorobenzyl)oxy)-2-methylbenzofuran-3-carboxamido)pyrrololidine-1-carboxylate (compound 256). [ka] Step 1: Tert-butyl(S)-3-aminopyrrololidine-1-carboxylate (1.1 g, 5.7 mmol) was added to 5-hydroxy-2-methylbenzofuran-3-carboxylic acid (1 g) in DMF (10 mL). , 5.2 mmol), HATU (1.98 g, 5.2 mmol), and DIPEA (2.7 mL, 15.6 mmol). After 60 hours, the reaction was concentrated under reduced pressure. The residue was partitioned between water and EtOAc. After separation, the aqueous layer was extracted twice with EtOAc. The combined EtOAc extracts were dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of MeOH in DCM (0-6%) to give 0.94 g (50%) of the desired compound as a white solid. M / Z(+):361(M+H).M / Z(-):359(M-H). 1 H NMR(DMSO-d 6 ,300MHz)δppm:9.26(s,1H),8.17(d,J=6.4Hz,1H),7.32(d,J=9.0Hz,1H),6.99(d,J=1.88Hz,1H),6.70( dd,J=8.9,2.1Hz,1H),4.35-4.50(m,1H),3.51-3.3.65(m,1H),3.35-3.49(m,1H),3.15-3.31(m,1H), 2.53(s.,3H),2.02-2.19(m,1H),1.84-1.99(m,1H),1.41(s,9H).
[0215] Step 2: Add tributylphosphine (0.103 mL, 0.39 mmol) to tert-butyl-(S)-3-(5-hydroxy-2-methylbenzofuran-3-carboxamide)pyrrolidine in dry THF (5 mL) under argon. Added dropwise to a stirred mixture of -1-carboxylate (0.100 g, 0.28 mmol), (2,3-difluorophenyl)methanol (0.063 g, 0.42 mmol), and ADDP (0.100 g, 0.39 mmol). The mixture was stirred at room temperature for 2 hours, then the reaction was concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of EtOAc in heptane (7-100%) to give 0.119 (83%) tert-butyl(S)-3-(5-((2, 3-Difluorobenzyl)oxy)-2-methylbenzofuran-3-carboxamido)pyrrolidine-1-carboxylate (Compound 256) was obtained.
[0216] Compound 224, Compound 242, Compound 245, Compound 250, Compound 257, Compound 260, Compound 261, Compound 267, Compound 293, Compound 294, Compound 295, and Compound 296 were prepared in the same manner as Compound 256 (as known to those skilled in the art). (using appropriate reagents and purification methods).
[0217] Synthesis of 5-((2,6-difluorobenzyl)oxy)-2-methylbenzofuran-3-carboxylic acid (compound 019). [ka] Step 1: Ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (0.5 g, 2.2 mmol), (2,6 -difluorophenyl)methanol (0.48 g, 3.2 mmol), and ADDP (0.78 g, 3 mmol) dropwise. The mixture was stirred for 2 hours, then concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of EtOAc in heptane (3-30%) to give 0.73 g (97%) of ethyl 5-((2,6-difluorobenzyl)oxy)- 2-Methylbenzofuran-3-carboxylate was obtained. M / Z(+):347(M+H).
[0218] Step 2: Solution of ethyl 5-((2,6-difluorobenzyl)oxy)-2-methylbenzofuran-3-carboxylate (0.73 g, 2.1 mmol) in a mixture of MeOH-THF (1:1, 6 mL) To the solution, sodium hydroxide solution (2N, 4.5 mL, 9 mmol) was added and the RM was heated at 75° C. overnight. After cooling, the volatiles were removed under reduced pressure and the remaining residue was dissolved in water. The mixture was acidified using HCl solution (6N) until the pH was approximately 5. The white precipitate was filtered, washed with water, and dried under reduced pressure to yield 0.64 g (96%) of the desired compound (Compound 019).
[0219] Compound 034 was prepared in a similar manner to compound 019 (using appropriate reagents and purification methods known to those skilled in the art).
[0220] Synthesis of tert-butyl 3-(5-(benzyloxy)-2-methylbenzofuran-3-carboxamide)-4-fluoropiperidine-1-carboxylate (compound 255). [ka] A solution of 5-(benzyloxy)-2-methylbenzofuran-3-carbonyl chloride (200 mg, 0.66 mmol) in DCM (2 mL) was added to a solution of tert-butyl 3-amino-4-fluoropiperidine-1-carboxylate (174 mg , 0.8 mmol), DIPEA (0.46 mL, 2.7 mmol), and DCM (2 mL). The RM was stirred at room temperature for 36 hours. The volatiles were removed under reduced pressure and the crude material was purified by FCC on silica gel using a gradient of EtOAc in heptane (4% to 40%) to yield 60 mg (18.75%) of tert-butyl 3- (5-(benzyloxy)-2-methylbenzofuran-3-carboxamide)-4-fluoropiperidine-1-carboxylate (compound 255-Dia1) and 150 mg (46.87%) of tert-butyl 3-(5-(benzyl) Oxy)-2-methylbenzofuran-3-carboxamide)-4-fluoropiperidine-1-carboxylate (compound 255-Dia2) was obtained.
[0221] Synthesis of 5-(benzyloxy)-2-methyl-N-(7-azaspiro[3.5]nonan-2-yl)benzofuran-3-carboxamide (compound 180). [ka] A solution of hydrogen chloride in 1,4-dioxane (4M, 4mL, 16mmol) was dissolved in tert-butyl 2-(5-(benzyloxy)-2-methylbenzofuran-3-carboxamide)-7 in DCM (2mL). -Azaspiro[3.5]nonane-7-carboxylate (Compound 264) (0.124g, 0.077mmol) was added to the solution. The mixture was stirred at room temperature overnight and concentrated under reduced pressure. The residue was then purified by FCC on silica gel using a gradient (1-12%) of 3N ammonia in MeOH in DCM to yield 0.035 g (35.4%) of 5-(benzyloxy)- 2-Methyl-N-(7-azaspiro[3.5]nonan-2-yl)benzofuran-3-carboxamide (compound 180) was obtained.
[0222] The following compounds were prepared in a similar manner to compound 180 (using appropriate reagents and purification methods known to those skilled in the art): Compounds 042, 048, 049, 073, 074, 075, 077, 078, 082, 083, 084, 085, 093, 094, 095, 096, 097, 103, 114, 115, 116, 119, 120, 121, 126 , 127, 130-Dia1, 130-Dia2, 131, 135, 136, 137, 140, 141, 143, 157, 173, 184, 190, 191, 201, 202, 203, 204, 211, 220, 223, 226 , 227, 231, and 240.
[0223] Synthesis of (S)-5-(benzyloxy)-2-methyl-N-(1-(methylsulfonyl)pyrrolidin-3-yl)benzofuran-3-carboxamide (compound 215). [ka] Step 1: Solution of (S)-5-(benzyloxy)-2-methyl-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide (Compound 049) (75 mg, 0.21 mmol) in DCM (4 mL) To this, methanesulfonyl chloride (18 μL, 0.23 mmol) and TEA (33 μL, 0.23 mmol) were added at room temperature. RM was stirred at room temperature until consumption of compound 049. The volatiles were removed under reduced pressure and the crude material was purified by FCC on silica gel using a gradient of EtOAc in heptane (50% to 100%) to yield 51 mg (56%) of (S)-5 -(Benzyloxy)-2-methyl-N-(1-(methylsulfonyl)pyrrolidin-3-yl)benzofuran-3-carboxamide (Compound 215) was obtained.
[0224] Synthesis of (S)-N-(1-acetylpyrrolidin-3-yl)-5-(benzyloxy)-2-methylbenzofuran-3-carboxamide (compound 145) [ka] A solution of (S)-5-(benzyloxy)-2-methyl-N-(pyrrolidin-3-yl)benzofuran-3-carboxamide (Compound 049) (75 mg, 0.21 mmol) in DCM (4 mL) was added to Acetyl (13 μL, 0.23 mmol) and TEA (33 μL, 0.23 mmol) were added at room temperature. The RM was stirred at room temperature overnight. The volatiles were removed under reduced pressure and the crude material was purified by FCC on silica gel using a gradient of first EtOAc (100%) and then MeOH (2%) in DCM to yield 50 mg (59%). (S)-N-(1-acetylpyrrolidin-3-yl)-5-(benzyloxy)-2-methylbenzofuran-3-carboxamide (compound 145) was obtained.
[0225] Synthesis 5-(benzyloxy)-2-methyl-N-(methylsulfonyl)benzofuran-3-carboxamide (compound 063) [ka] Step 1: Sodium hydride (60% in oil, 70.84 mg, 1.77 mmol) was added to a cooled (0 °C) solution of methanesulfonamide (40.4 mg, 0.425 mmol) in THF (3 mL). The resulting suspension was stirred for 1.5 h and a solution of 5-(benzyloxy)-2-methylbenzofuran-3-carbonyl chloride (described above) (106 mg, 0.35 mmol) in THF (3 mL) was added over 10 min. Added dropwise and then the RM was stirred at room temperature for 18 hours. The RM was then cooled to 0°C, quenched with water and stirred at room temperature for 20 minutes. The mixture was extracted with DCM and EtOAc. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of EtOAc in heptane (20% to 100%) followed by MeOH in EtOAc (0% to 25%) to give 101.5 mg (74%) of 5 -(benzyloxy)-2-methyl-N-(methylsulfonyl)benzofuran-3-carboxamide (compound 063) was obtained.
[0226] Compound 133, Compound 169, Compound 170, Compound 175, Compound 176, Compound 177, Compound 195, and Compound 199 were prepared in a similar manner to Compound 063 (using appropriate reagents and purification methods known to those skilled in the art). .
[0227] Synthesis of 5-((2-(hydroxymethyl)benzyl)oxy)-2-methyl-N-(1-methylpiperidin-4-yl)benzofuran-3-carboxamide (compound 192) [ka] A solution of HCl (2N in water, 3mL, 6mmol) in MeOH (3mL) was prepared by adding 2-methyl-N-(1-methylpiperidin-4-yl)-5-((2-(((tetrahydro-2H-pyran) -2-yl)oxy)methyl)benzyl)oxy)benzofuran-3-carboxamide (compound 260) (135 mg, 0.27 mmol). The RM was stirred at room temperature for 2 hours. Then 20 mL of ammonia solution (10%) in MeOH was added to the RM. The volatiles were evaporated under reduced pressure. The residue was first purified by FCC on silica gel using a gradient (2-10%) of MeOH (with ammonia) in DCM. The crude product was purified by preparative HPLC (Method H1) to yield 10 mg (8%) of the desired product (Compound 192).
[0228] Synthesis of 5-(benzyloxy)-N-(1-ethyl-2-oxopyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide (compound 147) [ka] Cesium hydroxide (46 mg, 0.27 mmol) was added to 5-(benzyloxy)-2-methyl-N-(2-oxopyrrolidin-3-yl)benzofuran-3-carboxamide (compound 070) in DMF (2 mL). 100 mg, 0.27 mmol). Ethyl iodide (0.05 mL, 0.55 mmol) was then added to the reaction. The mixture was stirred at room temperature for 2 hours, quenched with ice, and acidified with 1N aqueous HCl. The mixture was extracted with EtOAc and concentrated under reduced pressure. The crude mixture was purified by FCC on silica gel using a gradient of MeOH in DCM (0-20%). The residual oil was purified by preparative HPLC (Method H1) to yield 39 mg (36.2%) of the desired compound (Compound 147).
[0229] Synthesis of 4-(5-(benzyloxy)-2-methylbenzofuran-3-carboxamide)tetrahydro-2H-pyran-4-carboxylic acid (compound 193) [ka] An aqueous solution of NaOH (2N, 1 mL) was added to methyl 4-(5-(benzyloxy)-2-methylbenzofuran-3-carboxamide)tetrahydro-2H-pyran-4-carboxylate (compound 212) in MeOH (1 mL). and the mixture was stirred at room temperature for 5 days. RM was concentrated under reduced pressure, dissolved in water and acidified by addition of aqueous HCl (6N) dropwise. The solid formed was filtered and the residue was purified by FCC on silica gel using a gradient of EtOAc in heptane (20-100%) to yield 0.036 g (28%) of 4-(5-(benzyl) Oxy)-2-methylbenzofuran-3-carboxamido)tetrahydro-2H-pyran-4-carboxylic acid (Compound 193) was obtained.
[0230] Compound 160, Compound 161, and Compound 162 were prepared in a similar manner as Compound 193 (using appropriate reagents and purification methods known to those skilled in the art).
[0231] Synthesis of (2S,4R)-4-(5-(benzyloxy)-2-methylbenzofuran-3-carboxamide)pyrrolidine-2-carboxamide (compound 158). [ka] Step 1: DIPEA (0.93 mL, 5.3 mmol) was combined with 5 5-(benzyloxy)-2-methylbenzofuran-3-carboxylic acid (compound 002) (0.500 g, 1.77 mmol), HATU ( 0.808g, 2.13mmol), and 1-(tert-butyl)2-methyl(2S,4R)-4-aminopyrrolidine-1,2-dicarboxylate (0.519g, 2.13mmol). The mixture was stirred at room temperature for 36 hours and concentrated under reduced pressure. The residue was partitioned between a saturated aqueous solution of sodium bicarbonate and DCM, and after separation, the organic layer was concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of EtOAc in heptane (20-100%) to yield 0.708 g (79%) of 1-(tert-butyl)2-methyl (2S,4R). -4-(5-(benzyloxy)-2-methylbenzofuran-3-carboxamido)pyrrolidine-1,2-dicarboxylate was obtained as a white solid. 1 H NMR(300MHz, CDCl 3 )δppm:7.18-7.57(m,6H);7.06(d,1H);6.96(dd,1H);5.77(br.s.,1H);5.12(s,2H);4.65-4.84(m,1H );4.25-4.56(m,1H);3.85-4.04(m,1H);3.77(s,3H);3.23-3.60(m,1H);2.68(s,3H);2.11-2.55(m,2H );1.32-1.53(m,9H);1.19-1.32(m,1H).
[0232] Step 2: Add aqueous NaOH (2N, 0.28mL, 0.56mmol) to 1-(tert-butyl)2-methyl(2S,4R)-4-(5-(benzyloxy)-2- Added to a solution of methylbenzofuran-3-carboxamido)pyrrolidine-1,2-dicarboxylate (0.286 g, 0.56 mmol). The mixture was stirred at room temperature for 2 hours and the volume of the mixture was reduced by half under reduced pressure. Aqueous HCl (1N) was added, the precipitate formed was collected by filtration, dried and 0.278 g (100%) of (2S,4R)-4-(5-(benzyloxy)-2-methyl Benzofuran-3-carboxamide)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid was obtained. 1 H NMR(300MHz,DMSO-d 6 )δppm:8.27(t,1H);7.28-7.58(m,5H);7.21(s,1H);6.97(dd,1H);5.13(s,2H);4.20-4.40(m,1H);4.31 -4.28(m,1H);3.59-3.82(m,1H);2.56(s,3H);1.98-2.45(m,3H);1.37(d,9H).
[0233] Step 3: Add DIPEA (0.09 mL, 0.5 mmol) to (2S,4R)-4-(5-(benzyloxy)-2-methylbenzofuran-3-carboxamide)-1-(tert- Butoxycarbonyl)pyrrolidine-2-carboxylic acid (0.09 g, 0.18 mmol), HATU (0.1 g, 0.27 mmol), and ammoniac (0.5 M, 0.54 mL, 0.27 mmol) in dioxane were added to a solution of . The mixture was stirred at room temperature for 60 hours. Mixture, KHSO 4Partitioned between aqueous solution (2N) and EtOAc, the organic phase was washed with saturated sodium bicarbonate, dried and concentrated under reduced pressure. The crude residue was purified by FCC on silica using a gradient of MeOH in DCM (0-20%) to yield 0.081 g (90%) of tert-butyl(2S,4R)-4-(5- (Benzyloxy)-2-methylbenzofuran-3-carboxamide)-2-carbamoylpyrrolidine-1-carboxylate was obtained. M / Z(+):494(M+H).M / Z(-):492(M-H).
[0234] Step 4: Prepare a solution of HCl in 1,4-dioxane (4M, 2mL) with tert-butyl(2S,4R)-4-(5-(benzyloxy)-2-methylbenzofuran-3-carboxamide)-2 -carbamoylpyrrolidine-1-carboxylate (81 mg, 0.16 mmol). The mixture was stirred at room temperature for 4 hours and concentrated under reduced pressure. The residue was purified by a supported SiliaBond-propylsulfonic acid column. The column was first washed with a gradient of DCM in MeOH (0% to 100%) and finally with a 3N solution of ammonia in MeOH to give 48 mg (73%) of (2S,4R)-4-( 5-(Benzyloxy)-2-methylbenzofuran-3-carboxamide)pyrrolidine-2-carboxamide (Compound 158) was obtained.
[0235] Compound 188 was prepared in a similar manner to compound 158 (using appropriate reagents and purification methods known to those skilled in the art).
[0236] Diastereoisomer separation of 5-(benzyloxy)-N-(hexahydro-1H-pyrrolidin-1-yl)-2-methylbenzofuran-3-carboxamide (compound 144) resulted in (compound 144-Dia1) and (compound 144-Dia2). 5-(benzyloxy)-N-(hexahydro-1H-pyrrolidin-1-yl)-2-methylbenzofuran-3-carboxamide (compound 144) (0.090 g) was purified by preparative HPLC (method: H1). Separation into stereoisomers yielded 38.7 mg of the faster eluting diastereoisomer (Compound 144-Dia1) and 27.8 mg of the slower eluting diastereoisomer (Compound 144-Dia2). The absolute stereochemistry shown for all compounds was only randomized but not confirmed.
[0237] Synthesis of 5-(benzyloxy)-4-cyano-N-(4,4-difluoropyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide (compound 297) [ka] Step 1: NBS (24.2 g, 136.22 mmol) was added to a solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (20.0 g, 90.81 mmol) in MeCN (600 mL) under an argon atmosphere at room temperature. Added with. RM was stirred at room temperature for 16 hours. The progress of the reaction was monitored by TLC. RM was diluted with water (300 mL) and acidified with 1N-HCl until pH was approximately 2. The crude product was extracted with EtOAc (2 x 300 mL). The combined organic layers were washed with water (200 mL) followed by brine (200 mL). The organic layer is treated with anhydrous Na 2 S.O. 4 Dry on top and concentrate under reduced pressure. The crude product was purified by FCC on silica gel using 0-20% EtOAc and PET-ether as eluent to give ethyl 4-bromo-5-hydroxy-2-methylbenzofuran-3-carboxylate ( 5.0g, 19%) was obtained.
[0238] Step 2: CuCN (0.74 g, 8.36 mmol) was added to a solution of ethyl 4-bromo-5-hydroxy-2-methylbenzofuran-3-carboxylate (1.0 g, 3.44 mmol) in DMF (25 mL) under an argon atmosphere. The mixture was added at room temperature. The resulting mixture was heated to 160°C and maintained for 3 hours. The progress of the reaction was monitored by TLC. The RM was cooled to room temperature, poured into water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with water (2 x 50 mL) followed by brine (50 mL). The organic layer is treated with anhydrous Na 2 S.O. 4 Dry on top and concentrate under reduced pressure. The crude product was purified by FCC on silica gel using 0-20% EtOAc in PET-ether as eluent to give ethyl 4-cyano-5-hydroxy-2-methylbenzofuran-3-carboxylate. (0.45g, 55%) was obtained.
[0239] Step 3: Phenylmethanol (0.36 mL, 2.75 mmol), ADDP (0.646 g, 2.56 mmol), and tri-n-butylphosphine (0.63 mL, 2.56 mmol) were dissolved in ethyl 4-cyano-5 in THF (20 mL). -Hydroxy-2-methylbenzofuran-3-carboxylate (0.45 g, 1.83 mmol) was added continuously to a pre-stirred solution at 0° C. under an argon atmosphere. The RM was brought to room temperature and stirred for 3 hours. The progress of the reaction was monitored by TLC. The RM was poured into water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was passed through a column of silica gel using 0-20% EtOAc in PET-ether as eluent to give ethyl 5-(benzyloxy)-4-cyano-2-methylbenzofuran-3- Carboxylate (0.36g, 58%) was obtained.
[0240] Step 4: A solution of NaOH (0.166 g, 4.16 mmol) in water (5.0 mL) was prepared using ethyl 5-(benzyloxy)-4-cyano-2-methyl in a mixture of MeOH (10 mL) and THF (10 mL). Added to a pre-stirred solution of benzofuran-3-carboxylate (0.36 g, 1.04 mmol) at room temperature. The resulting RM was heated to 60°C and maintained for 3 hours. The progress of the reaction was monitored by TLC. The RM was cooled to room temperature, poured into ice-cold water (50 mL), and acidified with 1N HCl (pH ˜2). The crude product was extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with water (2 x 50 mL), followed by brine (50 mL) and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure to give 5-(benzyloxy)-4-cyano-2-methylbenzofuran-3-carboxylic acid (0.29 g, 87%). The crude product thus obtained was used in the next step without further purification.
[0241] Step 5: 5-(benzyloxy)-4-cyano-2-methylbenzofuran-3-carboxylic acid (0.29 g, 0.94 mmol) and tert-butyl 4-amino-3,3-difluoropyrrolidine in DMF (10 mL). To a pre-stirred solution of a mixture of -1-carboxylate (0.251 g, 1.13 mmol) at 0 °C under an argon atmosphere was added DIPEA (0.46 mL, 2.83 mmol), followed by HATU (0.717 g, 1.88 mmol) was added. The RM was brought to room temperature and stirred for 3 hours. The progress of the reaction was monitored by TLC. The RM was diluted with water (50 mL) and the crude product was extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product tert-butyl 4-(5-(benzyloxy)-4-cyano-2-methylbenzofuran-3-carboxamide)-3,3-difluoropyrrolidine- was obtained as an off-white solid. 1-Carboxylate (0.25g, 51%) was used further without purification.
[0242] Step 6: tert-Butyl 4-(5-(benzyloxy)-4-cyano-2-methylbenzofuran-3-carboxamide)-3,3-difluoropyrrolidine-1-carboxylate (0.25 To the pre-stirred solution of g) was added TFA (2.5 mL) dropwise at 0° C. under an argon atmosphere. The RM was brought to room temperature and stirred for 16 hours. The progress of the reaction was monitored by TLC. Concentrate the RM under reduced pressure with NaHCO 3 (pH approximately 8). The crude product was extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with water (50 mL) then brine (50 mL) and diluted with anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0-50% acetonitrile in 0.1% FA in water as eluent to give racemic compound 297 (0.18 g, 89%). Preparative chiral SFC was performed on racemic compound 297 to yield compound 297-En1 and compound 297-En2.
[0243] 5-(benzyloxy)-N-(4,4-difluoropyrrolidin-3-yl)-4-fluoro-2-methylbenzofuran-3-carboxamide (compound 298) and 5-(benzyloxy)-N-(4 Synthesis of ,4-difluoropyrrolidin-3-yl)-6-fluoro-2-methylbenzofuran-3-carboxamide (compound 302) [ka] Step 1: To a pre-stirred solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (5.0 g, 22.7 mmol) in MeCN (300 mL) was added selectfluor (9.65 g, 27.2 mmol) under an argon atmosphere. and added at room temperature. The resulting RM was stirred at room temperature for 16 hours. The progress of the reaction was monitored by TLC. Excess solvent was removed under reduced pressure and the crude compound was dissolved in EtOAc (500 mL). The above solution was washed with water (2 x 250 mL), brine (250 mL), anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was purified by FCC on silica using 0-20% EtOAc in PET-ether as eluent, followed by 0-47% acetonitrile in 0.1% FA in water as eluent. ethyl 4-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 6-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate A mixture (1.0 g, 19%) was obtained.
[0244] Step 2: Phenylmethanol (2 mL, 18.9 mmol), ADDP (4.45 g, 17.6 mmol), and tri-n-butylphosphine (3.56 g, 17.6 mmol) were dissolved in ethyl 4-fluoro-5- To a pre-stirred solution of a mixture of hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 6-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate (3.0 g, 12.6 mmol) was added under an argon atmosphere. , and 0°C. The RM was brought to room temperature and stirred for 3 hours. The progress of the reaction was monitored by TLC. The RM was poured into water (250 mL) and extracted with EtOAc (3 x 200 mL). The combined organic layers were washed with brine (2 x 100 mL) and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was purified by FCC on silica using 10-20% EtOAc in pet-ether as eluent to give ethyl 5-(benzyloxy)-4-fluoro-2-methylbenzofuran-3. -carboxylate and ethyl 5-(benzyloxy)-6-fluoro-2-methylbenzofuran-3-carboxylate (2.1 g, 50%) was obtained.
[0245] Step 3: Add 2N NaOH (30 mL) to ethyl 5-(benzyloxy)-4-fluoro-2-methylbenzofuran-3-carboxylate and ethyl 5-(benzyloxy)-4-fluoro-2-methylbenzofuran-3-carboxylate in a mixture of MeOH (50 mL) and THF (20 mL). Added to a pre-stirred solution of a mixture of (oxy)-6-fluoro-2-methylbenzofuran-3-carboxylate (2.0 g, 6.0 mmol). The resulting RM was heated to 60°C and maintained for 3 hours. The progress of the reaction was monitored by TLC. The RM was cooled to room temperature, poured into ice-cold water (250 mL), and acidified with 1N HCl (pH ˜2). The crude product was extracted with EtOAc (3 x 200 mL). The combined organic layers were washed with water (2 x 200 mL) followed by brine (200 mL) and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure to give 5-(benzyloxy)-4-fluoro-2-methylbenzofuran-3-carboxylic acid and 5-(benzyloxy)-6-fluoro-2-methylbenzofuran-3- A mixture of carboxylic acids (1.3g, 71%) was obtained. The resulting mixture of crude products was used in the next step without further purification.
[0246] Step 4: 5-(benzyloxy)-4-fluoro-2-methylbenzofuran-3-carboxylic acid and 5-(benzyloxy)-6-fluoro-2-methylbenzofuran-3-carboxylic acid in DMF (25 mL) (1.3 g, 4.33 mmol) and tert-butyl 4-amino-3,3-difluoropyrrolidine-1-carboxylate (1.15 g, 5.19 mmol) at 0 °C under an argon atmosphere. Then, DIPEA (1.6 mL, 8.6 mmol) was added followed by HATU (3.29 g, 8.6 mmol). The RM was brought to room temperature and stirred for 1 hour. The progress of the reaction was monitored by TLC. The RM was diluted with cold water (50 mL) and filtered. The solid thus obtained was washed with water (200 mL) and dried under reduced pressure to produce tert-butyl 4-(5-(benzyloxy)-4-fluoro-2-methylbenzofuran-3-carboxamide). -3,3-difluoropyrrolidine-1-carboxylate and tert-butyl 4-(5-(benzyloxy)-6-fluoro-2-methylbenzofuran-3-carboxamide)-3,3-difluoropyrrolidine-1-carboxylate A mixture of rates (1.2g, 57%) was obtained.
[0247] Step 5: Add 4M HCl in dioxane (6 mL) to tert-butyl 4-(5-(benzyloxy)-4-fluoro-2-methylbenzofuran-3-carboxamide)-3,3- in DCM (25 mL). Mixture of difluoropyrrolidine-1-carboxylate and tert-butyl 4-(5-(benzyloxy)-6-fluoro-2-methylbenzofuran-3-carboxamide)-3,3-difluoropyrrolidine-1-carboxylate (1.2 g, 2.3 mmol) dropwise at 0° C. under an argon atmosphere. The RM was allowed to warm to room temperature and stirred for 5 hours. The progress of the reaction was monitored by TLC. Excess solvent was evaporated in vacuo, the residue cooled to 0 °C and saturated NaHCO 3 (pH ~9) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0-50% acetonitrile and 0.1% FA in water as eluent to yield a mixture of racemic compound 298 and racemic compound 302 (0.6 g, 62%). Ta. Preparative chiral SFC was performed on the mixture of compound 298 and compound 302 to yield compound 298-En1, compound 298-En2, compound 302-En1, and compound 302-En2.
[0248] Synthesis of 5-(benzyloxy)-N-(4,4-difluoropyrrolidin-3-yl)-2,4-dimethylbenzofuran-3-carboxamide (compound 299) [ka] Step 1: NBS (24.2 g, 136.22 mmol) was added to a solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (20.0 g, 90.81 mmol) in acetonitrile (600 mL). RM was stirred at the same temperature for 16 hours. The progress of the reaction was monitored by TLC. The RM was diluted with water (300 mL) and acidified with 1N-HCl until pH ~2. The crude product was extracted with EtOAc (2 x 300 mL). The combined organic layers were washed with water (200 mL) followed by brine (200 mL). The organic layer is treated with anhydrous Na 2 S.O. 4 Dry on top and concentrate under reduced pressure. The crude product was purified by column chromatography on silica gel using 0-20% EtOAc and PET-ether as eluent to give ethyl 4-bromo-5-hydroxy-2-methylbenzofuran-3-carboxy rate (5.0g, 19%) was obtained.
[0249] Step 2: Phenylmethanol (0.678 mL, 6.52 mmol), ADDP (1.77 g, 7.02 mmol), and tri-n-butylphosphine (1.42 g, 7.02 mmol) were dissolved in ethyl 4-bromo-5 in THF (50 mL). -Hydroxy-2-methylbenzofuran-3-carboxylate was added continuously to a pre-stirred solution at 0° C. under an argon atmosphere. The RM was allowed to warm to room temperature and stirred for 2 hours. The progress of the reaction was monitored by TLC. The RM was poured into water (80 mL) and extracted with EtOAc (2 x 60 mL). The combined organic layers were washed sequentially with water (30 mL), brine (30 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was purified by FCC on silica gel using 0-20% EtOAc in pet-ether as eluent to give ethyl 5-(benzyloxy)-4-bromo-2-methylbenzofuran-3. -carboxylate (0.95g, 48%) was obtained.
[0250] Step 3: In a sealed tube, K 3 P.O. 4 (1.81 g, 8.54 mmol) was mixed with ethyl 5-(benzyloxy)-4-bromo-2-methylbenzofuran-3-carboxylate (0.95 g, 2.44 mmol) in a mixture of toluene (9 mL) and water (1 mL). and methylboronic acid (292.1 mg, 4.88 mmol) at room temperature under an argon atmosphere. The resulting RM was degassed with argon for 10 min and then (Cy) 3 P(60mg, 0.22mmol) followed by Pd(OAc) 2 (65.73mg, 0.29mmol) was added. The RM was degassed for an additional 10 minutes. The RM was heated to 120°C and maintained for 18 hours. The progress of the reaction was monitored by LC-MS. The RM was cooled to room temperature and filtered through a pad of Celite. The Celite pad was washed with EtOAc (2 x 30 mL). Clear filtrate with anhydrous Na 2 S.O. 4and evaporated in vacuo. The crude product was purified by FCC on silica gel using 0-20% EtOAc in pet-ether as eluent to give ethyl 5-(benzyloxy)-2,4-dimethylbenzofuran-3-carboxy rate (0.59g, 74%) was obtained.
[0251] Step 4: Add a solution of NaOH (0.287g, 7.18mmol) in water (4mL) to ethyl 5-(benzyloxy)-2,4-dimethylbenzofuran-3 in a mixture of MeOH (7mL) and THF (7mL). -Carboxylate (0.58 g, 1.79 mmol) was added dropwise to a pre-stirred solution at room temperature. The resulting RM was heated to 60°C and maintained for 4 hours. The progress of the reaction was monitored by TLC. The RM was cooled to room temperature, poured into ice-cold water (30 mL), and acidified with 1N HCl until pH was approximately 2. The crude product was extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with water (30 mL), followed by brine (30 mL) and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure to give 5-(benzyloxy)-2,4-dimethylbenzofuran-3-carboxylate (0.52 g, 98%).
[0252] Step 5: 5-(benzyloxy)-2,4-dimethylbenzofuran-3-carboxylic acid (0.52 g, 1.76 mmol) and tert-butyl 4-amino-3,3-difluoropyrrolidine-1 in DMF (20 mL) -To a pre-stirred solution of carboxylate (0.508 g, 2.28 mmol) at 0 °C under an argon atmosphere was added DIPEA (2.4 mL, 14.08 mmol) followed by HATU (1.34 g, 3.52 mmol). Added. The RM was brought to room temperature and stirred for 2 hours. The progress of the reaction was monitored by LC-MS. The RM was diluted with water (80 mL) and the organic compounds were extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with water (30 mL), brine (30 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0-80% acetonitrile and 0.1% FA in water as eluent to give tert-butyl 4-(5-(benzyloxy)-2,4-dimethyl Benzofuran-3-carboxamide)-3,3-difluoropyrrolidine-1-carboxylate (0.56 g, 63%) was obtained.
[0253] Step 6: Add a solution of TFA (5 mL) in DCM (5 mL) to tert-butyl 4-(5-(benzyloxy)-2,4-dimethylbenzofuran-3-carboxamide)-3, To a pre-stirred solution of 3-difluoropyrrolidine-1-carboxylate (0.55 g, 1.10 mmol) was added dropwise at 0° C. under an argon atmosphere. The RM was brought to room temperature and stirred for 16 hours. The progress of the reaction was monitored by TLC. The RM was concentrated under reduced pressure and the residue was dissolved in saturated NaHCO 3 (60 mL) and the organic compounds were extracted with 10% MeOH in DCM (3 x 50 mL). The combined organic layers were washed with water (40 mL), brine (40 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0-60% acetonitrile and 0.1% FA in water as eluent to give racemic compound 299 (0.12 g, 26%). Preparative chiral SFC was performed on racemic compound 299 to yield compound 299-En1 and compound 299-En2.
[0254] 5-(benzyloxy)-6-cyano-N-(4,4-difluoropyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide (compound 301) and 5-(benzyloxy)-7-cyano- Synthesis of N-(4,4-difluoropyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide (compound 305). [ka] Step 1: Ethyl 6-chloro-5-hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 7-chloro-5-hydroxy-2-methylbenzofuran-3-carboxylate (1.0 g) in dimethylacetamide (12 mL) , 3.93mmol) and Zn(CN) 2 A solution of a mixture of (2.01 g, 17.71 mmol) was degassed with argon for 10 min. In the above RM, Pd(P(t-Bu) 3 ) 2 (0.60 g, 1.18 mmol) was added in one portion and degassed for 5 minutes. The resulting mixture was heated to 160°C and kept under microwave for 2 hours. The progress of the reaction was monitored by TLC. The RM was poured into water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with water (2 x 50 mL) and brine (50 mL). The organic layer is treated with anhydrous Na 2 S.O. 4 Dry on top and concentrate under reduced pressure. The crude product was purified by column chromatography on silica gel using 0-20% EtOAc in PET-ether as eluent to give ethyl 6-cyano-5-hydroxy-2-methylbenzofuran-3- A mixture of carboxylate and ethyl 7-cyano-5-hydroxy-2-methylbenzofuran-3-carboxylate (0.6 g, 62.5%) was obtained.
[0255] Step 2: Benzyl alcohol (0.72 g, 6.73 mmol), ADDP (1.58 g, 6.28 mmol), and tri-n-butylphosphine (1.47 mL, 6.28 mmol) in THF (30 mL) with ethyl 6-cyano-5 -Hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 7-cyano-5-hydroxy-2-methylbenzofuran-3-carboxylate (1.1 g, 4.48 mmol) in a pre-stirred solution under an argon atmosphere. and were added continuously at room temperature. The resulting RM was stirred at room temperature for 2 hours. The progress of the reaction was monitored by TLC. The RM was poured into water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel using a gradient mixture of 0-20% EtOAc in PET-ether as eluent to give ethyl 5-(benzyloxy)-6-cyano-2 A mixture (1.2 g, 73%) of -methylbenzofuran-3-carboxylate and ethyl 5-(benzyloxy)-7-cyano-2-methylbenzofuran-3-carboxylate was obtained.
[0256] Step 3: A solution of NaOH (0.57 g, 14.32 mmol) in water (10 mL) was prepared using ethyl 5-(benzyloxy)-6-cyano-2-methylbenzofuran in a mixture of MeOH (20 mL) and THF (20 mL). -3-carboxylate and ethyl 5-(benzyloxy)-7-cyano-2-methylbenzofuran-3-carboxylate (1.2 g, 3.58 mmol) was added dropwise at room temperature. The resulting RM was heated to 60°C and kept under stirring for 4 hours. The progress of the reaction was monitored by TLC. The RM was cooled to room temperature, poured into ice-cold water (50 mL), and acidified with 1N HCl (pH ˜2). The crude product was extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with water (50 mL), followed by brine (50 mL) and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure to give 5-(benzyloxy)-6-cyano-2-methylbenzofuran-3-carboxylic acid and 5-(benzyloxy)-7-cyano-2-methylbenzofuran-3- A mixture of carboxylic acids (1.0 g, 91%) was obtained.
[0257] Step 4: 5-(benzyloxy)-6-cyano-2-methylbenzofuran-3-carboxylic acid and 5-(benzyloxy)-7-cyano-2-methylbenzofuran-3-carboxylic acid in DMF (15 mL). A mixture of acids (1.0 g, 3.25 mmol) and a pre-stirred solution of tert-butyl 4-mino-3,3-difluoropyrrolidine-1-carboxylate (1.08 g, 4.88 mmol) were added under an argon atmosphere to At <0>C, DIPEA (1.68 mL, 9.77 mmol) was added followed by HATU (2.47 g, 6.51 mmol). The resulting RM was brought to room temperature and stirred for 16 hours. The progress of the reaction was monitored by TLC. The RM was diluted with water (70 mL) and the organic compounds were extracted with EtOAc (2 x 70 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel using a gradient mixture of 0 to 55% EtOAc and PET-ether as eluent to give tert-butyl 4-(5-(benzyloxy)- 6-cyano-2-methylbenzofuran-3-carboxamide)-3,3-difluoropyrrolidine-1-carboxylate and tert-butyl 4-(5-(benzyloxy)-7-cyano-2-methylbenzofuran-3- A mixture of (carboxamide)-3,3-difluoropyrrolidine-1-carboxylate (1.0 g, 60%) was obtained.
[0258] Step 5: Add 4.0 M HCl in dioxane (10 mL) to tert-butyl 4-(5-(benzyloxy)-6-cyano-2-methylbenzofuran-3-carboxamide)-3,3 in DCM (20 mL). -Difluoropyrrolidine-1-carboxylate and tert-butyl 4-(5-(benzyloxy)-7-cyano-2-methylbenzofuran-3-carboxamide)-3,3-difluoropyrrolidine-1-carboxylate mixture ( 1.0 g, 1.95 mmol) dropwise at 0°C. The resulting RM was stirred at room temperature for 5 hours. The progress of the reaction was monitored by TLC. RM was concentrated under reduced pressure. The residue is saturated with NaHCO 3 The solution (100 mL) was partitioned between 10% MeOH in DCM (3 x 50 mL). The combined organic extracts were washed with water (50 mL), brine (50 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0.1% FA in water and acetonitrile as eluent to give a mixture of compound 301 and compound 305 (0.6 g, 75%). Preparative chiral SFC was performed on the mixture of racemic compound 301 and racemic compound 305 to yield compound 301-En1, compound 301-En2, compound 305-En1 and compound 305-En2.
[0259] 5-(benzyloxy)-6-chloro-N-(4,4-difluoropyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide (compound 300) and 5-(benzyloxy)-7-chloro- Synthesis of N-(4,4-difluoropyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide (compound 304) [ka] Step 1: To a pre-stirred solution of CAN (199.18 g, 363.32 mmol) in water (500 mL) was added 2-chlorobenzene-1,4-diol (25.0 g, 173.01 mmol) at 0 °C. The resulting RM was stirred at room temperature for 4 hours. The progress of the reaction was monitored by TLC. Organic compounds were extracted with diethyl ether (3 x 200 mL). The combined organic layers were washed with brine (50 mL) and anhydrous Na 2 S.O. 4 dried with. The dried organic layer was passed through a silica gel column using diethyl ether as eluent and the fractions thus collected were concentrated under reduced pressure to give 2-chlorocyclohexa-2,5-diene- 1,4-dione (20g, 83%) was obtained.
[0260] Step 2: To a pre-stirred solution of 2-chlorocyclohexa-2,5-diene-1,4-dione (20 g, 140.84 mmol) in toluene (300 mL) was added 3-oxobutanoate (54.92 g, 422.53 mmol), followed by anhydrous ZnCl 2 (23.0 g, 169.0 mmol) was added at room temperature under an argon atmosphere. The resulting RM was heated to reflux and maintained for 16 hours using a Dean-Stark apparatus. The progress of the reaction was monitored by TLC. The RM was cooled to room temperature, filtered through a pad of Celite, and the pad of Celite was washed with EtOAc (500 mL). The combined clear filtrates were concentrated under reduced pressure. The crude product was purified by FCC on silica gel to give ethyl 6-chloro-5-hydroxy-2-methylbenzofuran-3-carboxylate using 0-10% EtOAc in PET-ether as eluent. A mixture of ethyl 7-chloro-5-hydroxy-2-methylbenzofuran-3-carboxylate (7.0 g, 20%) was obtained.
[0261] Step 3: Phenylmethanol (0.36 g, 5.90 mmol), ADDP (1.38 g, 5.51 mmol), and tri-n-butylphosphine (1.35 mL, 5.51 mmol) were dissolved in ethyl 6-chloro-5 in THF (30 mL). - Hydroxy-2-methylbenzofuran-3-carboxylate compound and ethyl 7-chloro-5-hydroxy-2-methylbenzofuran-3-carboxylate mixture (1.0 g, 3.93 mmol) were added to a pre-stirred solution under an argon atmosphere. The additions were made continuously at room temperature. RM was stirred for 2 hours. The progress of the reaction was monitored by TLC. The RM was poured into water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was purified by column chromatography on silica using 0-20% EtOAc in pet-ether as eluent to give ethyl 5-(benzyloxy)-6-chloro-2-methylbenzofuran. A mixture of -3-carboxylate and ethyl 5-(benzyloxy)-7-chloro-2-methylbenzofuran-3-carboxylate (1.2 g, 89%) was obtained.
[0262] Step 4: A solution of NaOH (0.46 g, 11.62 mmol) in water (8 mL) was prepared using ethyl 5-(benzyloxy)-6-chloro-2-methylbenzofuran in a mixture of MeOH (15 mL) and THF (7 mL). -3-carboxylate and ethyl 5-(benzyloxy)-7-chloro-2-methylbenzofuran-3-carboxylate (1.0 g, 2.90 mmol) was added dropwise at room temperature to a pre-stirred solution. The resulting RM was heated to 60°C and maintained for 4 hours. The progress of the reaction was monitored by TLC. The RM was cooled to room temperature, poured into ice-cold water (50 mL), and acidified with 1N HCl (pH ˜2). The crude product was extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with water (50 mL), followed by brine (50 mL) and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure to give 5-(benzyloxy)-6-chloro-2-methylbenzofuran-3-carboxylic acid and 5-(benzyloxy)-7-chloro-2-methylbenzofuran-3- A mixture of carboxylic acids (0.8g, 87%) was obtained.
[0263] Step 5: 5-(benzyloxy)-6-chloro-2-methylbenzofuran-3-carboxylic acid and 5-(benzyloxy)-7-chloro-2-methylbenzofuran-3-carboxylic acid in DMF (15 mL) (0.8 g, 2.53 mmol) and tert-butyl 4-amino-3,3-difluoropyrrolidine-1-carboxylate (0.85 g, 3.84 mmol) at 0 °C under an argon atmosphere. Then DIPEA (1.35 mL, 7.59 mmol) was added followed by HATU (1.92 g, 5.06 mmol). The RM was brought to room temperature and stirred for 16 hours. The progress of the reaction was monitored by TLC. The RM was diluted with water (70 mL) and the organic compounds were extracted with EtOAc (2 x 70 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was purified by column chromatography on silica using 0-55% EtOAc and pet-ether as eluent to give tert-butyl 4-(5-(benzyloxy)-6-chloro- 2-Methylbenzofuran-3-carboxamide)-3,3-difluoropyrrolidine-1-carboxylate and tert-butyl 4-(5-(benzyloxy)-7-chloro-2-methylbenzofuran-3-carboxamide)-3 A mixture of ,3-difluoropyrrolidine-1-carboxylate (0.75 g, 57%) was obtained.
[0264] Step 6: 4.0 M HCl (2.88 mL, 11.53 mmol) in dioxane to tert-butyl 4-(5-(benzyloxy)-6-chloro-2-methylbenzofuran-3-carboxamide) in DCM (10 mL) -3,3-difluoropyrrolidine-1-carboxylate and tert-butyl 4-(5-(benzyloxy)-7-chloro-2-methylbenzofuran-3-carboxamide)-3,3-difluoropyrrolidine-1-carboxylate Added dropwise to a pre-stirred solution of the mixture of esters (0.75 g, 1.44 mmol) at 0°C. The RM was brought to room temperature and stirred for 5 hours. The progress of the reaction was monitored by TLC. Concentrate the RM under reduced pressure with saturated NaHCO 3 It was basified with an aqueous solution (100 mL). The organic compounds were extracted with 10% MeOH in DCM (3 x 50 mL) and washed with water (50 mL) and brine (50 mL). The organic layer is treated with anhydrous Na 2 S.O. 4 Dry on top and concentrate under reduced pressure. The crude product was purified by GRACE flash chromatography using 0-60% acetonitrile and 0.1% FA in water as eluent to give a mixture of compound 300 and compound 304. Preparative chiral SFC was performed on the mixture of racemate 300 and racemate 304 to yield compound 300-En1, compound 300-En2, compound 304-En1, and compound 304-En2.
[0265] 5-(benzyloxy)-N-(4,4-difluoropyrrolidin-3-yl)-6-fluoro-2-methylbenzofuran-3-carboxamide (compound 302) and 6-fluoro-N-(4-(hydroxy Synthesis of methyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((4-methylthiazol-5-yl)methoxy)benzofuran-3-carboxamide (compound 306) [ka] Step 1: To a pre-stirred solution of CAN (27.41 g, 50.00 mmol) in water (60 mL) was added 2-chlorobenzene-1,4-diol (3.0 g, 23.80 mmol) at 0 °C. The resulting RM was stirred at room temperature for 4 hours. The progress of the reaction was monitored by TLC. Organic compounds were extracted with diethyl ether (3 x 50 mL). The combined organic layers were washed with brine (50 mL) and anhydrous Na 2 S.O. 4 and filtered. The clear filtrate was passed over a silica gel column, eluted with diethyl ether, and the collected fractions were evaporated under vacuum to give 2-fluorocyclohexa-2,5-diene-1,4-dione (2.5 g, 84%).
[0266] Step 2: To a pre-stirred solution of 2-fluorocyclohexa-2,5-diene-1,4-dione (2.5 g, 20.16 mmol) in toluene (30 mL) was added ethyl -oxobutanoate (7.86g, 60.48mmol) was added followed by anhydrous ZnCl 2 (3.29g, 24.19mmol) was added. The resulting RM was heated to reflux and maintained for 16 hours using a Dean-Stark apparatus. The progress of the reaction was monitored by TLC. The RM was cooled to room temperature, filtered through a pad of Celite, and the pad of Celite was washed with EtOAc (70 mL). The combined clear filtrates were concentrated under reduced pressure. The crude product was purified by FCC on silica gel using 0-10% EtOAc in PET-ether as eluent to give ethyl 7-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate. and ethyl 6-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate (0.8 g, 21%) was obtained.
[0267] Step 3: Phenylmethanol (0.47 mL, 3.3 mmol), ADDP (1.18 g, 4.7 mmol), and tri-n-butylphosphine (0.95 g, 4.7 mmol) were dissolved in ethyl 7-fluoro-5 in THF (25 mL). -Hydroxy-2-methylbenzofuran-3-carboxylate and ethyl 6-fluoro-5-hydroxy-2-methylbenzofuran-3-carboxylate (800 mg, 3.3 mmol) in a pre-stirred solution under an argon atmosphere. , and 0°C. The RM was brought to room temperature and stirred for 3 hours. The progress of the reaction was monitored by TLC. The RM was poured into water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (100 mL) and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was purified by column chromatography on silica using 10-20% EtOAc in PET-ether as eluent to give ethyl 5-(benzyloxy)-7-fluoro-2-methylbenzofuran. A mixture of -3-carboxylate and ethyl 5-(benzyloxy)-6-fluoro-2-methylbenzofuran-3-carboxylate (600 mg, 54%) was obtained.
[0268] Step 4: Add 2N NaOH (20 mL) to ethyl 5-(benzyloxy)-7-fluoro-2-methylbenzofuran-3-carboxylate and ethyl 5-( Benzyloxy)-6-fluoro-2-methylbenzofuran-3-carboxylate mixture (600 mg, 1.82 mmol) was added dropwise at room temperature to a pre-stirred solution. The resulting RM was heated to 60°C and maintained for 3 hours. The progress of the reaction was monitored by TLC. The RM was cooled to room temperature, poured into ice-cold water (100 mL), and acidified with 1N HCl (pH ~2). The crude product was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (100 mL) followed by brine (100 mL) and washed with anhydrous Na 2 S.O. 4 and concentrated under reduced pressure to give 5-(benzyloxy)-7-fluoro-2-methylbenzofuran-3-carboxylic acid and 5-(benzyloxy)-6-fluoro-2-methylbenzofuran-3- A mixture of carboxylic acids (450 mg, 82%) was obtained. The resulting mixture of crude products was used in the next step without further purification.
[0269] Step 5: 5-(benzyloxy)-7-fluoro-2-methylbenzofuran-3-carboxylic acid and 5-(benzyloxy)-6-fluoro-2-methylbenzofuran-3-carboxylic acid in DMF (20 mL) (400 mg, 1.33 mmol) and tert-butyl 4-amino-3,3-difluoropyrrolidine-1-carboxylate (355 mg, 1.59 mmol) at 0 °C under an argon atmosphere. DIPEA (0.49 mL, 2.66 mmol) was added followed by HATU (1.01 g, 2.66 mmol). The RM was brought to room temperature and stirred for 1 hour. The progress of the reaction was monitored by TLC. The RM was diluted with ice-cold water (100 mL) and filtered. The resulting solid was washed with water (50 mL) and dried under reduced pressure to give tert-butyl 4-(5-(benzyloxy)-7-fluoro-2-methylbenzofuran-3-carboxamide)-3,3 -Difluoropyrrolidine-1-carboxylate and tert-butyl 4-(5-(benzyloxy)-6-fluoro-2-methylbenzofuran-3-carboxamide)-3,3-difluoropyrrolidine-1-carboxylate mixture ( 550mg, 82%) was obtained.
[0270] Step 6: Add 4M HCl in dioxane (6 mL) to tert-butyl 4-(5-(benzyloxy)-7-fluoro-2-methylbenzofuran-3-carboxamide)-3,3- in DCM (20 mL). Mixture of difluoropyrrolidine-1-carboxylate and tert-butyl 4-(5-(benzyloxy)-6-fluoro-2-methylbenzofuran-3-carboxamide)-3,3-difluoropyrrolidine-1-carboxylate (0.55 g, 1.0 mmol) dropwise at 0° C. under an argon atmosphere. The RM was allowed to warm to room temperature and stirred for 5 hours. The progress of the reaction was monitored by TLC. Excess solvent was evaporated in vacuo. The resulting crude product was purified with saturated NaHCO 3 (pH approx. 9). The free base product was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0-50% acetonitrile and 0.1% FA in water as eluent to give a mixture of compound 306 and compound 302 (0.4 g, 90%). Preparative chiral SFC was performed on the mixture of racemic compound 306 and racemic compound 302 to yield compound 306-En1, compound 306-En2, compound 302-En1, and compound 302-En2.
[0271] 5-(benzyloxy)-N-(4,4-difluoropyrrolidin-3-yl)-2,6-dimethylbenzofuran-3-carboxamide (compound 303) and 5-(benzyloxy)-N-(4,4 Synthesis of -difluoropyrrolidin-3-yl)-2,7-dimethylbenzofuran-3-carboxamide (compound 307) [ka] Step 1: To a pre-stirred solution of 2-methylcyclohexa-2,5-diene-1,4-dione (10.0 g, 81.96 mmol) in toluene (250 mL) was added ethyl 3-oxobutanoate (31.9 g , 245.89 mmol), followed by anhydrous ZnCl 2 (13.4g, 98.35mmol) was added at room temperature under an argon atmosphere. The resulting RM was heated to reflux and maintained for 16 hours using a Dean-Stark apparatus. The progress of the reaction was monitored by TLC. The RM was cooled to room temperature, filtered through a pad of Celite, and the pad of Celite was washed with EtOAc (300 mL). The combined clear filtrates were concentrated under reduced pressure. The crude product was purified by FCC on silica gel using 0-10% EtOAc in PET-ether as eluent to give ethyl 5-hydroxy-2,7-dimethylbenzofuran-3-carboxylate and ethyl A mixture of 5-hydroxy-2,6-dimethylbenzofuran-3-carboxylate (10.0 g, 52%) was obtained.
[0272] Step 2: Phenylmethanol (4.7 g, 32.05 mmol), ADDP (7.53 g, 29.91 mmol), and tri-n-butylphosphine (7.36 mL, 29.91 mmol) were dissolved in ethyl 5-hydroxy-2 in THF (250 mL). ,7-Dimethylbenzofuran-3-carboxylate and ethyl 5-hydroxy-2,6-dimethylbenzofuran-3-carboxylate (5.0 g, 21.36 mmol) were added to a pre-stirred solution at 0°C under an argon atmosphere. It was added continuously. The RM was brought to room temperature and stirred for 3 hours. The progress of the reaction was monitored by TLC. The RM was poured into water (150 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with brine (100 mL) and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0-60% acetonitrile and 0.1% FA in water as eluent to give ethyl 5-(benzyloxy)-2,7-dimethylbenzofuran-3-carboxy A mixture of ethyl 5-(benzyloxy)-2,6-dimethylbenzofuran-3-carboxylate (4.0 g, 41%) was obtained.
[0273] Step 3: Prepare a solution of NaOH (2.4 g, 61.7 mmol) in water (32 mL) with ethyl 5-(benzyloxy)-2,7-dimethylbenzofuran-3 in a mixture of MeOH (40 mL) and THF (40 mL). -carboxylate and ethyl 5-(benzyloxy)-2,6-dimethylbenzofuran-3-carboxylate (4.0 g, 12.3 mmol) at room temperature. The resulting RM was heated to 60°C and maintained for 3 hours. The progress of the reaction was monitored by TLC. The RM was cooled to room temperature, poured into ice-cold water (200 mL), and acidified with 1N HCl (pH ˜2). The crude product was extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with water (2 x 100 mL), followed by brine (100 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure to give a mixture of 5-(benzyloxy)-2,7-dimethylbenzofuran-3-carboxylic acid and 5-(benzyloxy)-2,6-dimethylbenzofuran-3-carboxylic acid. (2.0g, 54%) was obtained. The resulting mixture of crude products was used in the next step without further purification.
[0274] Step 4: A mixture of 5-(benzyloxy)-2,7-dimethylbenzofuran-3-carboxylic acid and 5-(benzyloxy)-2,6-dimethylbenzofuran-3-carboxylic acid (15 g) in DMF (20 mL). , 5.1 mmol) and tert-butyl 4-amino-3,3-difluoropyrrolidine-1-carboxylate (1.12 g, 5.1 mmol) was added DIPEA (2.7 mL, 15.2 mmol) followed by HATU (3.85 g, 10.1 mmol). The RM was brought to room temperature and stirred for 3 hours. The progress of the reaction was monitored by TLC. The RM was diluted with ice-cold water (50 mL) and filtered. The resulting solid was washed with water (200 mL) and dried under reduced pressure to give tert-butyl 4-(5-(benzyloxy)-2,7-dimethylbenzofuran-3-carboxamide)-3,3-difluoro. A mixture of pyrrolidine-1-carboxylate and tert-butyl 4-(5-(benzyloxy)-2,6-dimethylbenzofuran-3-carboxamide)-3,3-difluoropyrrolidine-1-carboxylate (0.9 g, 65 %) was obtained.
[0275] Step 5: Add TFA (1.0 mL) to tert-butyl 4-(5-(benzyloxy)-2,7-dimethylbenzofuran-3-carboxamide)-3,3-difluoropyrrolidine-1- in DCM (10 mL). Solution of a mixture of carboxylate and tert-butyl 4-(5-(benzyloxy)-2,6-dimethylbenzofuran-3-carboxamide)-3,3-difluoropyrrolidine-1-carboxylate (0.9 g, 1.79 mmol) was added at 0°C under an argon atmosphere. The RM was allowed to warm to room temperature and stirred for 16 hours. The progress of the reaction was monitored by TLC. Excess solvent was evaporated in vacuo. The crude product was dissolved in saturated NaHCO 3 (pH approx. 9). The free base product was extracted with EtOAc (2 x 100 mL). The organic layer is treated with anhydrous Na 2 S.O. 4 and the solvent was removed under reduced pressure. The crude product was purified by GRACE flash chromatography using 0-60% acetonitrile and 0.1% FA in water as eluent to give a mixture of compound 307 and compound 303. Preparative chiral SFC was performed on the mixture of racemic compound 307 and racemic compound 303 to yield compound 307-En1, compound 307-En2, compound 303-En1, and compound 303-En2.
[0276] Synthesis of N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-(1-phenylethoxy)benzofuran-3-carboxamide (compound 308) [ka] Step 1: Ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (1.5 g, 6.818 mmol), (1-bromoethyl)benzene (1.89 g, 10.227 mmol), and K in acetone (50 mL). 2 C.O. 3 A suspension of (2.35g, 17.045mmol) was stirred at 60°C for 16 hours. The RM was filtered through a Celite pad and the bed was washed with EtOAc. The combined filtrates were washed with 2N NaOH solution (2 x 30 mL), water (50 mL), brine (50 mL) and diluted with anhydrous NaOH. 2 S.O. 4 and concentrated under reduced pressure to give ethyl 2-methyl-5-(1-phenylethoxy)benzofuran-3-carboxylate (2.5 g, 52%). The crude product thus obtained was used in the next step without further purification.
[0277] Step 2: A solution of NaOH (1.23 g, 30.864 mmol) in water (10.0 mL) was prepared using ethyl 2-methyl-5-(1-phenylethoxy)benzofuran- in a mixture of MeOH (20 mL) and THF (20 mL). Added to a pre-stirred solution of 3-carboxylate (2.5g, 7.716mmol) at room temperature. The resulting RM was heated to 60°C and maintained for 4 hours. The progress of the reaction was monitored by TLC. The RM was cooled to room temperature, poured into ice-cold water (75 mL), acidified with 1N HCl (pH ˜2.0), and extracted with EtOAc (2×75 mL). The combined organic layers were washed with water (2 x 50 mL), brine (50 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude solid was reprecipitated with DCM and PET-ether and the resulting solid was dried and purified with 2-methyl-5-(1-phenylethoxy)benzofuran-3-carboxylic acid (1.4 g, 70 g in two steps). %) was obtained.
[0278] Step 3: 2-Methyl-5-(1-phenylethoxy)benzofuran-3-carboxylic acid (300 mg, 1.013 mmol) and (4-aminotetrahydro-2H-pyran-4-yl)methanol ( To a pre-stirred solution of 199 mg, 1.520 mmol) was added DIPEA (0.53 mL, 3.039 mmol) at 0° C. under an argon atmosphere, followed by HATU (577 mg, 1.52 mmol). The RM was stirred at room temperature for 16 hours. The progress of the reaction was monitored by TLC. The RM was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude product was reprecipitated with DCM and n-pentane and the solid thus obtained was dried to give compound 308 (250 mg, 60%). Preparative chiral SFC was performed on racemic compound 308 to yield compound 308-En1 and compound 308-En2.
[0279] The following compounds were prepared in a similar manner (using appropriate reagents and purification methods known to those skilled in the art) as Compound 308-En1 and Compound 308-En2: Compound 336-Dia1 and Compound 336-Dia2.
[0280] Synthesis of N-(1-carbamoylcyclobutyl)-2-methyl-5-(1-phenylethoxy)benzofuran-3-carboxamide (compound 343) [ka]
[0281] Step 1: Add methyl 1-aminocyclobutane-1-carboxylate hydrochloride (334 mg, 2.02 mmol) to 2-methyl-5-(1-phenylethoxy)benzofuran-3-carboxylic acid (400 mg, 1.35 mmol), HATU (1.00 g, 2.70 mmol), and DIPEA (0.74 mL, 4.00 mmol) at room temperature. The RM was stirred at room temperature for 1 hour under an argon atmosphere. The progress of the reaction was monitored by TLC. The RM was diluted with water (25 mL) and stirred for 15 minutes. The precipitated solid was filtered and dried under vacuum to give 400 mg (72%) of methyl 1-(2-methyl-5-(1-phenylethoxy)benzofuran-3-carboxamido)cyclobutane-1-carboxylate as an off-white Obtained as a colored solid. TLC system: 30% ethyl acetate in PET ether, RF: 0.4.
[0282] Step 2: Add 2N NaOH (5 mL) to methyl 1-(2-methyl-5-(1-phenylethoxy)benzofuran-3-carboxamido)cyclobutane-1-carboxylate in methanol (5 mL) and THF (5 mL). (0.4 g, 0.98 mmol) at room temperature and the RM was stirred at room temperature for 16 hours. The progress of the reaction was monitored by TLC. The RM was diluted with water (25 mL), acidified with 1N aqueous HCl (10 mL) until pH was approximately 2, and stirred for 15 minutes. The precipitated solid was filtered and dried under vacuum to give 300 mg (79%) of 1-(2-methyl-5-(1-phenylethoxy)benzofuran-3-carboxamido)cyclobutane-1-carboxylic acid as an off-white Obtained as a colored solid. TLC system: 50% ethyl acetate in PET ether, RF: 0.1.
[0283] Step 3: Add NH4Cl (202 mg, 3.81 mmol) to 1-(2-methyl-5-(1-phenylethoxy)benzofuran-3-carboxamido)cyclobutane-1-carboxylic acid (300 mg, 0.76 mmol) in DMF (10 mL). ), HATU (580 mg, 1.52 mmol), and DIPEA (0.42 mL, 2.29 mmol) at room temperature and the RM was stirred at room temperature for 1 hour. RM was diluted with ice-cold water (25 mL) and stirred for 30 minutes. The precipitated solid was filtered and dried under vacuum to give N-(1-carbamoylcyclobutyl)-2-methyl-5-(1-phenylethoxy)benzofuran-3-carboxamide (Compound 343) (290 mg, 96% ) was obtained. Preparative chiral SFC was performed on racemic compound 343 to yield compound 343-En1 and compound 343-En2.
[0284] The following compounds were prepared in a similar manner (using appropriate reagents and purification methods known to those skilled in the art, including chiral HPLC or chiral SFC) as described for compound 343: Compound 344.
[0285] Synthesis of N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-phenylpropan-2-yl)oxy)benzofuran-3-carboxamide (compound 345) [ka]
[0286] Step 1: To a suspension of 10% Pd / C (300 mg) in ethyl acetate (10 mL), add 5-(benzyloxy)-N-(1-carbamoylcyclobutyl)-2- Methylbenzofuran-3-carboxamide (compound 344) (0.8 g, 2.11 mmol) was added at room temperature and the resulting reaction mixture was stirred at room temperature under hydrogen gas balloon pressure for 16 hours. The progress of the reaction was monitored by TLC. RM was filtered. The solid was washed with ethyl acetate (50 mL). The combined organic layers were concentrated under reduced pressure to give N-(1-carbamoylcyclobutyl)-5-hydroxy-2-methylbenzofuran-3-carboxamide (600 mg, crude) as a pale yellow solid. TLC system: 100% ethyl acetate, RF: 0.2.
[0287] Step 2: Add cesium carbonate (1.35 g, 4.16 mmol) to N-(1-carbamoylcyclobutyl)-5-hydroxy-2-methylbenzofuran-3-carboxamide (600 mg, 2.08 mmol) and methyl Added to a stirred solution of -2-bromo-2-(2-fluorophenyl)acetate (617 mg, 2.49 mmol) at room temperature. The RM was stirred at room temperature for 4 hours and reaction progress was monitored by TLC. The RM is filtered and concentrated under reduced pressure to give methyl 2-((3-((1-carbamoylcyclobutyl)carbamoyl)-2-methylbenzofuran-5-yl)oxy)-2-(2-fluorophenyl ) Acetate (700 mg) was obtained as a pale yellow solid. TLC system: 70% ethyl acetate in PET ether, RF: 0.4.
[0288] Step 3: NaBH 4 (150 mg, 3.96 mmol) of methyl 2-((3-((1-carbamoylcyclobutyl)carbamoyl)-2-methylbenzofuran-5-yl)oxy)-2-(2-fluoro To a stirred solution of phenyl)acetate (0.6 g, 1.32 mmol) was added at 0° C. and the RM was stirred at room temperature for 2 hours. The progress of the reaction was monitored by TLC. The RM was diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The residue was purified by grace flash chromatography using 0.1% formic acid in water and acetonitrile as eluent to give N-(1-carbamoylcyclobutyl)-5-(1-(2-fluorophenyl)-2-hydroxy Ethoxy)-2-methylbenzofuran-3-carboxamide (240 mg, 16% over 6 steps) was obtained (compound 345). Preparative chiral SFC was performed on racemic compound 345 to yield compound 345-En1 and compound 345-En2.
[0289] N-((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)-5-(2-methoxy-1-phenylethoxy)-2-methylbenzofuran-3-carboxamide (compound 346) synthesis of [ka]
[0290] Step 1: Ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (3) (500 mg, 2.27 mmol) and 1-bromo-2-methoxyethyl)benzene (732.9 mg, 3.40 mmol) in acetonitrile (10 mL) Cs in a stirred solution of 2 C.O. 3 (2.60g, 6.81mmol) was added at room temperature. The RM was warmed to 80°C and stirred for 16 hours. The progress of the reaction was monitored by TLC. The RM was filtered and the filtrate was concentrated under reduced pressure to give ethyl 5-(2-methoxy-1-phenylethoxy)-2-methylbenzofuran-3-carboxylate (140 mg, 17.4%) as a brown liquid. TLC system: 20% ethyl acetate in PET ether, RF: 0.6.
[0291] Step 2: A solution of NaOH (158.19g, 3.954mmol) in water (10mL) was prepared using ethyl 5-(2-methoxy-1-phenylethoxy)-2-methylbenzofuran in methanol (5mL) and THF (5mL). Added to a stirred solution of -3-carboxylate (140 mg, 0.3954 mmol) at room temperature. RM was stirred at room temperature for 16 hours. The progress of the reaction was monitored by TLC. The RM was concentrated under reduced pressure, diluted with water (15 mL), and adjusted to pH approximately 6 using 1N aqueous HCl. The precipitated solid was filtered and dried under vacuum to yield 5-(2-methoxy-1-phenylethoxy)-2-methylbenzofuran-3-carboxylic acid (5) (110 mg, 85%) as a brown solid. Ta. TLC system: 100% ethyl acetate, RF: 0.2.
[0292] Step 3: 5-(2-methoxy-1-phenylethoxy)-2-methylbenzofuran-3-carboxylic acid (110 mg, 0.551 mmol), HATU (314.6 mg, 0.8281 mmol), and DIPEA ( To a stirred solution of L-serinamide.HCl (116.4 g, 0.8281 mmol) was added at room temperature under an argon atmosphere. The RM was stirred at room temperature for 2 hours. The progress of the reaction was monitored by TLC. The RM was poured into ice water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with water (2 x 100 mL), brine (100 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The residue was purified by column chromatography using silica gel (60-120) and 30-60% ethyl acetate in PET ether as eluent to give N-((S)-1-amino-3-hydroxy-1 -Oxopropan-2-yl)-5-(2-methoxy-1-phenylethoxy)-2-methylbenzofuran-3-carboxamide (Compound 346) (100 mg, 71%) was obtained. Preparative chiral SFC was performed on racemic compound 346 to yield compound 346-En1 and compound 346-En2.
[0293] N-((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)-5-(2-(dimethylamino)-1-phenylethoxy)-2-methylbenzofuran-3-carboxamide( Synthesis of compound 347) [ka]
[0294] Step 1: Add thionyl chloride (6.05 g, 50.88 mmol) to a stirred solution of 2-(dimethylamino)-1-phenylethan-1-ol (6.0 g, 36.36 mmol) in chloroform (30 mL) at room temperature. Added slowly. The RM was stirred at room temperature for 1 hour. The solids were filtered and the filter cake was washed with ethyl acetate (20 mL). The combined filtrates were dried under reduced pressure to yield 2-chloro-N,N-dimethyl-2-phenylethan-1-amine (3.1 g, 46.6%) as a white solid.
[0295] Step 2: Ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (1.0 g, 4.54 mmol) and 2-chloro-N,N-dimethyl-2-phenylethan-1-amine ( 1.672g, 9.09mmol) of Cs 2 C.O. 3 (5.202g, 13.62mmol) was added at room temperature. The RM was warmed to 70°C and stirred for 16 hours. The progress of the reaction was monitored by TLC. Filter the RM and concentrate the filtrate under reduced pressure to obtain ethyl 5-(2-(dimethylamino)-1-phenylethoxy)-2-methylbenzofuran-3-carboxylate (1.2 g, 75%). It was obtained as a brownish liquid. TLC system: 20% ethyl acetate in PET ether, RF: 0.4.
[0296] Step 3: A solution of NaOH (1.31 g, 32.96 mmol) in water (3.0 mL) was combined with ethyl 5-(2-(dimethylamino)-1-phenylethoxy) in MeOH (10 mL) and THF (10 mL). Added to a stirred solution of -2-methylbenzofuran-3-carboxylate (1.2 g, 3.296 mmol) at room temperature. RM was stirred at room temperature for 16 hours. The progress of the reaction was monitored by TLC. The RM was concentrated under reduced pressure, diluted with water (15 mL), and adjusted to pH approximately 6 using 1N aqueous HCl. The precipitated solid was filtered and dried under vacuum to give 5-(2-(dimethylamino)-1-phenylethoxy)-2-methylbenzofuran-3-carboxylic acid (1.0 g, 90%) as a brown solid. Obtained. The crude material was used in the next step without further purification. TLC system: 10% MeOH in dichloromethane; RF: 0.2.
[0297] Step 4: 5-(2-(dimethylamino)-1-phenylethoxy)-2-methylbenzofuran-3-carboxylic acid (1.0 g, 2.94 mmol), HATU (1.67 g, 4.42 mmol) in DMF (10 mL) , and DIPEA (1.142 g, 8.82 mmol) was added L-serinamide.HCl (621.6 g, 4.42 mmol) at 0° C. under an argon atmosphere. The RM was stirred at room temperature for 2 hours. The progress of the reaction was monitored by TLC. The RM was poured into ice water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with water (2 x 100 mL), brine (100 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The residue was washed with dichloromethane, n-pentane and dried under reduced pressure to give N-((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)-5-(2-( Dimethylamino)-1-phenylethoxy)-2-methylbenzofuran-3-carboxamide (compound 347) (572 mg, 45.76%) was obtained. Preparative chiral SFC was performed on racemic compound 347 to yield compound 347-En1 and compound 347-En2.
[0298] Synthesis of N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methyl-5-((2-phenylpropan-2-yl)oxy)benzofuran-3-carboxamide (compound 316) [ka]
[0299] Step 1: 2-phenylpropan-2-ol (927 mg, 6.82 mmol), ADDP (1.72 g, 6.82 mmol), and tri-n-butylphosphine (1.6 mL, 6.82 mmol) were dissolved in ethyl chloride in THF (50 mL). It was added continuously to a pre-stirred solution of 5-hydroxy-2-methylbenzofuran-3-carboxylate (1 g, 4.54 mmol) at room temperature under an argon atmosphere. The RM was brought to room temperature and stirred for 18 hours. The progress of the reaction was monitored by TLC. After 18 hours, the solvent was evaporated to dryness under vacuum. The crude material was purified by FCC using 12% EtOAc in pet-ether as eluent to give ethyl 2-methyl-5-(2-phenylpropan-2-yloxy)benzofuran-3-carboxylate ( 450mg, 30%) was obtained.
[0300] Step 2: EtOH:THF:H2O (1:1:1), ethyl 2-methyl-5-(2-phenylpropan-2-yloxy)benzofuran-3-carboxylate (450 mg, 1.33 mmol) in (21 mL) To a stirred solution of was added NaOH (213 mg, 5.32 mmol) at 0°C. The RM was stirred at 80°C for 18 hours. Progress of the reaction was observed by TLC. After completion of the reaction, the RM was cooled to room temperature and the solvent was evaporated under reduced pressure. The crude material was diluted with ice water (10 mL), acidified using 1N aqueous HCl (10 mL) until pH was approximately 1, and extracted with DCM (3 x 100 mL). The combined organic layers were washed with brine solution (100 mL) and anhydrous Na 2 S.O. 4 , filtered and concentrated under vacuum to give 2-methyl-5-(2-phenylpropan-2-yloxy)benzofuran-3-carboxylic acid (250 mg, 61%).
[0301] Step 3: To a stirred solution of 2-methyl-5-(2-phenylpropan-2-yloxy)benzofuran-3-carboxylic acid (250 mg, 0.81 mmol) in DMF (5 mL) was added HATU (460 mg, 1.21 mmol). , DIPEA (0.3 mL, 1.61 mmol), and (4-aminotetrahydro-2H-pyran-4-yl)methanol (158 mg, 1.21 mmol) at 0 °C. RM was stirred at room temperature for 18 hours. The progress of the reaction was monitored by LCMS. After completion of the reaction, the RM was diluted with ice water (50ml) and extracted with DCM (4x100ml). The combined organic layers were washed with brine solution (50 mL) and anhydrous Na 2 S.O. 4 Dry, filter, and concentrate to obtain the crude material. The crude product was purified by reverse phase preparative HPLC purification to yield compound 316 (101 mg, 30%).
[0302] The following compounds were prepared in a similar manner (using appropriate reagents and purification methods known to those skilled in the art, including chiral HPLC or chiral SFC) as described for compound 316: compound 338, compound 339, compound 340, compound 341, compound 342.
[0303] Synthesis of 5-(2-hydroxy-1-phenylethoxy)-N-(4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-2-methylbenzofuran-3-carboxamide (compound 317) [ka]
[0304] Step 1: 2-((tert-butyldimethylsilyl)oxy)-1-phenylethan-1-ol (3.2 g, 12.73 mmol), ADDP (3.43 g, 13.64 mmol), and tri-n-butylphosphine (3.3 mL, 13.64 mmol) was added to a pre-stirred solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (2 g, 9.09 mmol) in THF (100 mL) at room temperature under an argon atmosphere. and added. The RM was brought to room temperature and stirred for 18 hours. The progress of the reaction was monitored by TLC. After the reaction was completed, the solvent was evaporated to dryness. The crude material was purified by FCC using 12% EtOAc in pet-ether as eluent to give ethyl 5-(2-((tert-butyldimethylsilyl)oxy)-1-phenylethoxy)-2 -Methylbenzofuran-3-carboxylate (480 mg, 11%) was obtained.
[0305] Step 2: Ethyl 5-(2-((tert-butyldimethylsilyl)oxy)-1-phenylethoxy)-2-methylbenzofuran-3-carboxy in EtOH:THF:H2O (1:1:1, 20 mL) To a stirred solution of LiOH.H 2 O (333 mg, 7.93 mmol) was added at 0°C. RM was stirred at room temperature for 24 hours. The progress of the reaction was monitored by TLC. After the completion of the reaction, the RM was poured into ice water (20 mL), acidified using 1N aqueous HCl (25 mL) until the pH was approximately 1, extracted with DCM (5 x 100 mL), and the combined organic The layer was washed with brine solution (100 mL) and anhydrous Na 2 S.O. 4 , filtered and concentrated under reduced pressure to give 5-(2-hydroxy-1-phenylethoxy)-2-methylbenzofuran-3-carboxylic acid (380 mg, crude).
[0306] Step 3: To a stirred solution of 5-(2-hydroxy-1-phenylethoxy)-2-methylbenzofuran-3-carboxylic acid (380 mg, 1.22 mmol) in DMF (5 mL) was added HATU (694 mg, 1.83 mmol). , DIPEA (0.4 mL, 2.43 mmol), and (4-aminotetrahydro-2H-pyran-4-yl)methanol (239 mg, 1.83 mmol) were added at 0°C. RM was stirred at room temperature for 18 hours. The progress of the reaction was monitored by LCMS. After the completion of the reaction, the RM was diluted with EtOAc (400 ml) and the organic layer was washed with water (6x100 ml), brine solution (100 ml) and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude material was purified by reverse phase preparative HPLC purification to yield compound 317 (130 mg, 31% over two steps). Preparative chiral SFC was performed on racemic compound 317 to yield compound 317-En1 and compound 317-En2.
[0307] 5-((2-fluorobenzyl)oxy)-N-(1-(2-hydroxyethyl)-2-oxopyrrolidin-3-yl)-2-methylbenzofuran-3-carboxamide (compound 311) [ka]
[0308] 5-((2-fluorobenzyl)oxy)-2-methylbenzofuran-3-carboxamide (600 mg, 2.0 mmol) and 3-amino-1-(2-hydroxyethyl)pyrrolidin-2-one in DMF (20 mL) To a solution mixture of hydrochloride (396 mg, 2.2 mmol) was added DIPEA (0.92 mL, 5.0 mmol) followed by HATU (1.52 g, 4.0 mmol) at 0° C. under an argon atmosphere. The resulting reaction mixture was stirred at room temperature for 2 hours. The progress of the reaction was monitored by TLC. The RM was diluted with water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by GRACE flash chromatography using 0.1% formic acid in water and MeCN as eluent to give compound 311 (330 mg, 39%). Preparative chiral SFC was performed on racemic compound 311 to yield compound 311-En1 and compound 311-En2.
[0309] The following compounds were prepared in a similar manner (using appropriate reagents and purification methods known to those skilled in the art) as compounds 311-En1 and 311-En2: compounds 314-En1, 314-En2, 320-En1, 320-En2, 329-En1, 329-En2, 330-En1, 330-En2, 331-En1, 331-En2
[0310] N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-5-((2-fluorophenoxy)methyl)-2-methylbenzofuran-3-carboxamide (Compound 321) [ka]
[0311] Step 1: DABCO (2.78 g, 24.75 mmol) was mixed with a stirred solution of 3-bromo-4-hydroxybenzaldehyde (5.0 g, 24.75 mmol), ethyl but-2-inoate (3.32 g, 29.70 mmol) in acetonitrile (100 mL). Added to the mixture at room temperature, the RM was stirred at reflux temperature for 4 hours. Solvent was removed under reduced pressure. The residue was diluted with EtOAc (300 mL) and washed sequentially with 1N HCl (100 mL), 1N aqueous NaOH (2 x 75 mL), water (100 mL), brine (150 mL), and anhydrous NaOH. 2 S.O. 4 and concentrated under reduced pressure. The crude material was purified by FCC on silica gel using 10% EtOAc in pet-ether as eluent to give ethyl 3-(2-bromo-4-formylphenoxy)but-2-enoate (1.5 g, 29%).
[0312] Step 2: A solution mixture of ethyl 3-(2-bromo-4-formylphenoxy)but-2-enoate (1.5 g, 4.75 mmol) and TEA (0.26 mL, 1.91 mmol) in acetonitrile (25 mL) was added with argon. Degas for 5 minutes and then add bis(tri-tert-butylphosphine)palladium(0)] (195 mg, 0.382 mmol). RM was maintained at reflux for 2 hours. The progress of the reaction was monitored by TLC. RM was directly concentrated under reduced pressure. The crude material was partitioned between water (100 mL) and EtOAc (2 x 100 mL). The combined organic layers were washed with brine (150 mL) and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure to give ethyl 5-formyl-2-methylbenzofuran-3-carboxylate (1.0 g, 90%).
[0313] Step 3: NaBH4 (398 mg, 10.8 mmol) is added to a solution mixture of ethyl 5-formyl-2-methylbenzofuran-3-carboxylate (1.0 g, 4.31 mmol) in EtOH:THF (1:1) (40 mL). , at 0 °C, was added in portions and the RM was stirred for 30 min. Water (5.0 mL) was then added to the RM and concentrated under reduced pressure. The crude material was diluted with EtOAc (50 mL), washed with water (2 x 50 mL), brine (100 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure to give ethyl 5-(hydroxymethyl)-2-methylbenzofuran-3-carboxylate (900 mg, crude).
[0314] Step 4: Ethyl 5-(hydroxymethyl)-2-methylbenzofuran-3-carboxylate (700 mg, 2.99 mmol) in THF (40 mL), PPh 3 (1.17g, 4.49mmol), and CBr 4 A solution mixture of (1.48 g, 4.49 mmol) was stirred at 0° C. and then at room temperature for 2 hours. The progress of the reaction was monitored by TLC. RM was diluted with EtOAc (100 mL) and NaHCO 3 solution (50 mL), washed with water (50 mL), brine (50 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure to give ethyl 5-(bromomethyl)-2-methylbenzofuran-3-carboxylate (1.25 g, crude).
[0315] Step 5: 2-fluorophenol (700 mg, 6.25 mmol), ethyl 5-(bromomethyl)-2-methylbenzofuran-3-carboxylate (2.2 g, 7.50 mmol), and K in acetonitrile (20 mL). 2 C.O. 3 A suspension of (1.72g, 12.50mmol) was stirred at 60°C for 2 hours. The progress of the reaction was monitored by TLC. The RM was cooled and the solids were filtered. The filtrate was diluted with EtOAc (100 mL), washed with water, brine, and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude material was purified by FCC on silica using a solvent gradient mixture of 2% EtOAc in pet-ether as eluent to give 5-((2-fluorophenoxy)methyl)-2-methylbenzofuran-3 -carboxylate (1.5g, 73%) was obtained.
[0316] Step 6: A solution of NaOH (395 mg, 9.9 mmol) dissolved in water (10 mL) was added to ethyl 5-((2-fluorophenoxy)methyl-2 in a mixture of ethanol:THF (1:1) (24.0 mL). -Methylbenzofuran-3-carboxylate (1.3 g, 1.09 mmol) was added at room temperature and the RM was kept under stirring at 70 °C for 4 h. The progress of the reaction was monitored by TLC. The RM was added under reduced pressure. The residue was dissolved in water and adjusted to pH approximately 4.0 with 1N HCl. The resulting precipitate was collected by filtration, washed with water, dried, and the 5-( (2-fluorophenoxy)methyl-2-methylbenzofuran-3-carboxylic acid (1.0 g, 84%) was obtained.
[0317] Step 7: 5-((2-fluorophenoxy)methyl-2-methylbenzofuran-3-carboxylic acid (500 mg, 1.66 mmol), HATU (823 g, 2.17 mmol), and DIPEA (0.58 mL) in DMF (10 mL). 2-Amino-3-hydroxypropanamide.HCl (932.9 mg, 6.664 mmol) was added at room temperature. The RM was stirred at room temperature for 2 hours. The progress of the reaction was monitored by TLC. The RM was diluted with ice water (50 mL) and the precipitate was collected by filtration and dried. The solid was dissolved in EtOAc (50 mL), treated with activated carbon and filtered through a pad of Celite. The filtrate was removed under reduced pressure. to give compound 321 (320 mg, 54%). Preparative chiral SFC was performed on racemic compound 321 to give compound 321-En1 and compound 321-En2.
[0318] The following compounds were prepared in a manner similar to Compound 321-En1 and Compound 321-En2 (using appropriate reagents and purification methods known to those skilled in the art): Compounds 318 and 319
[0319] N-(3-carbamoyltetrahydrofuran-3-yl)-5-((2-fluorobenzyl)oxy)-2-methylbenzofuran-3-carboxamide (compound 323) [ka]
[0320] Step 1: 5-((2-fluorobenzyl)oxy)-2-methylbenzofuran-3-carboxylic acid (0.5 g, 1.66 mmol), HATU (1.26 g, 3.33 mmol), and DIPEA ( Methyl 3-aminotetrahydrofuran-3-carboxylate hydrochloride (0.363 g, 1.99 mmol) was added to a solution mixture of 0.61 mL, 3.33 mmol) at 0° C. and the RM was stirred at room temperature for 2 hours. The progress of the reaction was monitored by TLC. The reaction mixture was diluted with ice-cold water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (2 x 25 mL), brine (25 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure to give methyl 3-(5-((2-fluorobenzyl)oxy)-2-methylbenzofuran-3-carboxamido)tetrahydrofuran-3-carboxylate (650 mg, crude). Ta.
[0321] Step 2: Add 2N NaOH (25 mL) to methyl 3-(5-((2-fluorobenzyl)oxy)-2-methylbenzofuran-3-carboxamido)tetrahydrofuran-3- in MeOH (20 mL) and THF (10 mL). To a solution of carboxylate (650 mg, 1.52 mmol) was added and RM was added for 16 hours at room temperature. The progress of the reaction was monitored by TLC. The RM was diluted with ice-cold water (50 mL), acidified with 1N HCl, and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (2 x 25 mL), brine (25 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure to give 3-(5-((2-fluorobenzyl)oxy)-2-methylbenzofuran-3-carboxamido)tetrahydrofuran-3-carboxylic acid (450 mg, crude). .
[0322] Step 3: 3-(5-((2-fluorobenzyl)oxy)-2-methylbenzofuran-3-carboxamido)tetrahydrofuran-3-carboxylic acid (0.45 g, 1.08 mmol) in DMF (15 mL), HATU (0.828 Ammonium chloride (0.290 g, 5.4 mmol) was added to a solution mixture of g, 2.17 mmol) and DIPEA (0.4 mL, 2.17 mmol) at 0*C and the RM was stirred at room temperature for 2 hours. The progress of the reaction was monitored by TLC. The RM was diluted with ice-cold water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (2 x 50 mL), brine (50 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude material was purified by GRACE flash chromatography using 0.1% formic acid in water and acetonitrile as eluent to give compound 323 (320 mg, 47% over 3 steps). Preparative chiral SFC was performed on racemic compound 323 to yield compound 323-En1 and compound 323-En2.
[0323] The following compounds were prepared in a similar manner to Compound 323-En1 and Compound 323-En2 (using appropriate reagents and purification methods known to those skilled in the art): Compound 322
[0324] 5-((2-fluorobenzyl)oxy)-N-(3-(hydroxymethyl)tetrahydrofuran-3-yl)-2-methylbenzofuran-3-carboxamide (compound 327) [ka]
[0325] Step 1: Add 1 M LAH (2.34 mL, 2.34 mmol) in THF to methyl 3-(5-((2-fluorobenzyl)oxy)-2-methylbenzofuran-3-carboxamido)tetrahydrofuran- in THF (20 mL). Added to a solution of 3-carboxylate (0.500g, 1.17mmol) at 0°C, the RM was stirred at room temperature for 1 hour. The progress of the reaction was monitored by TLC. The RM was slowly quenched with saturated sodium sulfate solution (5 mL), diluted with EtOAc (50 mL), and filtered. The filtrate is Na 2 S.O. 4 and concentrated. The crude material was purified by GRACE flash chromatography using 0.1% formic acid in water and acetonitrile as eluent to give compound 237 (280 mg, 60%). Preparative chiral SFC was performed on racemic compound 327 to yield compound 327-En1 and compound 327-En2.
[0326] Compound 324, Compound 325, Compound 334-En1, and Compound 334-En2 were prepared in a similar manner to Compound 327-En1 (using appropriate reagents and purification methods known to those skilled in the art).
[0327] N-(3,3-difluoropiperidin-4-yl)-2-methyl-5-((2-(methylsulfonyl)benzyl)oxy)benzofuran-3-carboxamide (compound 333) [ka]
[0328] Step 1: (2-(methylsulfonyl)phenyl)methanol (1.8g, 9.54mmol), ADDP (2.8g, 11.13mmol), and PBu 3 (2.7 ml, 11.13 mmol) was added to a solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate (1.75 g, 7.95 mmol) in THF (60 mL) under Ar atmosphere at 0 °C. and added. The RM was stirred at room temperature for 16 hours. The progress of the reaction was monitored by TLC. The RM was diluted with water (50 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with water (1 x 50 mL), brine (1 x 50 mL), and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude material was purified by column chromatography on silica gel (100-200 mesh) using 0-30% EtOAc in PET-ether as eluent to give ethyl 2-methyl-5-((2- (Methylsulfonyl)benzyl)oxy)benzofuran-3-carboxylate (1.2 g, 39%) was obtained.
[0329] Step 2: Solution of ethyl 2-methyl-5-((2-(methylsulfonyl)benzyl)oxy)benzofuran-3-carboxylate (1.2 g, 3.092 mmol) in THF:MeOH (1:1) (40 ml) To the mixture was added 2N NaOH (8 ml) at room temperature and heated to 60°C. The RM was stirred at 60° C. for 6 hours and reaction progress was monitored by TLC. The RM was concentrated, then diluted with ice water and adjusted to pH approximately 2 using 1N HCl solution to obtain a solid. The solid was filtered and dried under reduced pressure to give 2-methyl-5-((2-(methylsulfonyl)benzyl)oxy)benzofuran-3-carboxylic acid (1 g, crude).
[0330] Step 3: Add DIPEA (1.3 ml, 7.7 mmol), HATU (1.0 g, 2.721 mmol) was added at 0 °C, followed by tert-butyl 4-amino-3,3-difluoropiperidine-1-carboxylate (550 mg, 2.332 mmol), The RM was then stirred at room temperature for 16 hours. The progress of the reaction was monitored by TLC. The RM was diluted with water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined extracts were washed with brine solution (20 ml) and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure. The crude material was purified by FCC using 40% EtOAc in PET ether as eluent to give compound 333 (800 mg, 71%). Preparative chiral SFC was performed on racemic compound 333 to yield compound 333-En1 and compound 333-En2.
[0331] Compound 332 was prepared in a similar manner to compound 333 (using appropriate reagents and purification methods known to those skilled in the art).
[0332] N-((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)-5-(1-(2-fluorophenyl)-2-hydroxyethoxy)-2-methylbenzofuran-3- Carboxamide (compound 335) [ka]
[0333] Step 1: In a Parr hydrogenator flask, add (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)-5-(benzyloxy) in ethanol (20 mL). )-2-Methylbenzofuran-3-carboxamide (800 mg, 2.17 mmol) was charged and 10% Pd / C (250 mg) was added at room temperature. The RM was stirred at room temperature for 16 hours under hydrogen gas (70 psi). The progress of the reaction was monitored by TLC. The RM was diluted with EtOAc (50 mL), filtered through Celite, and the Celite was washed with EtOAc (20 mL). The combined filtrates were concentrated under reduced pressure to give (S)-N-(1-amino-3-hydroxy-1-oxopropan-2-yl)oxy)-5-(benzyloxy)-2-methylbenzofuran- 3-carboxamide (0.45g, 92%) was obtained.
[0334] Step 2: (S)-N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-5-hydroxy-2-methylbenzofuran-3-carboxamide (250 mg, 0.89 mmol), methyl 2-bromo-2-(2-fluorophenyl)acetate (222.1 mg, 0.89 mmol), and K 2 C.O. 3 A suspension of (0.148, 1.07 mmol) was stirred at room temperature for 1 hour. The progress of the reaction was monitored by TLC. The RM was diluted with ice water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with brine (40 mL) and anhydrous Na 2 S.O. 4 and concentrated under reduced pressure to give methyl 2-((3-(((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)carbamoyl)-2-methylbenzofuran-5 -yl)oxy)-2-(2-fluorophenyl)acetate (500 mg, crude) was obtained.
[0335] Step 3: Add LAH (1M in THF) (1.3 mL, 1.3 mmol) to methyl 2-((3-(((S)-1-amino-3-hydroxy-1-oxopropane) in THF (10 mL). -2-yl)carbamoyl)-2-methylbenzofuran-5-yl)oxy)-2-(2-fluorophenyl)acetate (500 mg, 1.12 mmol) was added at 0° C. under Ar. The RM was stirred at room temperature for 1 hour. The progress of the reaction was monitored by TLC. RM, saturated Na 2 S.O. 4 Quench the solution (5 mL), dilute with EtOAc (20 mL) and filter through a pad of Celite. The filtrate is anhydrous Na 2 S.O. 4 and concentrated under reduced pressure to give compound 335 (0.250 g, 34% over 2 steps). Preparative chiral SFC was performed on racemic compound 335 to yield compound 335-En1 and compound 335-En2. [Table 7-1] [Table 7-2] [Table 7-3] [Table 7-4] [Table 7-5] [Table 7-6] [Table 7-7] [Table 7-8] [Table 7-9] [Table 7-10] [Table 7-11] [Table 8-1] [Table 8-2] [Table 8-3] [Table 8-4] In all cases above, the analytical LCMS and data collected for En2 1 H NMR data were consistent with that for En1.
[0336] chiral analysis data [Table 9-1] [Table 9-2] [Table 9-3]
[0337] Part B TRPM3 ion channel driven Ca 2± Uptake monitoring.
[0338] To monitor the inhibition of the murine TRPM3α2 (mTRPM3) ion channel by compounds of the invention, cell lines using mTRPM3alpha2 or hTRPM3 overexpressing cell lines (Flip-in HEK293) were used. TRPM3 channel, Ca 2+ Stimulated / opened with pregnenolone sulfate (PS) (50 μM) resulting in influx.
[0339] For mTRPM3, intracellular Ca 2+ was measured with a calcium-responsive dye, Fluor-4 AM ester (Invitrogen). Cells were cultured to 80-90% confluence, washed with Versene (Invitrogen), and detached from the surface by brief incubation with 0.05% trypsin (Invitrogen). The trypsinization process was stopped by addition of complete cell culture medium (DMEM, glutamax, 10% FCS, NEAA, Pen-Strep). Cells were collected and resuspended in calcium-free Krebs buffer at room temperature.
[0340] Prior to cell seeding (±2000 cells / well into black 384-well plates (Greiner)), diluted compounds were added to the assay plate along with PS dissolved in Krebs buffer containing calcium. This results in 2.4mM Ca 2+ An assay solution was obtained. Immediately after cell addition, plates were read on an Envision fluorescence reader (Perkin Elmer) with excitation of 485 nM and emission of 535 nM.
[0341] Channel inhibition was calculated with vehicle compared to PS (50 μM) stimulated conditions and compared to non-PS stimulated controls. The ability of compounds of the invention to inhibit this activity was determined as follows: Percentage inhibition = [1 - ((RFU determined for samples with test compound present - samples with positive control inhibitor) RFU determined for the sample) / (RFU determined in the presence of vehicle - RFU determined for the sample with positive control inhibitor)]×100.
[0342] The activity of the tested example compounds is shown in the table below. Activity ranges A, B, and C refer to IC50 values in the Fluo-4AM assay below. "A":IC 50 <1μM, “B”: 1μM≦IC 50 ≦20μM, and “C”: IC 50 >20μM [Table 10-1] [Table 10-2]
Claims
1. Formula (I): [Formula 1] [In the formula, R 1 is -F, -Cl, -Br, -I, -CN, -R W , -OR W , -OC(=O)R W , -NR W R X , -NR W C(=O)R X , -SR W , -S(=O)R W , -S(=O) 2 R W , -C(=O)R W , -C(=O)OR W or -C(=O)NR W R X represents Q is -NR 3 R 4 represents R 3 is -OH or -R Y represents R 4 is -R Y Or -S(=O) 2 R Y represents or Or, R 3 and R 4 together form a saturated or unsaturated, unsubstituted, mono- or polysubstituted 4-, 5-, 6-, 7-, or 8-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S; T represents -O- and U represents -CR 5 R 5 '- or T represents -CR 5 R 5 '-, U represents -O-, R 5 and R 5 ' are each independently -R Y represents or Alternatively, T represents -O- and U is -CR 5 R 5'-, alternatively R 5 and R 9 together form a saturated or unsaturated, unsubstituted, or mono- or polysubstituted 4- to 8-membered carbocyclic ring or a saturated or unsaturated, unsubstituted, or mono- or polysubstituted 4- to 8-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S; R 6 , R 7 , and R 8 are each independently -F, -Cl, -Br, -I, -CN, or -NO 2 , -SF 5 , -R W , -OR W , -OC(=O)R W , -NR W R X , -NR W C(=O)R X , -SR W , -S(=O)R W , -S(=O) 2 R W , -C(=O)R W , -C(=O)OR W or -C(=O)NR W R X represents R 9 , R 10 , R 11 , R 12 , and R 13 are each independently -F, -Cl, -Br, -I, -CN, -NO, -NO 2 , =O, =S, -SF 5 , -R Y , -OR Y , -OC(=O)R Y , -NR Y R Z , -NR Y C(=O)R Z , -SR Y , -S(=O)R Y , -S(=O) 2 R Y , -C(=O)R Y , -C(=O)OR Y or -C(=O)NR Y R Z represents Where: R W and R X are, independently of one another, and in each case independently, -H, Saturated or unsaturated, unsubstituted, mono- or poly-substituted -C 1 -C 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or poly-substituted -C 1 -C 6 -heteroalkyl, A saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, said 3- to 14-membered cycloalkyl being -C 1 -C 6 -Alkylene- or -C 1 -C 6 -heteroalkylene-, in each case a saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, or A saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl, said 3- to 14-membered heterocycloalkyl being -C 1 -C 6 -Alkylene- or -C 1 -C 6 -heteroalkylene-, in each case a saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl represents R Y and R Z are, independently of one another, and in each case independently, -H, Saturated or unsaturated, unsubstituted, mono- or poly-substituted -C 1 -C 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or poly-substituted -C 1 -C 6 -heteroalkyl, A saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, said 3- to 14-membered cycloalkyl being -C 1 -C 6 -Alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, A saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl, said 3- to 14-membered heterocycloalkyl being -C 1 -C 6 -Alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl, An unsubstituted, mono- or polysubstituted 6- to 14-membered aryl, wherein the 6- to 14-membered aryl is -C 1 -C 6 -Alkylene- or -C 1 -C 6 -heteroalkylene-, in each case a saturated or unsaturated, unsubstituted, mono- or polysubstituted 6- to 14-membered aryl, or An unsubstituted, mono- or polysubstituted 5- to 14-membered heteroaryl, wherein the 5- to 14-membered heteroaryl is -C 1 -C 6 -Alkylene- or -C 1 -C 6 -heteroalkylene-, in each case a saturated or unsaturated, unsubstituted, mono- or polysubstituted 5- to 14-membered heteroaryl represents "Mono- or polysubstituted" means, in each occurrence, independently and independently of each other, -F, -Cl, -Br, -I, -CN, -C 1-6 -Alkyl, -CF 3 , -CF 2 H, -CFH 2 , -CF 2Cl, -CFCl 2 , -C 1-6 -Alkylene-CF 3 , -C 1-6 -Alkylene-CF 2 H, -C 1-6 -Alkylene-CFH 2 , -C 1-6 -Alkylene-NH-C 1-6 -Alkylene-CF 3 , -C 1-6 -Alkylene-N(C 1-6 -alkyl)-C 1-6 -Alkylene-CF 3 , -C(=O)-C 1-6 -alkyl, -C 1-6 -Alkylene-C(=O)-C 1-6 -alkyl, -C(=O)OH, -C 1-6 -Alkylene-C(=O)-OH, -C(=O)-OC 1-6 -alkyl, -C 1-6 -Alkylene-C(=O)-OC 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)-NH 2 , -C 1-6 -Alkylene-C(=O)-NH 2 , -C(=O)-NH(C 1-6 -alkyl), -C 1-6 -Alkylene-C(=O)-NH(C 1-6 -alkyl), -C(=O)-N(C 1-6 -alkyl) 2 , -C 1-6 -Alkylene-C(=O)-N(C 1-6 -alkyl) 2 , -C(=O)-NH(OH), -C 1-6 -Alkylene-C(=O)-NH(OH), -OH, -C 1-6 -Alkylene-OH, =O, -OCF 3 , -OCF 2 H, -OCFH 2 , -OCF 2 Cl, -OCFCl 2 , -O-C 1-6 -alkyl, -C 1-6 -Alkylene-O-C 1-6 -alkyl, -O-C 1-6 -Alkylene-O-C 1-6 -alkyl, -O-C 1-6 -Alkylene-NH 2 , -O-C 1-6 -Alkylene-NH-C 1-6 -alkyl, -O-C 1-6 -Alkylene-N(C 1-6 -alkyl) 2 , -OC(=O)-C 1-6 -alkyl, -C 1-6 -Alkylene-O-C(=O)-C 1-6 -alkyl, -O-C(=O)-O-C 1-6 -alkyl, -C 1-6 -Alkylene-O-C(=O)-O-C 1-6 -Alkyl, -O-C(=O)-NH(C 1-6 -alkyl), -C 1-6 -Alkylene-O-C(=O)-NH(C 1-6 -alkyl), -O-C(=O)-N(C 1-6 -alkyl) 2 , -C 1-6 -Alkylene-O-C(=O)-N(C 1-6 -alkyl) 2 , -OS(=O) 2 -NH 2 , -C 1-6 -Alkylene-O-S(=O) 2 -NH 2 , -OS(=O) 2 -NH(C 1-6 -alkyl), -C 1-6 -Alkylene-O-S(=O) 2 -NH(C 1-6 -alkyl), -O-S(=O) 2 -N(C 1-6 -alkyl) 2 , -C 1-6 -Alkylene-O-S(=O) 2 -N(C 1-6 -alkyl) 2 , -NH 2 , -NO, -NO 2 , -C 1-6 -Alkylene-NH 2 , -NH(C 1-6 -alkyl), -C 1-6 -Alkylene-NH(C 1-6 -alkyl), -N(C 1-6 -alkyl) 2 , -C 1-6 -Alkylene-N(C 1-6 -alkyl) 2 , -NH-C(=O)-C 1-6 -alkyl, -C 1-6 -Alkylene-NH-C(=O)-C 1-6 -Alkyl, -NH-C(=O)-O-C 1-6 -alkyl, -C 1-6 -Alkylene-NH-C(=O)-O-C 1-6 -Alkyl, -NH-C(=O)-NH 2 , -C 1-6 -Alkylene-NH-C(=O)-NH 2 , -NH-C(=O)-NH(C 1-6 -alkyl), -C 1-6 -Alkylene-NH-C(=O)-NH(C 1-6 -alkyl), -NH-C(=O)-N(C 1-6 -alkyl) 2 , -C 1-6 -Alkylene-NH-C(=O)-N(C 1-6 -alkyl) 2 , -N(C 1-6 -alkyl)-C(=O)-C 1-6 -alkyl, -C 1-6 -Alkylene-N(C 1-6 -alkyl)-C(=O)-C 1-6 -Alkyl, -N(C 1-6 -alkyl)-C(=O)-O-C 1-6 -alkyl, -C 1-6 -Alkylene-N(C 1-6 -alkyl)-C(=O)-O-C 1-6 -Alkyl, -N(C 1-6 -alkyl)-C(=O)-NH 2 , -C 1-6 -Alkylene-N(C 1-6 -alkyl)-C(=O)-NH 2 , -N(C 1-6 -alkyl)-C(=O)-NH(C 1-6 -alkyl), -C 1-6 -Alkylene-N(C 1-6 -alkyl)-C(=O)-NH(C 1-6 -alkyl), -N(C 1-6 -alkyl)-C(=O)-N(C 1-6 -alkyl) 2 , -C 1-6 -Alkylene-N(C 1-6 -alkyl)-C(=O)-N(C 1-6 -alkyl) 2 , -NH-S (=O) 2 OH, -C 1-6 -Alkylene-NH-S(=O) 2 OH, -NH-S (=O) 2 -C 1-6 -alkyl, -C 1-6 -Alkylene-NH-S(=O) 2 -C 1-6 -Alkyl, -NH-S(=O) 2 -O-C 1-6 -alkyl, -C 1-6 -Alkylene-NH-S(=O) 2 -O-C 1-6 -Alkyl, -NH-S(=O) 2 -NH 2 , -C 1-6 -Alkylene-NH-S(=O) 2 -NH 2 , -NH-S (=O) 2 -NH(C 1-6 -alkyl), -C 1-6 -Alkylene-NH-S(=O) 2 -NH(C 1-6 -alkyl), -NH-S(=O) 2 N (C 1-6 -alkyl) 2 , -C 1-6 -Alkylene-NH-S(=O) 2 N (C 1-6 -alkyl) 2 , -N(C 1-6 -alkyl)-S(=O) 2 -OH, -C 1-6 -Alkylene-N(C 1-6 -alkyl)-S(=O) 2-OH, -N(C 1-6 -alkyl)-S(=O) 2 -C 1-6 -alkyl, -C 1-6 -Alkylene-N(C 1-6 -alkyl)-S(=O) 2 -C 1-6 -Alkyl, -N(C 1-6 -alkyl)-S(=O) 2 -O-C 1-6 -alkyl, -C 1-6 -Alkylene-N(C 1-6 -alkyl)-S(=O) 2 -O-C 1-6 -Alkyl, -N(C 1-6 -alkyl)-S(=O) 2 -NH 2 , -C 1-6 -Alkylene-N(C 1-6 -alkyl)-S(=O) 2 -NH 2 , -N(C 1-6 -alkyl)-S(=O) 2 -NH(C 1-6 -alkyl), -C 1-6 -Alkylene-N(C 1-6 -alkyl)-S(=O) 2 -NH(C 1-6 -alkyl), -N(C 1-6 -alkyl)-S(=O) 2 -N(C 1-6 -alkyl) 2 , -C 1-6 -Alkylene-N(C 1-6 -alkyl)-S(=O) 2 -N(C 1-6 -alkyl) 2 , -SH, =S, -SF 5 , -SCF 3 , -SCF 2 H, -SCFH 2 , -S-C 1-6 -alkyl, -C 1-6 -Alkylene-S-C 1-6 -Alkyl, -S(=O)-C 1-6 -alkyl, -C 1-6 -Alkylene-S(=O)-C 1-6-Alkyl, -S(=O) 2 -C 1-6 -alkyl, -C 1-6 -Alkylene-S(=O) 2 -C 1-6 -Alkyl, -S(=O) 2 -OH, -C 1-6 -Alkylene-S(=O) 2 -OH, -S (=O) 2 -O-C 1-6 -alkyl, -C 1-6 -Alkylene-S(=O) 2 -O-C 1-6 -Alkyl, -S(=O) 2 -NH 2 , -C 1-6 -Alkylene-S(=O) 2 -NH 2 , -S(=O) 2 -NH(C 1-6 -alkyl), -C 1-6 -Alkylene-S(=O) 2 -NH(C 1-6 -alkyl), -S(=O) 2 -N(C 1-6 -alkyl) 2 , -C 1-6 -Alkylene-S(=O) 2 -N(C 1-6 -alkyl) 2 , 3- to 14-membered cycloalkyl, —C 1-6 -alkylene-(3- to 14-membered cycloalkyl), 3- to 14-membered heterocycloalkyl, -C 1-6 -alkylene-(3 to 14 membered heterocycloalkyl), -phenyl, -C 1-6 -alkylene-phenyl, 5- to 14-membered heteroaryl, -C 1-6 -alkylene-(5-14 membered heteroaryl), -O-(3-14 membered cycloalkyl), -O-(3-14 membered heterocycloalkyl), -O-phenyl, -O-(5-14 membered heteroaryl), -C(=O)-(3-14 membered cycloalkyl), -C(=O)-(3-14 membered heterocycloalkyl), -C(=O)-phenyl, -C(=O)-(5-14 membered heteroaryl), -S(=O) 2 -(3 to 14 membered cycloalkyl), -S(=O) 2-(3 to 14 membered heterocycloalkyl), -S(=O) 2 -phenyl, -S(=O) 2 -(5- to 14-membered heteroaryl) or a stereoisomer, physiologically acceptable salt, solvate, and / or polymorph thereof.
2. R 3 represents -H, R 4 but, Saturated or unsaturated, unsubstituted, mono- or poly-substituted -C 1 -C 6 -alkyl, A saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, said 3- to 14-membered cycloalkyl being -C 1 -C 6 -Alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, A saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl, said 3- to 14-membered heterocycloalkyl being -C 1 -C 6 -Alkylene- or -C 1 -C 6 -heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered heterocycloalkyl, An unsubstituted, mono- or polysubstituted 6- to 14-membered aryl, wherein the 6- to 14-membered aryl is -C 1 -C 6 -Alkylene- or -C 1 -C 6 -heteroalkylene-, in each case a saturated or unsaturated, unsubstituted, mono- or polysubstituted 6- to 14-membered aryl, or An unsubstituted, mono- or polysubstituted 5- to 14-membered heteroaryl, wherein the 5- to 14-membered heteroaryl is -C 1 -C 6 -Alkylene- or -C 1 -C 6 -heteroalkylene-, in each case a saturated or unsaturated, unsubstituted, mono- or polysubstituted 5- to 14-membered heteroaryl represents R 9 , R 10 , R 11 , R 12 , and R 13 does not represent -H; 2. A compound according to claim 1 or a stereoisomer, physiologically acceptable salt, solvate, and / or polymorph thereof.
3. R 9 , R 10 , R 11 , R 12 , and R 13 at least one of does not represent -H, The following compound: [chemical 2] provided that it does not include 3. A compound according to claims 1 and 2 or a stereoisomer, physiologically acceptable salt, solvate and / or polymorph thereof.
4. R 6 , R 7 , and R 8 at least one of does not represent -H, The following compound: [C3] provided that it does not include A compound according to any one of claims 1 to 3 or a stereoisomer, physiologically acceptable salt, solvate and / or polymorph thereof.
5. T represents -O- and U represents -CR 5 R 55. The compound according to claim 1, or a stereoisomer, physiologically acceptable salt, solvate and / or polymorph thereof, wherein R 1 represents 1-R 2 '-.
6. R 1 is -H, -F, -Cl, -Br, -I, -C 1-6 -alkyl, -O-C 1-6 -alkyl, -C 1-6 -Alkylene-O-C 1-6 -alkyl, -C 1-6 -Alkylene-NH(C 1-6 -alkyl), -C 1-6 -Alkylene-N(C 1-6 -alkyl) 2 , -CF 3 , -CF 2 H, -CFH 2 , -CF 2 Cl, -CFCl 2 , -C 1-6 -Alkylene-CF 3 , -C 1-6 -Alkylene-CF 2 H, -C 1-6 -Alkylene-CFH 2 , -C 1-6 -Alkylene-NH-C 1-6 -Alkylene-CF 3 , -C 1-6 -Alkylene-N(C 1-6 -alkylene)-C 1-6 -Alkylene-CF 3 , -C(=O)C 1-6 -Alkyl, -C(=O)OC 1-6 -Alkyl, -C(=O)NHC 1-6 -Alkyl, -C(=O)N(C 1-6 -alkyl) 2 , -S(=O)-C 1-6 -Alkyl, -S(=O) 2 -C 1-6 -alkyl, -O-C 1 - 66. The compound according to claim 1, wherein R represents -alkyl, unsubstituted-cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl or unsubstituted cyclohexyl, or a stereoisomer, physiologically acceptable salt, solvate and / or polymorph thereof.
7. R 3 -H, -OH, -C 1-6 -alkyl, -C 1-6 -Alkylene-OH, -C 1-6 -Alkylene-O-C 1-6 -alkyl, -C 1-6 -Alkylene-NH 2 , -C 1-6 -Alkylene-NH(C 1-6 -alkyl), -C 1-6 -Alkylene-N(C 1-6 -alkyl) 2 , -CF 3 , -CF 2 H, -CFH 2 , -CF 2 Cl, -CFCl 2 , -C 1-6 -Alkylene-CF 3 , -C 1-6 -Alkylene-CF 2 H, -C 1-6 -Alkylene-CFH 2 , -C 1-6 -Alkylene-NH-C 1-6 -Alkylene-CF 3 , or -C 1-6 -Alkylene-N(C 1-6 -alkyl)-C 1-6 -Alkylene-CF 3 or a stereoisomer, physiologically acceptable salt, solvate and / or polymorph thereof, according to any one of claims 1 and 3 to 6, which represents:
8. R 4 but, -H, Saturated, unsubstituted, mono- or polysubstituted with -F, -S(=O) 2 C 1-6 -alkyl, Saturated, unsubstituted -S(=O) 2(3 to 14 membered cycloalkyl), Saturated, unsubstituted, independently of each other, —OH, ═O, —OC 1-6 -Alkyl, -NH 2 , -NHC 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 , -C 1-6 -Alkylene-NH 2 , -C 1-6 -Alkylene-NH-C 1-6 -Alkyl, -C(=O)NH 2 , -C(=O)-NH-C 1-3 -Alkyl, -C(=O)-N(C 1-3 -alkyl) 2 or unsubstituted phenyl; 1-6 -alkyl, 3 to 14 membered cycloalkyl or -C 1-6 -alkylene-(3 to 14 membered cycloalkyl) 1-6 -alkylene- is unsubstituted or monosubstituted with -OH, and said 3- to 14-membered cycloalkyl is saturated, unsubstituted, independently of each other, -C 1-6 -alkyl, -C 1-6 -Alkylene-NH 2 , -C 1-6 -Alkylene-NH-C 1-6 -Alkylene-CF 3 , -C 1-6 -Alkylene-OH, -C 1-6 -Alkylene-NHC(=O)O-C 1-6 -Alkyl, -OH, -OC 1-6 -Alkyl, -NH 2 , -N(C 1-6 -alkyl) 2 , -NHC(=O)OC 1-6 -3- to 14-membered cycloalkyl, mono- or di-substituted with a substituent selected from the group consisting of -alkyl, 1-6 -alkylene-(3 to 14 membered cycloalkyl), 3 to 14 membered heterocycloalkyl or -C 1-6 -alkylene-(3 to 14 membered heterocycloalkyl) 1-6 -alkylene- is unsubstituted or monosubstituted by -OH, and said 3- to 14-membered heterocycloalkyl is, in each occurrence, azetane, 1,4-oxazepane, pyrrolidine, piperidine, azepane, diazepane, tetrahydrofuran, tetrahydropyran, oxetane, morpholine, piperazine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, octahydropyran, selected from pyrrolo[1,2-a]pyrazine, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, quinuclidine, hexahydro-1H-pyrrolidine, 2-oxaspiro[3.3]heptane, 2-azaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 1,1-dioxothiacylcyclohexane, in each case unsubstituted, independently of one another, -F, -OH, =O, -C 1-6 -alkyl, -C 1-6 -Alkylene-CF 3 , -C 1-6 -Alkylene-OH, -C 1-6 -Alkylene-O-C 1-6 -Alkyl, -NH 2 , -N(C 1-6 -alkyl) 2 , -C 1-6 -Alkylene-NH 2 , -C 1-6 -Alkylene-N(C 1-6 -alkyl) 2 , -C(=O)-C 1-6 -Alkyl, -C(=O)OH, -C(=O)O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkylene-CF 3 , -C(=O)NH 2 , -C(=O)NH(C 1-6 -alkyl), -S(=O) 2 C 1-6 -alkyl, oxetanyl, pyrimidinyl, -C 1-6 -3-14 membered heterocycloalkyl, mono- or polysubstituted with substituents selected from the group consisting of -alkylene-phenyl, 1-6 -alkylene-(3 to 14 membered heterocycloalkyl), unsubstituted phenyl, 5-14 membered heteroaryl or -C 1-6 -alkylene-(5-14 membered heteroaryl) 1-6 -alkylene- is unsubstituted or monosubstituted with -OH, and said 5- to 14-membered heteroaryl is, at each occurrence, selected from the group consisting of pyridine, pyridazine, pyrazine, pyrazole, isoxazole, triazole, and [1,2,4]triazolo[4,3-a]pyrimidine, and is, at each occurrence, unsubstituted, independently of each other, -C 1-6 -alkyl, -OH, or -C 1-6 -alkylene-(5-14 membered heteroaryl) or a stereoisomer, physiologically acceptable salt, solvate and / or polymorph thereof, according to any one of claims 1 and 3 to 7,
9. R 3 and R 4 together form a heterocycle selected from the group consisting of pyrrolidine, piperidine, morpholine, and piperazine, in each occurrence unsubstituted or, independently of each other, -C 1-6 -Alkyl, -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(=O)NH-C 1-6 -Alkyl, -C(=O)N(C 1-6 -alkyl) 2 , -C(=O)OC 1-6 -Alkyl, -NHC(=O)O-C 1-6 -alkyl, unsubstituted-pyridyl, and unsubstituted or -C 1-6 7. The compound according to any one of claims 1 and 3 to 6, or a stereoisomer, physiologically acceptable salt, solvate and / or polymorph thereof, wherein the compound is mono- or polysubstituted with a substituent selected from the group consisting of 1,2,4-oxadiazole mono-substituted with alkyl.
10. R 5 and R 5 ' but independently of each other, -H, Saturated or unsaturated, unsubstituted, mono- or poly-substituted -C 1 -C 6 -alkyl, Saturated or unsaturated, unsubstituted, mono- or poly-substituted -C 1 -C 6 -heteroalkyl, A saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl, said 3- to 14-membered cycloalkyl being -C 1 -C 6 -Alkylene- or -C 1 -C 6 -heteroalkylene-, in each case a saturated or unsaturated, unsubstituted, mono- or polysubstituted 3- to 14-membered cycloalkyl or a stereoisomer, physiologically acceptable salt, solvate and / or polymorph thereof, according to any one of claims 1 to 9,
11. R 6 , R 7 , and R 8 But independently of each other, -H, -F, -Cl, -Br, -I, -OH, -SH, -SF 5 , -CN, -NO 2 , -C(=O)OH, -NH 2 , -C 1-6 -Alkyl, -CF 3 , -CHF 2 , -CH 2 F. -O-C 1-6 -alkyl, -OCF 3 , -OCHF 2 , -OCH 2 F. unsubstituted or, independently of each other, -OH, ═O, -F, -Cl, -Br, -I, -SH, ═S, -CN, -CF 3 , -CHF 2 , -CH 2 F, -OCF 3 , -OCHF 2 , -OCH 2 F, S.F. 5 , -NO 2 , -C(=O)OH, -NH 2 and -C(=O)NH 2 -NHC 1-6 -alkyl, unsubstituted or, independently of each other, -OH, ═O, -F, -Cl, -Br, -I, -SH, ═S, -CN, -CF 3 , -CHF 2 , -CH 2 F, -OCF 3 , -OCHF 2 , -OCH 2 F, S.F. 5 , -NO 2 , -C(=O)OH, -NH 2 and -C(=O)NH 2 -N(C 1-6 -alkyl) 2 , unsubstituted or, independently of each other, -OH, ═O, -F, -Cl, -Br, -I, -SH, ═S, -CN, -CF 3 , -CHF 2 , -CH 2 F, -OCF 3 , -OCHF 2 , -OCH 2 F, S.F. 5 , -NO 2 , -C(=O)OH, -NH 2 and -C(=O)NH 2 -C(=O)OC 1-6 -alkyl, unsubstituted or, independently of each other, -OH, ═O, -F, -Cl, -Br, -I, -SH, ═S, -CN, -CF 3 , -CHF 2 , -CH 2 F, -OCF 3 , -OCHF 2 , -OCH 2 F, S.F. 5 , -NO 2 , -C(=O)OH, -NH 2and -C(=O)NH 2 -OC(=O)C 1-6 -alkyl, unsubstituted or, independently of each other, -OH, ═O, -F, -Cl, -Br, -I, -SH, ═S, -CN, -CF 3 , -CHF 2 , -CH 2 F, -OCF 3 , -OCHF 2 , -OCH 2 F, S.F. 5 , -NO 2 , -C(=O)OH, -NH 2 and -C(=O)NH 2 -C 1-6 -Heteroalkyl or a stereoisomer, physiologically acceptable salt, solvate and / or polymorph thereof, according to any one of claims 1 to 10,
12. R 9 , R 10 , R 11 , R 12 , and R 13 are each independently -H, -F, -Cl, -CN, -OH, ═O, -C 1-6 -Alkyl, -CHF 2 , -CF 3 , -C 1-6 -Alkylene-NH 2 , -C 1-6 -Alkylene-NHC(=O)O-C 1-6 -alkyl, -C 1-6 -Alkylene-OH, -C 1-6 -Alkylene-NHC(=O)-O-C 1-6 -Alkyl, -C(=O)O-C 1-6 -Alkyl, -N(C 1-6 -alkyl) 2 , -OC 1-6 -alkyl, -OCF 3 , -O-C 1-6 -Alkylene-N(C 1-6 -alkyl) 2 , -S(=O) 2 -C 1-6 -Alkyl, -azetidine, -C 1-6 -alkylene-O-tetrahydropyran, or -C 1-6 12. The compound according to any one of claims 1 to 11, which represents -alkyl-substituted-piperazine or a stereoisomer, physiologically acceptable salt, solvate and / or polymorph thereof.
13. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13] [Table 1-14] [Table 1-15] and physiologically acceptable salts thereof 13. The compound according to any one of claims 1 to 12, or a stereoisomer, physiologically acceptable salt, solvate and / or polymorph thereof, selected from the group consisting of:
14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 13 or a stereoisomer, physiologically acceptable salt, solvate and / or polymorph thereof.
15. 15. A pharmaceutical composition according to claim 14 for use in the treatment of pain.
16. 16. The pharmaceutical composition of claim 15, wherein the pain is selected from nociceptive pain, inflammatory pain, and neuropathic pain, preferably post-operative pain.
